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INTEGRATING STATEMENT 
Introduction 
When pursuing senior development in the field of Public Health, I decided to follow the Public Health and 
Policy Doctorate (DrPH) course because my main academic and career interests are in understanding how 
to bridge the gap between evidence and evidence-based health policy and practice. The aims of the DrPH 
– to equip its graduates with the skills required by managers and leaders in this field and to provide 
experience of dealing with the challenges of understanding and adapting scientific knowledge in order to 
achieve public health gains - seemed to be a “tailor made” opportunity for me.  
The following paragraphs summarise the academic knowledge I have accumulated over four years of 
studies; they also highlight the links between each academic component.  My final remarks offer some 
insights into how the DrPH has undoubtedly enhanced my career prospects in public health over a relatively 
short period of time. 
The taught component 
The taught component comprises two academic modules: Evidence Based Public Health Practice (EBPHP) 
and Leadership Management and Personal Development (LM&PD), now renamed as Understanding 
Leadership, Management & Organisations. I undertook both during October and December 2010.  
The aim of EBPHP is to help students to identify, assess, synthesise, present and use research-based 
information to improve public health. One of the tasks I was assigned was to provide evidence-based health 
policy on tobacco warnings targeting adolescent population to a Ministry of Health (MoH). This task was 
more challenging for me than I expected since my previous background as a medical doctor and senior 
organisational manager had given me the skills to be a decision-maker, rather than a rigorous academic 
researcher or technical advisor. By conducting the assigned task I learnt how to conduct systematic 
searches of the literature, appraise and synthesise the evidence. It was the first time I had to produce a 
policy brief for a policy maker myself. 
The second assignment for EBPHP was to design an ‘influencing and knowledge transfer strategy’ to put a 
research-based issue onto the policy agenda.  At that stage of my career I was involved with a policy project 
supported by the Colombian MoH. The idea of institutionalising Health Technology Assessment (HTA) had 
recently seized the attention of policymakers; hence my project consisted of designing strategies for such 
a policy solution to reach the policy agenda and be implemented in this country.  
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I conducted a policy analysis on the topic of interest using John Kingdon´s model of agenda setting to depict 
the problem, policy and politics streams that created a window of opportunity for policy action. I also 
conducted a stakeholder analysis and suggested some prospective strategies that should be considered to 
help successfully implement an HTA agency in this country. I did not envision at that moment that those 
were the first steps of what is today the Health Technology Assessment Institute of Colombia- IETS, the 
institution that I currently lead. 
The objective of the LM&PD is to provide students with the opportunities to explore a range of issues and 
theories relating to management, leadership, organisation, and to develop an understanding of what is 
required to become a future leader and manager in public health. At the time, the module had two 
compulsory assessed components. The first was an organisational management case study where I used 
my previous experience as senior health manager at a health insurance organization. Strengths, 
weaknesses, opportunities and threat analysis (SWOT) and Deming cycle were all familiar management 
tools to me, but whenever I used them to retrospectively analyse an organisational strategy, the do´s and 
don’ts emerged more clearly than ever before.  
The second task was to develop a personal development plan and produce a reflective commentary. In all 
honesty, I was initially very sceptical about the value of this module.  However, it turned out to be 
something of watershed moment in my career. Through the LM&PD I learnt to design a career plan, to 
reflect on my own personality and limitations, and to develop strategies and short-term goals to pursue a 
final objective: “to become a senior and effective health policymaker in Colombia”. I realized that by 
aligning my personal values: contribution, recognition, fairness and achievement with a career plan, I could 
achieve this final goal. 
The OPA fieldwork and report 
I had the immense opportunity to conduct my organisational placement and policy analysis (OPA) at the 
National Institute for Health & Care Excellence - NICE, at its international branch (NICE International, NI) in 
the UK. At that time the Inter-American Development Bank sponsored a consultancy project with NI aimed 
at advising the Colombian MoH on how to set up a local HTA agency. My supervisor was of great help to 
me in liaising with and meeting the right people in order to secure the position; additional networking with 
the Colombian counterpart was very important to be admitted for this placement.  
The OPA started in early 2011 and lasted 5 months; it consisted of supporting the NI team in locating and 
summarising the available information about how four western countries of interest for Colombia had 
established their own HTA institutions. My work also included advising on the most appropriate 
institutional arrangement for establishing a “NICE-like” institution in this setting. As part of the OPA, I 
conducted primary research, focus groups with relevant stakeholders in Colombia, and presented 
preliminary results to senior policymakers within the MoH. 
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Once the fieldwork was finalised I produced two different pieces of research, one for the host organisation 
(NI) and an OPA report for my academic institution (the LSHTM). This was probably the most challenging 
task of all. Besides being part of the team, I had to produce at the same time a consultancy report for NI 
and a rigorous academic essay for LSHTM. After six months of writing up I developed a framework for NI 
aimed at attracting project funding, and an OPA report for the academic faculty. I used all the skills acquired 
during this first year of studies and was challenged throughout the organisational placement; this period 
also provided me with valuable networks of co-operation within the UK and Colombia. 
The thesis 
The overall purpose of the DrPH research project is to help the student to learn about the role of research 
in public health practice.  However, the specific aim of my thesis was to assess the feasibility of conducting 
and using HTA to inform decision-making in Colombia, using severe haemophilia A as the main case study.  
To fulfil the aims of this research work, I used a mixed methods approach.  
The project was developed in Bogotá, Colombia and London. The issues around previous HTA work in this 
country were identified through a qualitative approach using semi-structured interviews. To assess 
whether primary prophylaxis should be a funding priority compared to a number of other (selected) health 
care technologies and to document potential difficulties in establishing formal HTA methods and 
procedures in Colombia a number of steps were undertaken. The main ones were conducting a de novo 
economic evaluation of primary prophylaxis with FVIII for people with severe haemophilia A, and using the 
Evidence and Value: Impact on Decision-Making (EVIDEM) framework to establish whether it should be a 
priority to fund, and establishing whether it is a credible / acceptable framework with which to make 
resource allocation decisions.  
The economic evaluation was undertaken using standard decision modelling techniques.  The use of 
EVIDEM as a decision making framework was applied and tested in a focus group emulating decision-
making with participants who compared four mini HTA reports of public resource-competing health care 
technologies. 
Final remarks 
The DrPH has been an extremely rewarding journey, but at the same time, the most challenging one.  It 
has a dual focus on developing the expertise to conduct and evaluate research and also on acquiring the 
skills crucial for leadership roles in public health policy and practice; I hope I have acquired both. It is worth 
mentioning that in order to expedite “travelling” throughout this academic programme, it is advisable that 
every new step should be interconnected with the previous and next one. EBPHP, LM&PD, the OPA and 
thesis in my case were all interconnected. 
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Currently I am the CEO of the first HTA agency in Spanish speaking America. I have no doubt that without 
the expertise, skills and exposure provided through the DrPH curriculum it would not have been possible 
to reconcile the aims of producing incremental public health and policy gains while achieving a personal 
goal of becoming a senior and effective health policymaker in my home country. 
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Abstract 
Health Technology Assessment (HTA) examines the consequences of the application of health 
technologies. HTA is aimed at better informing decision-makers. In November 2012 Colombia 
established its own HTA agency (IETS).  Up until the establishment of IETS, HTA had had a limited role 
in providing information to set priorities. Severe haemophilia A (SHA), an infrequent disorder of blood 
coagulation, serves as a good example of how the adoption of new technologies can change the course 
of a disease while challenging the financial sustainability of health systems.  
The aim of this study was to assess the feasibility of conducting and using HTA to inform decision-
making in Colombia.  To fulfil these aims a mixed methods approach was used. Because decision-
making is a task embedded in a complex and highly customised context, the case study method was 
considered as appropriate.  
Through a qualitative approach using semi- structured interviews ten “drivers” emerged with the 
ability to help or hinder HTA: availability and quality of data, implementation strategy, cultural aspects, 
local capacity, financial support, policy/political support, globalisation, stakeholder pressure, health 
system context and usefulness perception.  
A CUA from the Colombian health system perspective was developed to assess the cost-effectiveness 
of primary prophylaxis (PP) versus on-demand (OD) provision of FVIII for SHA. The ICER of PP with FVIII 
compared to OD was COL$105,081,022 (USD$55,204) per QALY gained. This is not considered cost-
effective using a hypothetical threshold of up to three times the GDP per-capita.  
Two approaches were used to assist decision-making for PP in Colombia, including EVIDEM. The final 
reimbursement decision about PP in Colombia would be “it would not be prioritised”. Nonetheless, 
the final valuation of technologies was sensitive to the methods and criteria used to assist decision-
making.  
The combined results of the research appear to suggest that HTA development and use in Colombia 
is feasible, even for technologies that are difficult to evaluate. Results of this research work could be 
of significant value to the field of public health and policy since resource-allocation decisions in many 
settings similar to Colombia have often been made without enough evidence-based information. 
Further research in the field of priority-setting is still required. 
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I. INTRODUCTION 
1. Health Technology Assessment supporting decision-making around the globe 
Health Technology Assessment (HTA) examines the consequences of the application of health 
technologies and is closely related to evidence-based medicine (EBM)1. Both HTA and EBM are aimed 
at better informing decision-makers. As such, HTA has become an issue of great interest, although it 
has also attracted controversy. Advocates of HTA argue that it helps to promote efficiency of resource-
allocation, whilst critics state HTA is simply a means to restrict access to new and costly technologies 
(O´Donnell et al, 2009).  
Over the past decades different countries have established specialised HTA organisations aimed at 
better informing health care policies and clinical practice. The first technology assessment institution, 
although not exclusively health related, was the Office for Technology Assessment (OTA), established 
in the United States (US) public sector in 1972 with the aim of informing the US congress of the 
advantages and disadvantages of newly developed technologies. This early initiative became 
attractive to other western countries that were similarly dealing with imperfect and asymmetric 
information to make decisions. Soon after Austria, Denmark, France, Germany, the United Kingdom, 
Netherlands, and Sweden created similar institutions.   
Early models of specialised HTA institutions2 were established in 1987 in Sweden (Statens beredning 
för medicinsk utvärdering-SBU) and in Canada (Conseil d’évaluation des technologies de la santé (CETS) 
and Australia (Pharmaceutical Benefits Advisory Committee-PBAC) in 1988. This latter is recognised as 
the first HTA committee with binding power over drug reimbursement policies in a public health 
system; it is considered to be one of the earliest versions of an HTA agency3. SBU is recognised as one 
of the co-founders of the International Network of Agencies for Health Technology Assessment- 
INAHTA in 19934. 
In 1999 the United Kingdom introduced the National Institute for Clinical Excellence, renamed later as 
the National Institute for Health and Clinical Excellence, and more recently as the National Institute 
for Health and Care Excellence (NICE). NICE perhaps remains the most well-known HTA organisation 
worldwide according to Morrison et al, 2009.  Its clear ability to establish a transparent review process 
to determine the clinical and cost effectiveness of health care interventions for the NHS5 continues to 
attract interest across the world.  
                                                          
1 The systematic collection and analysis of clinical evidence 
2 Also known as HTA agencies. 
3  When in 1992 it published its first formal guidelines for pharmaceutical reimbursement 
4 INAHTA (International Network of Agencies for Health Technology Assessment) a non-profit organization established in 1993 and has now 
grown to 57member agencies from 32 countries including North and Latin America, Europe, Africa, Asia, Australia, and New Zealand. All 
members are non-profit making organizations producing HTA and are linked to regional or national government. 
5 NHS National Health System England and Wales 
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HTA agencies have gained space in taxation-based and social health insurance systems.  This is 
evidenced by the development of these agencies in different settings. For example, in 2004, the 
Institute for Quality and Efficiency in Health care (Institut für Qualität und Wirtschaftlichkeit im 
Gesundheitswesen -IQWiG) was established in Germany. The US Oregon State Drug Effectiveness 
Review Project (DERP) has applied principles of EBM to formulary decision-making in the public sector 
since 2000 and in 2010 the PCORI (Patient Centered Outcomes Research Institute), an independent 
organisation aimed at helping patients, clinicians, purchasers and policymakers to make informed 
health decisions, was created. In fact, most HICs6 utilise some form of HTA process or agency to 
facilitate decision-making and priority-setting within their health systems (Bulfone et al, 2009 and 
Castro, 2011 and 2012).  
Recent examples of HTA agencies in the developing world are: the National Agency for Health 
Surveillance (ANVISA) established in 1999 and the Department of Science and Technology (DECIT) 
(both in Brazil and conducting HTA since the mid-2000s), as well as the Health Intervention and 
Technology Assessment Program (HiTAP) in Thailand, created in 2007. In 2011 at the HTAi7 global 
meeting in Rio de Janeiro, Latin America established a regional HTA network (RedETSA) initially 
comprising twelve countries (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Ecuador, 
México, Paraguay, Peru, Uruguay); more recently countries like Canada have been incorporated. In 
September 2012 Colombia established its Health Technology Assessment Institute (IETS) which started 
operations soon after. That same month the Pan-American Health Organisation (PAHO) member 
states enacted a Resolution of commitment to introduce the use of HTA to inform decision-making in 
the Americas8. Currently, Chile and Costa Rica, among others, are planning to establish their own HTA 
organisations.   
 
 
 
 
 
 
                                                          
6 High Income Countries 
7  HTAi: Health Technology Assessment International is a global scientific and professional society for all those who produce, use, or 
encounter HTA. HTAi embraces all stakeholders, including researchers, agencies, policymakers, industry, academia, health service providers, 
and patients/consumers, and acts as a neutral forum for collaboration and the sharing of information and expertise. With members from 
59 countries and six continents, HTAi is a thriving global network. Source HTAi web page http://www.htai.org/index.php?id=428 as per July 
13th 2013. 
8 Evaluación e Incorporación de tecnologías sanitarias en los sistemas de salud. CSP28.R9. 19 de Septiembre del 2012. OPS/OMS 
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2. Methodological considerations in conducting HTA and the process of decision-making 
It is often assumed that policies and decisions are made and implemented in a rational way (Simon, 
1957).  However, the real world is clearly more complex than this linear process, meaning that 
designing and implementing a successful policy change is unlikely to be this simple (Buse et al, 2010).  
Indeed authors like Lindblom (1959) have proposed that decision-makers take incremental steps for 
policy solutions by comparing only a small number of possible alternatives which are not substantially 
different form the status quo. Accordingly, decision-makers will test the political waters in deciding 
whether or not to pursue a given course of action (Buse et al, 2010), these representing a contested 
and dynamic policy process.   
Resource allocation decision-making is a complex policy process that takes place along a continuum 
that moves from evidence generation to deliberation and communication of the decision made 
(Goetghebeur et al, 2008).  HTA is only a part of this intricate process whereby the best available 
evidence is assessed with the aim of informing decision-makers about the most efficient use of 
resources under conditions of uncertainty. Although country-specific HTA health organizations and 
processes vary according to setting, some procedural principles (such as transparency, robust and 
appropriate methods for combining costs and benefits, explicit characterization of uncertainty and 
active engagement with stakeholders) have been associated with the robust operation of HTA 
programmes and institutions (Drummond et al, 2008 and Chalkidou et al, 2009). Nonetheless, 
according to Pichon-Riviere et al (2010) in Latin America, including Colombia where this project was 
developed, “the current level of application [of these principles] is considered uniformly poor”.  
Problems with quantity, quality, usability and accessibility of evidence have been identified as 
hindrances to informed policy-making (Jewell and Bero, 2008). Randomised clinical trials (RCTs) 
traditionally considered as a reliable source of evidence-based information are extremely valuable, 
but not always feasible due to cost or ethical considerations. Whenever conducted, RCTs operate 
under experimental circumstances, with rigid protocols that often differ from “real-world” conditions. 
HTA is a technique with the ability to bring together evidence and data from a variety of sources; 
whenever it is used alongside economic modelling, HTA is able to simulate “real world” conditions 
(Hjelmgren et al, 2001).  
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HTA reports usually draw on evidence from a broad array of sources and types of data, including 
clinical, use of resources, unit costs and health-related quality of life information. Broadly speaking, a 
comprehensive HTA report usually consists of a description of technologies, a summary of the 
evidence on safety, efficacy and clinical effectiveness and sometimes incorporates economic 
modelling and budget impact. Sources are likely to include RCTs, but also observational studies, and 
in some circumstances, even poorer quality evidence, such as expert opinion. Data could also be 
gathered from sources close to where such a decision needs to be made or from elsewhere.  
Decision analytic models provide a means of bringing evidence altogether in order to generate 
estimates of cost-effectiveness (Drummond et al, 2005). Nonetheless, economic evaluation results are 
conditional on the data and structural assumptions they incorporate. If relying on modelling, a good 
analytic model should be able to simulate reality, capture relevant costs and outcomes, and be 
transparent and explicit about assumptions and limitations.  
Authors such as Box and Draper (1987) state that all models are wrong, but some are useful. Recent 
methods guidelines for economic modelling have produced recommendations for good practice 
(Phillips et al, 2004 and Eddy et al, 2012). Currently there is reasonable consistency about what is 
considered good practice. According to Sculpher et al, 2000, there are “good and bad” decision models 
which thus need careful review and evaluation to ensure the value of their input into decision-making 
(Drummond el al, 2005).  
One of the implications of making comparisons across different health care interventions through 
analytic modelling is that in order to help decision-making, costs and outcomes should be measured 
in comparable units across interventions, and a decision rule needs to be set. Whenever conducting 
cost-benefit analysis this problem is potentially solved since both costs and outcomes are measured 
in monetary value, and for a health technology to be considered “worth doing” total benefits must 
outweigh total costs. 
In the case of cost-effectiveness (cost-utility) analyses this decision rule is less straightforward. Costs 
are measured and expressed in monetary terms, but outcomes are stated in either “natural” or 
combined units capable of capturing morbidity and mortality to allow cross comparison (e.g. Quality 
Adjusted Life Year- QALY). Hence, a threshold or ceiling ratio is required to assist decision-making. 
Ideally, this ceiling ratio represents the opportunity costs of any forgone programme within the system 
or elsewhere or the willingness to pay (WTP) of decision-makers; thus this threshold serves as a 
decision rule for a technology to be deemed cost-effective or not.  
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Some countries have proposed or implemented ceiling ratios (cost-effectiveness thresholds) as 
decision rules (Eichler et al, 2004). Many examples have been historically or arbitrarily set, such as the 
“rule of thumb” in the US of $50,000 per QALY gained (Weinstein, 1995 and Hirth et al, 2000), in 
Canada of CAN$20,000 per QALY gained (Laupacis et al, 1992) or the UK (where the CE ceiling ratio 
used by NICE ranges from £20,000 to £30,000 per QALY gained (Hutton et al, Loomes, Littlejohns, 
Towse and Pritchard, 2002). However, this latter figure has been refined by recently collected 
empirical data and now the central estimate seems to be nearer £13,000 per QALY gained (Claxton et 
al, 2013). 
The use of cost-effectiveness ratios has been criticised by different authors (Birch and Gafni 1992, 
1993 and 2002; Johannesson and Weinstein, 1993 and Donaldson et al 2002) who suggest that 
thresholds may not be able to capture all the relevant benefits of health care programmes, there might 
be issues about the transferability of data incorporated, and they may well represent an aggregated 
Willingness to Pay (WTP) per QALY gained instead of the real shadow prices of the programme under 
consideration. However, it is unlikely that decision-makers will be fully aware of the costs and benefits 
of every competing alternative (within and outside the health care sector) each time a decision needs 
to be made. Further concerns arise when considering the implementation of cost-effectiveness 
thresholds in contexts severely constrained by scarcity of data, as these preclude the possibility of 
reliably estimating forgone opportunity costs should a new technology be incorporated into their 
health systems.  
Methodological considerations aside, neither HTA reports nor the results of economic models or cost-
effectiveness thresholds should be blindly used in decision-making. Beyond scientific evidence and 
thresholds, decision-making also requires value judgements to be made (Eddy, 1990 and Tunis, 2007). 
“Decision-making can be regarded as the cognitive process resulting in the selection of a course of 
action among several alternative scenarios. Every decision-making process produces a final choice” 
(Reason, 1990).  
According to Goetghebeur et al (2008), decision-making can be broadly subdivided into scientific and 
value judgment components. Scientific judgment relies on globally accepted standards defining the 
quality of evidence, this is not highly dependent on the evaluator and in principle could be 
standardised across jurisdictions. Value judgments, on the other hand, are subject to evaluator 
preferences and would be difficult to standardise. This value consideration also requires for well-
organised decision-making processes, according to Rawlins (2004) those responsible for formulating 
NICE's advice have to make judgments both about what is good and bad in the available science 
(scientific value judgments) and about what is good for society (social value judgments). 
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It is worth mentioning that any viewpoint assumed during the analysis has an influence both on 
measurement and on the final decision made (Drummond, 2005). Decision-makers often represent a 
broad scope of individuals with different roles within the health and health care sector, ranging from 
clinical practitioners (micro level decision-makers) to those in charge of coverage and reimbursement 
policies for health care technologies (macro level decision-makers). According to Garrison et al (2007) 
decision-makers are increasingly seeking evidence on costs and outcomes on which to base their 
conclusions.  
Health care resource-allocation decisions are complex and involve the assessment and appraisal of 
available evidence, while bearing in mind societal values and ethical considerations (Miot et al, 2012). 
Most of the published literature on priority-setting and decision-making has focused primarily on the 
technical aspects of quantifying the burden of disease or assessing the cost-effectiveness of different 
interventions. Although these are relevant inputs into the process, priority-setting as a whole is a 
wider political process because it involves the distribution of benefits and responsibilities among 
society (Glassman et al, 2012).   
In many developing countries priority-setting and resource-allocation decision-making has been 
inconsistent and unstructured. Important criteria such as budget impact, equity, and disease severity 
have not always been taken into consideration, and if they have, it has often been in an ad-hoc manner 
with limited acknowledgement as to how they have impacted a final decision (Baltussen et al, 2006). 
In these cases the lack of coherence between limitless promise and limited resources leads to implicit 
and covert rationing through waiting lines, low quality, inequities, and other mechanisms (Glassman 
et al, 2012). 
In recent years Multi Criteria Decision Analysis (MCDA) has emerged as a tool to support complex 
decision-making in health care, moving beyond the evidence generation phase. Multi- criteria 
methods are designed to help people make ‘better’ choices when facing complex decisions involving 
several dimensions. “MCDA are especially helpful when there is a need to combine “hard data” with 
subjective preferences or make trade- offs that involve multiple decision-makers” (Dolan, 2010). In 
theory, MCDA allows a structured and objective consideration of the factors that are both measurable 
and value-based in an open and transparent manner (Baltussen et al, 2006). 
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In 2008 Goetghebeur et al conducted extensive analyses of the literature and documented decision-
making processes worldwide. They explored the steps used to make decisions (from evidence 
generation to communication of decisions) with the aim of constructing a MCDA framework able to 
capture the quantifiable components of decision-making into a matrix, thus the Evidence and Value: 
Impact on Decision-Making (EVIDEM) was developed. It includes core quantifiable components 
alongside a methodology to synthesise the evidence needed to assess each component.   
EVIDEM (according to the original authors), promotes transparent and efficient health care decision-
making through the systematic assessment and dissemination of the evidence and values on which 
each decision is based. Modified versions of the EVIDEM framework have incorporated additional 
criteria and been tested for clinical and resource-allocation decision-making in developed and 
developing countries including Canada, US, Nepal and recently in South Africa (Goetghebeur et al, 
2010 and 2012, Tony et al, 2011, and Miot et al, 2012). 
In the case of countries where no cost-effectiveness thresholds have been discussed or accepted, 
MCDA may have space to incorporate cost implications and societal values to rank health care 
interventions, departing from the “hard” methodological constraints imposed by unmeasured 
opportunity costs. Indeed, it has been stated that MCDA can be an important step toward rational 
priority-setting in developing countries (Baltussen et al, 2007, Miot, 2012).  
 
3. Colombia´s current problems prioritising and allocating resources for health care, and its 
recent interest in priority-setting and HTA 
Since the 1993 health sector reform (HSR), access to health care in Colombia has been facilitated by 
the issue of statutory health insurance which covers an explicit list of health care benefits (POS)9. As 
part of this reform, coverage is guaranteed and financed from contributions of employers and 
employees in the formal sector, and poor and unemployed citizens are subsidised by the Government 
via earmarked taxes. According to figures published by the Colombian Ministry of Health and Social 
Protection (MoHSP), Colombia invests 6.5-7.4% of the country´s GDP in health and POS now covers 
nearly 96% of the country´s population10. Many macro performance indicators have improved since 
the HSR was introduced (The World Health Organisation-WHO/ PAHO health indicators and Escobar, 
2005), nonetheless the country struggles to set priorities and allocate resources for health care in an 
efficient manner.  
                                                          
9 POS: Mandatory Health Plan, Spanish acronym 
10 46 million inhabitants by 2011 
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The first list of health care benefits, established in 1994, was thought to be inequitable (less 
comprehensive for those covered by the subsidiary scheme) and not regularly updated to reflect the 
growing availability of newly developed technologies. As such, the explicit benefits package was often 
challenged by patients who, via exceptional requests and judiciary claims (CTCs and tutelas) 11, were 
granted access to services that had not been initially budgeted for. Between 1999 and 2012 tutelas 
regarding health and health care services increased from 21,301 to 114,343 per-year respectively 
(Caballero- Uribe, 2012 and Defensoría del Pueblo, 2013). Unsurprisingly this has caused a strain on 
the public budget for health. 
Figures from the MoHSP estimated that up to 25% of total health spending was used to reimburse 
services not originally listed in POS. Most beneficiaries of these exceptional health services are wealthy 
and well-educated individuals, and just a few belong to the poorest quintile of the population.  At the 
peak of the crisis, the constitutional court mandated the government to amend any structural factors 
leading to inequitable coverage, and to update and equalise POS content for the entire population as 
soon as possible, all of which caused an additional financial burden to the system.  
In late 2009 the then president of Colombia announced a COL$2 billion (USD$ 1.045 billion)12 deficit 
in the health budget. The country is in epidemiological transition, and the strain has been exacerbated 
by soft entry criteria for new technological developments. The current government, elected in late 
2010, pushed by the financial crisis has attempted two major HSRs and taken incremental steps to 
control costs and strengthen its institutional capacity. In December 2011, in compliance with the 
constitutional court´s mandate, POS content was updated by the Regulatory Commission for Health 
(CRES). However, it received considerable criticism from the media13 and the academic community 
due to the inadequate use of evidence and weakness of methods, but also the lack of transparency 
within the decision-making process.  As part of the government´s efforts to set priorities for health, it 
created IETS in September 2012, disbanded CRES in December 2012, and re-assumed its role of 
resource-allocation decision-maker; nonetheless the process of incorporating HTA in a more 
systematic fashion is still under construction.  
 
 
 
                                                          
11 CTCs (Technical Scientific Committees) and Tutelas (Judiciary challenges and verdicts from the courts) are the exceptional mechanisms of 
citizens to access non POS services in Colombia. 
12  Currency exchange rate on July 12th 2013 at www.oanda.com. Notice a language difference on definition of billion. For billions measured 
in Spanish subtract 000 (divide by 1000).  
13 From press releases on POS update,  see editorials from el colombiano and el tiempo on reference section 
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Up until the establishment of IETS, HTA had played a limited role in Colombia in terms of providing 
information to set priorities, allocate resources or formulate evidence-based policies for health and 
health care.  However, a limited number of Colombian universities, out of academic interest from the 
late 1990s onwards have been involved in producing HTA reports.  Moreover, in recent years the 
Colombian pharmaceutical industry and international organisations like PAHO have requested HTA 
information to these institutions to inform their market access strategies or vaccination policies 
respectively.  
During the last decade the MoHSP, regional secretariats for health, former CRES and pharmaceutical 
companies have been the predominant users of HTA in Colombia, and a limited number of academic 
institutions the producers. A preliminary exploratory research on the feasibility to institutionalise HTA 
in Colombia conducted by the main researcher (Castro, 2011) found a positive social mood on the 
need to have rigorous HTA information to support decision-making; especially the central government 
and health care insurers are prompt to use it, however the level of support on HTA policies varied 
among stakeholders, being the pharmaceutical industry and the healthcare professionals the most 
reluctant to its implementation.   
 The government’s interest in relying on scientific evidence to better inform health policies began in 
the mid-2000s (IDB project 2011) but it has only been in the last two or three years that the methods 
and processes for assessing health technologies akin to those used by NICE in the UK or PBAC in 
Australia have attracted the attention of policymakers. Periodic meetings and technical support, 
especially from the international branch of NICE, have been influential.  
Technical aspects such as economic modelling and the use of the Quality Adjusted Life Year (QALY) as 
a relevant outcome unit have recently been used in constructing a set of 24 clinical practice guidelines 
commissioned by the MoHSP and the National Administrative Department for Science, Technology 
and Innovation (COLCIENCIAS) and released in July 201314. In Colombia there is no systematic process 
in place to set priorities, there is no “reference case” to standardise methods or methodologies to 
produce HTA, nor is there a transparent or active engagement process with stakeholders for coverage 
decision-making. 
 
 
 
                                                          
14 See the ToR of CPGs at http://www.COLCIENCIAS.gov.co/convocatoria/convocatoria-para-la-elaboraci-n-de-una-gu-metodol-gica-para-el-
desarrollo-de-gu-de-pr- 
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Despite current efforts, the system´s allocation of health care resources is still far from efficient and 
equitable. For example, up to late 2011 POS did not cover mammography testing for diagnosing breast 
cancer in women in the lowest socio-economic quintile of the population, whilst access to newly 
developed Monoclonal Anti-Bodies (MAB) for advanced cases of disease was granted via “tutelas” (De 
Charry et al, 2008). Further, effective coverage was not guaranteed for the poorest the population15 
(Florez and Soto, 2007) and the level of catastrophic health expenditure for households remained 
significant (Xu et al, 2003).  
A further example is the case of Fabry16 disease, a rare condition that affects a total of 31 to 37 citizens; 
opportunity costs of treatment for this health condition are equivalent to enrolling 664,000 additional 
people in the subsidised scheme (cited by Glassman et al, 2012). Some non-POS health care services 
prescribed and reimbursed via exceptional mechanisms are considered either as luxury goods or 
experimental interventions with no robust evidence whatsoever (e.g aesthetic procedures, fertility 
treatments, and equine or bird therapy for cerebral palsy)17. Off-label prescribed medicines were 
reimbursed by the system without any control. For example, bevacizumab was registered by the local 
authority, INVIMA,18  for use in the treatment of metastatic colorectal, lung and kidney cancer, and 
glioblastoma, but it was prescribed, used and reimbursed for age-related macular degeneration via 
tutelas.  
It seems from these findings that decision-making in Colombia has been ad-hoc and has not 
considered the best available evidence or the opportunity costs of decisions made. It may also not 
have explicitly considered good HTA practice or societal values or preferences. In this somewhat 
chaotic scenario, many health conditions and technologies are competing for public funding without 
a systematic and transparent process of resource-allocation in place.  
 
 
 
 
 
                                                          
15 Source: “Así vamos en salud 2007”- Equity comparison by gender, location and income. Universidad de los Andes. Fundación Corona at 
http://www.asivamosensalud.org/descargas/Presentacion_Equidad_Corona_DNP.pdf 
16  Fabry disease (also Anderson-Fabry disease, angiokeratoma corporis diffusum and alpha-galactosidase A deficiency).  Rare X-
linked (inherited) lysosomal storage disease, causes a wide range of systemic symptoms. The disease is named after Johannes Fabry. Source: 
James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. P 538 
17 According to datasets of FOSYGA (national funding pool) and the MoHSP years 2008 onwards 
18 INVIMA National Agency for Surveillance of Medicines and Food of Colombia 
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4. Severe haemophilia A and the availability of evidence on the clinical and cost-
effectiveness of primary prophylaxis 
Haemophilia A is an infrequent inherited disorder of blood coagulation, characterized by a permanent 
tendency to haemorrhage. Classic haemophilia (also known as type A), results from a deficiency of 
clotting factor VIII (FVIII) as an X-linked inherited disorder (Stachnik, 2010). Patients usually remain 
asymptomatic until the haemostatic system is stressed by a surgery or trauma. Nonetheless, severe 
haemophilic patients can also bleed spontaneously. Haemophilia A is rare, but is the most common 
type of haemophilia and affects 1 in every 5,000-10,000 male births.  
Debuting age, location and frequency of bleeding are all dependent on the severity of the disease, 
which is categorised by the Level of Activity (LoA) of FVIII. Disease is classified as mild (LoA from 5-40% 
[0.05- 0.4 IU/ml]), moderate (LoA from 1-5% [0.01- 0.05 IU/ml]) and severe (LoA less than 1% [<0.01 
IU/ml]) (White et al, 2001). Around 70-80% of all bleeding episodes occur in the joints (most frequently 
the knee), which leads to haemarthrosis (joint haemorrhage with pain and swelling) (Stachnik, 2010, 
Wong and Vdovin et al, 2011 and Kempton et al, 2012).  
Cumulative chronic bleeding episodes in the joints leads to progressive and chronic damage and 
scarring (haemophilic arthropathy); this is the most important long-term complication of recurrent 
bleeding (Wong et al, 2011). The development of clotting factor inhibitors (a neutralizing 
immunoglobulin which acts directly against FVIII) is also a serious and frequent complication 
associated with chronic exposure to exogenous clotting factor that may occur in up 30% of all cases 
of disease (Collowick et al, 2000 and Farrugia et al, 2013). Different therapeutic options for inhibitors 
have been trialled in recent years with different levels of success [high doses of FVIII or FEIBA19 (rFVIIa 
or APCC)]. 
There are two predominant approaches to treating severe haemophilia A. The first is on-demand (OD) 
administration of exogenous clotting factor either plasma derived (FVIII) or recombinant (rFVIII20) 
whenever joint or extra-articular bleeding occurs.  The second approach provides exogenous clotting 
factor to prevent patients from bleeding (prophylaxis) in this first instance and thus, developing 
arthropathy.  There are two forms of prophylaxis: primary and secondary. Primary prophylaxis (PP) 
provides frequent (typically at least three times a week) administration of missing clotting factor at 
early stages of life or once the first bleeding episode has occurred. Secondary prophylaxis on the other 
hand refers to the use of clotting factor after joint damage has already occurred, but prior to elective 
surgery or expected joint stress in order to reduce further joint injury.  
                                                          
19 FEIBA- Factor VIII Inhibitor Bypassing Activity [FVIIa- Activated Factor VII or APCC- Activated Prothrombin Complex Concentrate] 
20 rFVIII refers to the recombinant (synthetic) form of clotting FVIII. 
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PP has proven more effective in reducing joint sequelae than OD, and is currently considered the gold 
standard of care, especially for younger patients in HICs21  (Biss et al, 2008). In spite of this, OD 
treatment is still the prevailing approach in many affluent settings and more so in resource 
constrained contexts because PP is usually more costly to provide (Giangrande, 2004).  
In 2012 Castro et al conducted a search of the literature about the history and evolution of the clinical 
effectiveness of treatment for haemophilia type A. According to a number of studies, in the 1930s 
average life expectancy of haemophiliacs was less than 11 years, treatment was merely ‘supportive’, 
and death was commonly associated with severe intracranial or joint haemorrhage.  
In the 1940s, whole blood transfusion was introduced which enabled swifter access to treatment; as 
a result, life expectancy reached 39.7 years for American haemophiliacs in the post-World War II era 
(Lee, 2009). After 1964, when Pool discovered that cryoprecipitates22 were able to restore clotting 
function to normal, life expectancy of haemophiliacs who received this treatment reached 60 years. 
Nonetheless disability rates remained high due to cumulative joint damage associated with each new 
bleeding episode (Wong et al, 2011).  
During the late 1970s Nilsson and Ahlberg in Sweden pioneered a prophylactic scheme in which FVIII 
was regularly administered in order to prevent bleeding and avoid subsequent joint damage. Life 
expectancy for these patients reached an average of 68 years (Larsson, 1985). Currently in HICs life 
expectancy of mild and moderate haemophiliacs is around 70 years (close to that of the general 
population), whilst severe cases are still expected to live at least 15 years less than general population 
(Darby et al, 2007). Prophylaxis has been associated with the consumption of additional resources; 
these could be at least twice the average cost per-patient, when compared with OD treatment (Daliri 
et al, 2009).   
Regardless of this progress, in 1982 the first US haemophilic patient that had been infused with plasma 
derived FVIII infected with HIV 23  was diagnosed as positive. By the early 1990s HIV reached a 
prevalence of 60 cases per million in the USA, and 1 in every 7 haemophilic patients in the UK was 
infected (Evatt, 2006). In the same decade HIV/AIDS was the cause of at least a quarter of all deaths 
among haemophiliacs in the Netherlands (Ragni et al, 1986, Chorba et al, 1994, and Triemstra et al, 
1995). In 1992 an estimated 60% of all haemophiliacs, and 80% of all patients ever treated in the US 
with plasma-derived products had also become infected with hepatitis C (Makris et al, 1993  and Van 
Der Poel et al, 1991). It was only after the introduction of antiretroviral therapy (ARVT) that mortality 
from HIV in haemophilic patients decreased (Mocroft et al and Porter et al, 2003).  
                                                          
21 HICs- High Income Countries 
22 The cryoprecipitate fraction of plasma contains proportionally greater quantities of FVIII.  
23 HIV- Human Immunodeficiency Virus 
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Viral attenuation processes against the transmission of HIV and HCV 24  were introduced in the 
manufacture of FVIII concentrates in 1985 (Oldenburg et al, 2009). New technological developments 
led to the first successful treatment with recombinant (synthetic) factor VIII- rFVIII reported in the 
literature in 1987 (Mannucci et al, 2001). rFVIII concentrates have, over the years, practically 
eliminated the risk of blood-borne infections through human or animal plasma products (Oldenburg 
et al, 2009). Indeed, there has been no reported HIV transmission linked to the use of rFVIII in the 
developed world since 1985, and virally safe products for hepatitis C have been available since the 
early 1990s (Van Der Poel et al, 1991).   
Current methods of viral inactivation, such as improved viral-depleting processes, nano-filtration and 
donor screening practices, have resulted in safer plasma-derived clotting products and greatly reduced 
the risk of transmission of HIV, hepatitis B and C viruses, amongst others (Mannucci et al, 2001). 
According to Farrugia et al (2013) “we are currently facing an era of safe FVIII concentrates”. 
Nevertheless there are no screening tests available for the detection of prions, including the presumed 
causative agent of variant Creutzfeldt-Jakob disease (vCJD). Precautions are largely based on donor 
exclusion, and although no cases of the classic or variant form of CJD have been reported in 
haemophiliacs anywhere in the world or after long periods of observation in the UK, uncertainty still 
remains particularly over the threat of as yet unknown ‘future’ pathogens (Giangrande, 2002; Darby 
et al, 2007).    
The evidence base on the effectiveness of haemophilia A treatment has grown exponentially in recent 
decades, and although controlled studies remain the exception, a main concern of researchers now 
relate to the cost-effectiveness of PP and treatments for clotting factor inhibitors, especially in settings 
affected by the global economic downturn, and with competing demands on health care budgets 
(Castro et al, 2012). Long-term allocation concerns are expected to grow in the near future as longer 
acting exogenous clotting factors are in development by pharmaceutical companies, and will soon 
enter the market. According to O´Mahony (2011) and Farrugia et al (2012) all these factors are leading 
both advisory bodies and payers to explore HTA to obtain recommendations for reimbursement 
policies.  
 
 
 
                                                          
24 Hepatitis C Virus 
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In contrast with this increasing stock of knowledge on the clinical effectiveness of the prophylactic 
administration of exogenous clotting factors, published economic evaluations of haemophilia care 
remain very limited and their results are inconclusive  For example, a recent review of the literature 
by Miners (2013) found that while a number of economic evaluations of prophylaxis with FVIII have 
been undertaken, their results vary enormously from it being “dominant” to costing over €1 million 
per QALY gained.  
According to this review, only 11 published studies had conducted some form of full economic 
evaluation25. All studies have adopted different perspectives, made different structural assumptions, 
used different time horizons, discount rates and sources of data. A salient finding from this review was 
that “all the reviewed studies contained methodological weaknesses, but some were considered 
weaker than others” (Miners, 2013); and nearly all costs of treatment were attributable to clotting 
factor provision.  
From this wide range of published results it is still unclear if this intervention (either with FVIII or rFVIII) 
has reached the point of being considered “good value for money”. It is worth mentioning that even 
if prophylaxis is “worth-doing” in HICs, it might not be the case for all countries (Geraghty et al, 2006 
and De Moerloose et al, 2008). Most of the published evidence on the clinical effectiveness and cost-
effectiveness of prophylaxis comes from affluent settings.  According to Giangrande (2004), the 
prognosis for haemophiliacs is still bleak in many parts of the world. The World Federation of 
Haemophilia (WFH) estimates that two thirds of haemophiliacs worldwide receive little or no 
treatment for their condition. For instance 45% of the world´s population lives in India, Bangladesh, 
China and Indonesia: while 10% of diagnosed patients with haemophilia are located in these countries, 
their consumption of clotting products available in the global market for treatment is only 2%.  
5. The current context of severe haemophilia A  in Colombia 
In Colombia, haemophilia A care represents an important financial burden to the health system. Costs 
associated with clotting factor replacement for this condition were COL$140,164,400,000 (USD$73.72 
million) in 201026 or 0.46%27 of the country’s annual spending on health with the aim of treating 
approximately 2,000-2,600 patients, 800-1,040 of whom are classified as severe cases (Colombian 
League for Haemophilia (CLH), 2011).   
 
                                                          
25 Those considering the costs and health outcomes associated with treatment and  complications 
26 Figures published by the Colombian Medical Federation- FMC in October 2010. See http://www.observamed.org/ 
27 These costs do not include inpatient or ambulatory care arising from bleeding episodes or their complications, or the costs arising from 
the use of rFVIIa for patients with inhibitors 
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Primary prophylaxis (PP) and on-demand (OD) approaches to treat haemophilia A co-exist in Colombia 
with OD treatment based on plasma-derived products predominating clinical practice (National 
registry for medicines, SISMED, 2010) 28 . Nevertheless, the use of prophylaxis and recombinant 
therapy has steadily grown over the past seven years.  
There are no evidence-based clinical practice guidelines in place for this health condition.  Half of the 
haemophilic population in Colombia is under 18 years of age, and although mandatory insurance 
coverage for haemophiliacs has risen from 65% to 85% in the past five years, and death rates 
associated with bleeding episodes have decreased, long-term clinical outcomes are still far from 
optimal. Haemophilic arthopathy with its subsequent impact on health related quality of life (HR-QoL) 
and long-term disability is still a frequent finding (CLH, 2011).  
There are eight or nine registered centres for haemophilia care with heterogeneous levels of quality 
in Colombia according to the National Superintendence for Health (SNS). Haemophilia care while 
competing with other priorities has raised the awareness of the general public and seized the 
attention of the media and local Government in recent years. This is not only because, of all the 
orphan29 conditions, haemophilia accounts for the biggest proportion of the population, but also 
because not even in the upcoming new HSR has the issue of sustainable funding for orphan conditions 
been solved.   
In 2010, law 1392 stated that patients with orphan diseases should be granted access to quality health 
care and reimbursed via exceptional mechanisms. This law created confusion because it defined 
orphan diseases as those with a prevalence of less than 1 case per 2,000 people and categorised them 
in a similar way to neglected diseases.  This frequency definition, which is higher than global standards, 
raised considerable criticism from the media and expectations of full coverage30 from patients. The 
local confusion over the definition of “neglected” versus “orphan” diseases was resolved in further 
legislation enacted in January 2011 (Law 1438) and a new, more evidence-based definition of less than 
1 case in every 5,000 people for orphan conditions was issued.  
 
 
                                                          
28 According to internal data from the Colombian League for Haemophilia in 2010 nearly 34,000,000 IU of FVIII were sold in Colombia 
compared with 26,685,000 IU of rFVIII. 
29 Orphan means a rare disease. According to US criteria, an orphan disease is one that affects fewer than 200,000 people. The EU definition 
is less than 5 cases in 10,000. WHO suggest a frequency of less than 6.5- 10 in 10,000. In Colombia law 1438 defined orphan diseases as 
those affecting less than 1 person in every 5000 people. There are more than 5,000 such rare disorders. Source: 
/http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885017   
30 See press releases at http://www.elespectador.com/columna-211633-ley-sobre-enfermedades-huerfanas and 
http://www.prismatv.unal.edu.co/nc/detalle-serie/detalle-programa/article/enfermedades-huerfanas.html 
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The fifth international “rare disease day” on 29th February 2012 served as a focusing event for pressure 
groups. The former Colombian Minister of Health released a public statement backing the system´s 
commitment to provide and reimburse health care outside POS content in all cases of orphan 
diseases31 (including haemophilia). The (SNS) was commissioned to collect and update the list of 
queries and claims arising from faulty health care for patients suffering from orphan diseases. 
Although the commitment to exceptional mechanisms to grant unrestricted access to health care for 
this population was maintained, such access has not yet been accomplished since prophylaxis has not 
been explicitly included in POS. 
According to Rawlins (1999), “clinical care given to patients frequently departs from best practice; the 
fast adoption of new technologies without certainty about its clinical and cost-effectiveness, but also 
the slow adoption of those proven to be effective and “good value for money”, leads to inefficiency”. 
The case of severe haemophilia A, serves as a good example of how the progressive adoption of newly 
developed health care technologies can dramatically change the natural course of a historically fatal 
disease while challenging the financial sustainability of health systems. Haemophilia A has become a 
chronic and ‘manageable’ condition nowadays. Although this represents a remarkable achievement 
for science, it creates an additional burden for health systems due to longer survival rates and costly 
lifetime replacement therapy (Castro et al, 2014), Colombia is no exception.  
Colombia has faced in recent years a financial and “lack of trust” crisis within its health care system 
that has threatened its sustainability.  After two attempted reforms (Laws 1122 of 2007 and 1438 of 
2011) the country still struggles to set priorities in a systematic and transparent manner. Yet there is 
a global trend to use or institutionalise HTA to inform coverage decision-making in many parts of the 
world that has seized the attention of local policy makers. Just recently this country established its 
own HTA agency, however the contextual aspects that may facilitate or hinder successful HTA 
implementation have not been yet explored. Since resource allocation decision-making is an intricate 
process that goes beyond HTA methods and institutions, the relevance of this work for Colombia may 
be of value for both producers and users of HTA. 
 
 
 
 
                                                          
31 Public declaration from the Minister of Health source official web page of the MoHSP on Feb 29 2011 
http://www.minproteccionsocial.gov.co/Paginas/Super%20Salud%20deber%C3%A1%20tener%20registro%20de%20quejas%20y%20recla
mos%20de%20pacientes%20con%20enfermedades%20huerfanas.aspx 
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II. AIMS, OBJECTIVES, METHODS AND TIMEFRAME OVERVIEW 
The overall aim of this thesis was to assess the feasibility of conducting and using HTA to inform 
decision-making in Colombia, using primary prophylaxis (PP) for the treatment of severe haemophilia 
A as the main example.  To achieve this, a mixed methods approach was used and is presented in 
three empirical chapters. In the first chapter qualitative methods are used to further explore past and 
future issues with respect to establishing formal HTA processes and methods in Colombia. The second 
chapter contains a cost-utility analysis of PP, as an example of how an economic evaluation for a 
challenging disease could be undertaken. The third chapter consists of a quantitative report of an 
attempt to use EVIDEM, as a framework for producing evidence-based guidance on four brief HTA 
reports, one of which is the expansion of the CUA of PP from Chapter 2 which was complemented 
with a “full” HTA report. In summary, the main questions that are addressed in the thesis chapters are 
as follows:  
 What are the main aspects that may help or hinder HTA development and use in Colombia?  
 What is the incremental cost-effectiveness of primary prophylaxis compared to on- demand 
treatment in Colombia?  
 Can EVIDEM be used in Colombia to assist resource-allocation decision-making, and should 
the use of primary prophylaxis be prioritised over three other non-haemophilia health care 
technologies?  
  
The dynamic process of using the available evidence to inform decision-making creates a continuum 
that favours the use of a case study. Case studies have been used to analyse health services elsewhere 
(Keen, 2007) and gained renewed interest in recent decades. The project was undertaken in London 
and Bogotá, Colombia, where relevant stakeholder interviews and meetings were held.  
A timeline is shown in Figure 1 to explain the evolution of HTA in Colombia, my role as main researcher 
within it and the relation of these changes impact on and relate to this thesis.  In an overall period of 
less than three years, the main researcher´s roles ranged from being a consultant at NICE international 
to becoming the Chief Executive Director of the Colombian HTA agency (IETS).  This timeline analysis 
also served to support reflexivity of findings as it is presented in the overall discussion session. The 
triangulation of results from interviews, observation and focus group improved their validity.  This 
comparison of findings is presented in the section titled convergent, divergent and contradictory 
findings.  
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Figure 1. Timeline, HTA evolution in Colombia and roles played by researcher throughout the project  
 
The issues around previous HTA work in Colombia were identified through qualitative enquiry 
methods using semi- structured interviews, which are reported in Chapter 1. The qualitative enquiry 
methods were used to assess the feasibility of conducting HTA as well as its potential future role in 
Colombia. A series of semi-structured interviews helped to explore previous experiences of academics 
devoted to HTA over the past years, and also to explore their perception of the potential use HTA may 
have in the near future.  
The treatment for SHA was chosen as a case study to develop an economic evaluation in Colombia, 
since no local HTA for this health condition has been developed so far, it has captured substantial 
media attention in recent times and there is still the political promise of limitless health care coverage 
for orphan diseases. To do this, a de novo Cost-Utility Analysis (CUA) comparing PP versus OD 
treatment for severe cases of disease was conducted. This also served to identify methodological 
aspects that may make HTA and economic modelling difficult in Colombia. 
Finally, to assess the feasibility of HTA as a tool to assist decision-making, the MCDA framework known 
as EVIDEM was tested in a focus group resembling decision-makers comparing four mini HTA reports 
(including the expanded CUA form chapter 2). This also explored the needs and expectations of 
participants regarding HTA and the use of broader decision-making criteria; findings are presented in 
chapter 3. Participants in the focus group appraised HTA results of PP with FVIII for SHA with three 
other non-haemophilia health care technologies (zinc supply for diarrhoea prevention, anastrozole for 
breast cancer and ticagrelor for acute coronary syndrome). These were chosen for convenience by the 
researcher, since all three have recently had Colombian HTA summaries published, and are on the 
waiting list of technologies to be incorporated into POS. This focus group also acted as a pilot to advise 
the Colombian MoHSP on how to design a more systematic and transparent process to update the 
publicly reimbursed benefits package (POS) and incorporate the use of budget impact analysis into 
the process.  
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A detailed description of methods and findings is presented in each one of the empirical chapters, as 
follows: 
1) CHAPTER 1: Exploring the issues of previous experiences of conducting HTA, and academics’ 
perception of its role and future use in Colombia. 
2) CHAPTER 2: Cost-utility analysis of primary prophylaxis for the treatment of severe 
haemophilia A in Colombia. 
3) CHAPTER 3: Testing the MCDA-EVIDEM and the use of HTA for resource-allocation decision-
making in Colombia.  
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III. EMPIRICAL CHAPTERS 
 
1. CHAPTER 1- Exploring the issues of previous experiences of conducting HTA, and academics’ 
perception of its role and future use in Colombia: 
INTRODUCTION: 
The aim of this chapter is to identify and assess the various factors that may facilitate or hinder HTA 
production, and use, as a source of evidence-based information for decision-making in Colombia. As 
previously mentioned, common motivations for establishing HTA processes and agencies across the 
globe are the growing costs of health care, uncertainty about the cost or effectiveness of new and 
existing technologies, and the variability of clinical practice. HTA has become a focal point for the 
support of priority-setting in many countries which are dealing with budget constraints, expanding 
expenditure for health care, and market pressure for the entry of newly developed technologies.  
Increasing interest from different countries in developing or improving more systematic and 
transparent processes to set priorities and allocate resources has created a propitious trend for HTA 
and EBM to emerge and grow. According to Drummond et al (2000) country specific variables such as 
history, culture, politics, health-care systems organisation and rationale for undertaking HTA should 
be considered before implementing its use. HTA also seems to be surrounded by political and social 
values that need to be borne in mind alongside good methodological practice. Colombia is no 
exception and there is an opportunity through this research to identify those aspects that may help 
or hinder HTA development and use in this country. 
Colombia itself poses a challenge to conduct HTA because necessary data about disease incidence, 
prevalence, use of health care resources, and costs may be scarce or not available for many health 
conditions. Therefore, it is important to explore the needs and expectations of those devoted to HTA 
work in this interest. Authors such as Drummond et al, 2008 and Chalkidou et al, 2009 have identified 
some procedural principles associated with the robust operation of HTA programmes and institutions. 
Nonetheless, according to Pichon-Riviere et al (2010) in Latin America including Colombia, “the current 
level of application [of these principles] was considered uniformly poor”. All these aspects are 
explored in this chapter through qualitative enquiry methods with the aim of answering the research 
question of interest.  
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METHODS: 
To answer the empirical research question: What are the main aspects that may help or hinder HTA 
development and use in a setting such as Colombia? The in-depth semi- structured interview approach 
was selected as a means to collect data, and thematic content analysis was used to analyse it. As with 
many other forms of qualitative methods of data collection, the interviews aimed to collect data from 
a small sample of participants, since the size of sample was not determined by the need to ensure 
generalizability, but by the desire to fully investigate the topic of interest and gather information-rich 
data (Grbich, 1999).  Another reason for selecting this frequently used approach (Green & Thorogood, 
2009) was its usefulness for answering questions about salient issues among particular groups of 
participants.  
“The most basic way of characterising qualitative studies is to describe their aims as seeking answers 
to questions about the “what”, “how” or “why” of a phenomenon” (Green and Thorogood 2009). 
These studies are usually conducted to understand more about phenomena, rather than measuring 
them.  For the purpose of this chapter, qualitative enquiry methods were used to explore the issues 
of previous experience of conducting HTA in Colombia from the perspective of local academics 
involved in HTA research over the past decade, and to examine their views of the potential use of HTA 
in this context. 
Qualitative research methods are designed to test or build theories, but many others are designed to 
address empirical questions without any explicit theoretical aims (Green & Thorogood, 2009). Analysis 
of qualitative data has largely focused on three methodological approaches: grounded theory, 
phenomenology and ethnography. Nonetheless, authors like Murphy et al (1998) recognise many 
other forms of qualitative enquiry (Awoko, 2001).  
All three classic approaches of qualitative enquiry were considered before selecting the most suitable 
approach for this study. In the grounded theory approach explicit data receives analytic treatment 
through constant comparison to produce a theoretical foundation.  The Glaser and Strauss (1965, 
1967) methodological strategy of theory generation was not followed in this part of the research since 
the aim was to explore and describe issues of previous experiences of conducting HTA in Colombia 
and not to build up new theory; neither there was an intention to move beyond description into 
conceptualization or theorizing Glaser (1992) and Kendall (1999). 
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Phenomenological inquiry was also considered. This interpretative approach focuses on interviewing 
and gaining understanding of the meaning of the participant´s experiences (Van Manen, 2001). This 
approach is concerned with individual experience, and aims to making the unspoken “audible and 
visible” (Awoko, 2001). In this particular case phenomenology was not used because the aim of the 
study was not to understand the “essence” of HTA as a phenomenon, but to understand the overall 
HTA context in Colombia; hence the “life- world” (the everyday world experienced and taken for 
granted and constituted by members within that world [Schutz, 1964 and 1970]) was not explored in 
this case study. 
Finally, ethnography which refers to methods of participant observation, but also to the product of 
the ethnographic investigation (Green and Thorogood, 2009) is aimed at understanding how beliefs 
are embedded in local cultures through living and working with the community. In the case of this 
study there was no intention to live or work with the HTA research community in Colombia to identify 
enablers or barriers, mainly because of time and budget constraints.  
Thematic content analysis, on the other hand, was selected over the above-described options of 
analysis, because it is an analysis of the content of collected data that allows researchers to look at 
data from interview transcripts to categorise participants´ accounts in a way that can be summarised. 
In this type of approach themes that recur or are common are classified, compared and categorised.   
Sampling 
Purposive sampling was used in this part of the research, and concurring with Crookes and Davis 
(1998), sampling was judgemental and involved the conscious selection of participants to be included 
in the study. In this case individuals with similar characteristics were considered eligible (local 
academics with at least five years’ experience of leading research groups working on HTA in Colombia). 
Relevant variables were established before sampling started (reputed academics, leaders of research 
groups, with relevant MSc or PhD degrees in topics related to HTA). A total of eight senior researchers 
throughout the country were identified as potential target participants. All names were extracted 
from a list of research groups registered and publicly available on the COLCIENCIAS web page and 
currently conducting HTA.32  
During January and February 2013 five out of these senior eligible researchers were invited to 
participate in a set of semi-structured interviews, the remaining three senior researchers were not 
invited because they belonged to institutions already represented by the first five eligible participants.  
                                                          
32 Look for GrupLAC y CvLAC at: http://www.colciencias.gov.co/scienti 
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The sample strategy was homogeneous in nature; nonetheless in order to capture maximum variation 
within settings (different institutions and regions), participants were selected from research groups 
representing different regions and institutions within the country (North- Caribbean, North-West and 
Central Colombia). No prominent research groups or academics fulfilling eligibility criteria were 
identified throughout sampling in South Colombia. All individuals received an information sheet and 
consent form in Spanish which explained the objectives of the study, and stressed that their 
participation in the study was completely voluntary (Appendix 9). Participants were asked to consent 
to being audio-recorded during the interviews. All forms complied with the London School of Hygiene 
and Tropical Medicine (LSHTM) ethics approval requirements for non- interventional studies). All 
participants gave consent to participate in the study and to be recorded.  
Interview procedure 
Each semi-structured interview was planned to last between 30- 40 minutes which was considered 
enough time to capture the salient findings.  The interview guide followed a pre-determined set of 
topics that included the individual´s knowledge and experience of conducting HTA, quantity and skill 
mix of the teams to which they belonged, availability of resources devoted to HTA, and possible 
barriers, facilitators and challenges to conducting HTA in Colombia.  
The first question about previous individual experience of conducting HTA served to validate the 
expertise considered in the eligibility criteria. The potential role of HTA in the near future and its 
feasibility to be used in decision-making were also explored in the interviews. Interviews were open-
ended to allow the participants to guide the discussion as much as possible, and to diverge if necessary 
in order to address ideas and concepts not anticipated by the interviewer (Britten, 1995). 
The main researcher (a Colombian medical doctor and doctoral candidate in public health and policy 
at the London School of Hygiene & Tropical Medicine who was recently appointed as the Chief 
Executive Officer of the new HTA agency in Colombia- IETS) personally conducted the interviews in 
Spanish, which was his and the participants’ native language. During the interviews the main 
researcher summarised comments from each participant and encapsulated those considered as 
potential barriers or facilitators for HTA in Colombia.  Interviews took place in quiet, private 
environments, two at the workplace of participants, two at a neutral venue selected by the main 
researcher, and one at the home of the participant. All interviews were audio recorded. 
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Analysis 
Once finished, each interview was transcribed verbatim by an independent transcriber. Each interview 
was then uploaded to ATLAS- ti7 as a new hermeneutic unit. No preliminary hypothesis was 
considered, and the researcher aimed to interpret data instead of simply describing it (Braun and 
Clarke, 2006).  
Before starting coding, a panel comprising of the main researcher and two independent advisors (a 
psychologist and an engineer, both professors of qualitative methods at Pontificia Universidad 
Javeriana in Bogotá, Colombia) was set up to decide on a pre-selected labelling scheme of potentially 
emerging codes. This scheme took into consideration the guide of pre-selected topics discussed during 
the interviews, and later added labels to account for changes in time and their perceived level of 
importance as potential barriers and facilitators not only for the development, but also for the use of 
HTA to inform decision-making in Colombia.  
The first coding stage was independently performed by the main researcher and carried out in parallel 
by each one of the advisors. Instead of using the “scissors and paste” method described by Krueger 
and Casey (2002), all data were coded using ATLAS- ti7 based on memos and quotes selected by the 
research panel. Combined quotations considered as relevant were pre-selected for further analysis by 
the panel after this first round of coding. 
To enhance the rigour of research, a second panel meeting was held in April 2013 to analyse emerging 
data and decide on a potential taxonomy of codes. After this meeting, the term “drivers” for 
conducting and/or using HTA in Colombia emerged instead of “barriers and facilitators”. A second 
round of coding was then started, this time performed solely by the main researcher. At this stage 
coding was open and looked at previously depurated quotations (controlling for coinciding coded 
quotes) looking for emergent “drivers”.  
A third and final panel session was held in June 2013 to refine the final taxonomy of codes selected as 
“drivers” by the main researcher, and also to analyse the potential relationship among codes and to 
control for the accuracy of translated quotes from Spanish to English. The detailed description of the 
context of interest, participants´ profiles and the emergence of “drivers” and their relationship are 
given in the findings section of this chapter. 
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RESULTS: 
Background of participants 
It emerged from the interviews that all participants were physicians; four were male and one female. 
Four were affiliated to academic institutions and one to a public hospital; all except one belonged to 
public organisations such as universities or hospitals. Four were active academics and one a research 
leader at a public hospital.  All except one had an MSc in Clinical Epidemiology; the other had a PhD in 
Health Economics. Most of the academics (three out of five) are located in central Colombia. Figure 2 
provides a detailed profile of participants. Figure 2 provides a detailed profile of participants. 
Figure 2. Profile of participants 
 
Depth and breadth of knowledge about HTA varied among participants. Most of them were familiar 
with EBM methods, especially with systematic reviews of evidence, meta-analysis and clinical 
effectiveness. Recently HTA methods such as economic modelling have been incorporated into their 
research. Only one of the participants was formally trained in health economics and economic 
evaluation for health care. Their experience of the methods for producing HTA reports was 
heterogeneous.  
Evolution of HTA and local capacity for HTA in Colombia 
It emerged from the interviewees´ responses that HTA was first practiced in Colombia during the early 
1990s when a limited number of academics who had studied overseas returned to the country and 
started producing isolated pieces of research using methods related to those of evidence-based 
medicine (EBM) and health technology assessment (HTA).  
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Gender Female Male Male Male Male
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In 1994, the first school of Clinical Epidemiology was established in Colombia (at Pontificia Universidad 
Javeriana) further influencing the establishment of another three schools33 around the country in the 
early 2000s. Over the past decade these institutions have promoted the use of evidence-based 
medicine (EBM) to inform clinical decision-making.  
From the “emic”34 experience of participants it seems clinical effectiveness was the dominant topic of 
research up to the mid-2000s, when economic evaluation, burden of disease and budget impact 
analyses were incrementally incorporated into HTA reports and research agendas.  The continuity of 
work and stability of research groups have steadily grown over the past 4 or 5 years. Each of the 
research groups (currently led by participants) has an average of 20 full time equivalent committed 
researchers. All groups are mainly project-based funded institutions with modest infrastructures. 
By 2009 at least five research groups were involved in conducting HTA in Colombia, all commissioned 
by the MoHSP and COLCIENCIAS. These groups developed 24 Clinical Practice Guidelines (CPGs) that 
included HTA and economic modelling aimed at informing both macro and micro decision-making. 
Over the past four years there has been an increasing academic drive to develop HTA to inform 
decision-making. 
The local capacity to produce HTA is limited. Participants estimated there are around 150 clinical 
epidemiologists in the country capable of conducting HTA. Nonetheless it is estimated that the total 
number of health economists or bio-statisticians suitable for this task is ten times lower. The early 
academic interest in producing HTA has evolved and HTA is seen as a potential aid for resource-
allocation decision-making and health care planning. Current users of HTA reports in the country are: 
the MoHSP, regional secretariats of health, hospitals and clinics, pharmaceutical industry and medical 
device developers, health care insurers, National Institute for Health, and the former Health 
Regulatory Commission (CRES).  
Besides the academic interest of research groups to develop HTA in Colombia, at the end of 2010 the 
government commissioned a project funded by the Inter-American Development Bank (IADB) which 
was technically supported by the international team of the National Institute for Health and Care 
Excellence, NICE, to inform a blueprint for the establishment of a local specialised HTA institution. In 
November 2012 this local HTA agency (IETS) started operations in Colombia, initially at the piloting 
stage.  
 
                                                          
33 Universidad de Antioquia (2002), Universidad de Cartagena (2003) and Universidad Nacional de Colombia (2006) 
34"The emic approach investigates how local people think" (Kottak, 2006): How they perceive and categorize the world, their rules for 
behavior, what has meaning for them, and how they imagine and explain things. 
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At the time of writing (November 2013) no academic institution in Colombia had formally established 
a postgraduate HTA specialised Master’s degree, although basic HTA training is provided as short 
courses in postgraduate Masters Degrees in Science (MSc).  The current MoHSP commissioned IETS in 
2013 to assess 105 health care technologies to update POS before the end of that year. 
During the first round of coding knowledge and previous experience regarding HTA, availability of 
resources devoted to the development of HTA, the perceived barriers and facilitators to developing 
HTA, and the possible future role of HTA in Colombia were used as static labels to code participants´ 
quotations. Nonetheless it emerged soon, after a deeper round of coding, that a sub-set of codes 
accounting for changes in time and their perceived level of importance were relevant when 
considering the aspects that may help or hinder HTA development and use.   
The emergence of “drivers” 
After the first round of coding a total of 684 combined quotations emerged from the interviews; these 
were pre-selected for further analysis by the research panel.  After the panel meeting in April 2013, 
the advisors agreed with the main researchers´ view that the terms “barriers” and “facilitators” 
considered before were rather static whilst the aspects that may help or hinder HTA seemed more 
dynamic and interconnected, hence the term “driver” for conducting and/or using HTA in Colombia 
emerged from discussion.  
A “driver” was defined as a factor that could potentially have an impact on the development or use of 
HTA (or both) in Colombia. The potential impact of a “driver” implied directionality, as either being 
positive (facilitator) or negative (barrier); the potential impact of a “driver” could be perceived as being 
high or low (levelled) at specific moments of time. A current positive “driver” could become negative 
and vice-versa depending on the context and its dynamic evolution over time. 
A new round of coding performed by the main researcher alone looked at 367 previously depurated 
quotations looking for “drivers”. Ten possible “drivers” emerged as codes for the development and/or 
use of HTA in Colombia. A third meeting of the research panel in June 2013 refined the names of two 
of the emergent “drivers” and also described the possible inter-connections and relationships 
between all of them. Figure 3 depicts the taxonomy and interaction of these “drivers” on the 
development and/or use of HTA in Colombia.  
The list of emergent “drivers” includes the following: availability and quality of data, cultural aspects, 
financial support, globalisation, health system context, implementation strategy, local capacity, policy 
and political support, stakeholder pressure, and usefulness perception. Each driver is described below. 
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Figure 3. Emergent drivers for the development and/or use of HTA in Colombia 
  
All “drivers” have a potential (positive or negative) impact on HTA in the years to come, but also 
harbour the dynamic potential to switch the directionality of their impact over time.  Some “drivers” 
were considered capable of operating in association or interdependently; for instance, 
implementation strategy could be associated with installed capacity, and installed capacity with 
resources devoted to HTA, but availability and quality of data could have a potential impact with no 
interconnection with any other “driver”.  
a) Availability and quality of data: availability of data refers to the concerns of participants 
about the amount and quality of local data available to support the development of HTA. This may 
have an impact on the internal validity of HTA results, extrapolation or generalisation of the findings.  
“[…] as far as I am concerned, one of the limitations when you are evaluating [HTA], uhm is related to 
costs information […] so you need to rely on experts’ estimations […] what is becoming necessary, 
absolutely necessary is to have our own parameters, local data […]”P2 
This driver accounts for the limitations of local information about the clinical effectiveness of 
interventions, probabilities, costs, and health state preferences, all necessary to populate robust 
decision-making models. The uncertainty of results had a potential negative impact that may prevent 
the use of HTA as a reliable source of information for resource-allocation decision-making: 
“[…] the complexity of the Colombian Health System implies high levels of uncertainty [...] probably in 
Germany, Holland or England their systems carry less uncertainty than we have here, this could be a 
point to start with [...]” P3 
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 “[…] the sources of data, so I think this is a big weakness […] economic models and in general studies 
[HTA] are as good as the quality of data one has available, and that is a big limitation for us and the 
system, I mean we need to know about costs, frequencies of use of resources, distribution of variables 
that one may use to populate the models […]” P2 
b) Cultural aspects: emerged as a “driver” related to context-specific conduct or behaviours that 
may have an impact on HTA. This refers also to social conceptions determined by local custom, 
meanings and beliefs with the potential to influence the development or use of HTA. Most emerging 
cultural aspects were identified as having a potential negative impact, for instance the lack of tradition 
of priority setting or relying on the best available evidence to inform decision-making or a lack of long-
term planning: 
 “[...] well, as far as I know people are not willing to prioritise […]” P3 
 “[...] there is a resistance to accepting technocracy in this country […]” P4 
“Decision-makers are able to make decisions without considering it [HTA] and as a matter of fact they 
have done this all the time [...]”P5 
“Self-criticism [...] uhm it is hard for us to ask for help, am I right? Or to envision long-term plans […]” 
P2 
A cultural reluctance of health care professionals to follow evidence to harmonise clinical practice and 
promote self- regulation also emerged from participants’ remarks:  
“[...] I think is a hurdle too […] uhm collective imagination […]this topic [HTA] becomes […] a pressure 
– being told how to do things [...] they [health care professionals] feel like it [HTA]is an imposition on 
their practice, one of them may say: “are you telling me how to do things? […] and what to prescribe 
or not? […] that part is a barrier and could hinder further [HTA] development […]” P1 
Although corruption is not a country specific phenomenon, it emerged as a source of concern for the 
successful implementation of HTA in Colombia, this representing the lack of trust among stakeholders 
within the current context in this country: 
“[...] corruption is worse now than ever, here it is very complicated […] I think the development of HTA 
in contexts with much lesser corruption must be easier […]” P3 
c) Financial support: this “driver” refers to the potential sources of funding that could promote 
the development of new and on-going HTA projects. It emerged that most of the funding for research 
centres is project based and envisioned as short-term, nonetheless the availability of financial 
resources for HTA projects has increased in recent years: 
 44 
“[…] so all funding is project based […]” P1 
 “[...] and also that now we count with budget for that [HTA] so, so we have funding […]” P4 
“[…] I think everything has happened for good […] uhm and nowadays […] we that work in this area 
have gained a reputation and […] that has been evident through the existence of budgets to conduct 
HTA[…]” P5 
It also emerged that financial support was usually associated with another “driver”, policy and political 
support. Participants believe funding within academic institutions and government agencies is 
associated with policy commitment to support long-term research.  
“[… ] at Antioquia University there are a number of annual calls for research proposals [… ] and there 
are also other resources, for instance there is one […] named sustainability funding[…] which allows us 
to have more or less stable staff and basic resources for the research groups to operate […]” P1 
“So far the Clinical Practice Guidelines programme [...]has money each year [...] this budget is not 
permanent, so it means it is environmentally dependent [political context][...] and they provide us with 
[...] people trained in epidemiology to focus on the CPGs development and some support for 
logistics[...]” P2 
“Yes, we have CINETS35 which is supported [policy and financial support] from three universities […] 
now we have financial support for a year […]” P3 
The policy implementation of establishing an HTA agency in the country is seen as a new opportunity 
for financial support and institutional strengthening: 
 “[...]the establishment of new institutions [IETS], the existence of budgets, so I mean before there was 
no way to finance projects [HTA] it was more the interest of a group, I think that has strengthened over 
time […]”  P2 
“[…] on the other hand, counting on resources to guarantee sustainability for us [research group] 
apparently that is an achievement with the establishment of the institute [IETS] […]” P3 
d) Globalisation: emerged as a “driver” that has influenced the development and use of HTA in 
Colombia. It refers to a perceived global and social trend to produce and use HTA to inform decision-
making in different countries.  
                                                          
35 CINETS- Centro Nacional de investigación en Evidencia y Evaluación de Tecnologías en Salud (National Centre for Research on Evidence 
and Health Technology Assessment) is a national think tank created by Universidad Nacional de Colombia, Universidad de Antioquia and 
Pontificia Universidad Javeriana. 
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“[...] I also think the international context, the way this topic has evolved in different countries and how 
those countries that valued HTA […] have attained good health outcomes […]” P1 
“[...] right now there is a trend about that [HTA] and that is a key, good or bad trend, but there is a 
trend to conduct this assessment [HTA], we live in an economists era […] an era of evidence and 
evidence-based medicine that started a long time ago, but right now has gained influence at 
government level, I think that is key […]” P4 
“[...]if it is used [HTA] as happens in developed countries to inform decision-making through evidence 
generation it may be able to contribute in a huge manner[…]” P5 
Globalisation has influenced academics who returned to Colombia to implement HTA research 
agendas after studying overseas. Most of the participants´ remarks regarding globalisation were 
considered as having a potentially positive impact. 
  “[...]a professor that studied HTA, a Master’s degree overseas and came back; precisely his first 
research project at the University was an HTA proposal […]in US at John Hopkins we have some of 
them, there is a young professor studying evidence-based health policies at the University of 
McMaster, also in England […]” P1 
Also the concept of an international “peer pressure” to get involved in HTA or an opportunity to work 
with international organisations in co-operative networks regarding HTA projects emerged. 
Globalisation may also have an influence on the social perception or “mood” about HTA´s potential 
usefulness, and also on the possibility of international co-operation for research: 
“[...] the constant international peer pressure has made researchers do it [HTA], with or without 
resources; many researchers are members of HTAi […] INAHTA […] members of ISPOR […] so this has 
created a peer pressure […]” P2 
“[…] the mood at the social level […] after the government has noticed this trend [HTA], let´s say 
economist reaching health trend […]” P4 
“[...] we are a centre of excellence regarding HTA development for vaccines for PAHO have worked in 
co-operation with Albert Sabin Institute from Washington DC [...] because it is a research network.” P5 
According to participants’ remarks, globalisation may carry a negative impact if skilled researchers 
leave the country to work overseas, this potential ‘brain drain’ may have a negative impact on the 
stability of research groups: 
 “[…] with health economists there is a […] bizarre story of people that have studied this topic [HTA] 
[…]this staff is the most volatile of all […] and the other one in Canada; actually there were five because 
another one was hired by IADB […] and the last one was appointed as the Chief Officer at IETS.” P4 
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Globalisation also raised concerns about the possibility of generalising HTA reports across borders 
without the careful consideration of its methodological limitations. This arose from the current limited 
perception about its usefulness. Potential caveats of extrapolation of results, and a lack of confidence 
in HTA work produced by international think tanks also emerged:  
 “[...]if it works in US you could assume it also works in Colombia, so to conduct economic evaluation 
usually parameters of efficacy and effectiveness are extrapolated from other countries, what becomes 
necessary, absolutely necessary is to have our own  parameters, local data […]” P5 
“[...] from other countries clearly they have a vested interest to sell their products [HTA related] and 
sometimes they are not the best, but foreigners anyway […]” P4 
e) Health system context: the health system structure, the current context of financial crisis and 
the macro performance indicators emerged as a “driver” for potential HTA development and use in 
Colombia; this was labelled as health system context. The need to regularly update POS content, 
making use of the best available evidence, emerged as having a potential positive impact on HTA 
development: 
“[...] need, I feel right now the system which for a while has experienced complicated issues from all 
points of view […] has been overwhelmed and this [HTA] could be like an institutional solution to 
improve governance [...]” P1 
“[...] the current limitations to decide on the explicit basket of health care benefits of health insurers.” 
P3 
“[...] the pressing need to update POS content.” P5 
Currently the health system is facing a financial crisis and “lack of trust” that has threatened 
sustainability. This financial strain also emerged as an important factor, which may have a potential 
impact on HTA, to be incorporated into resource-allocation decision-making:  
“[...] probably a key factor is the fact that the health system has exploded, so when something 
explodes, well one starts thinking, one must do something and this leads to policy alternatives such as 
HTA […]” P4 
“[...] cost increases of health technologies, and an important fact in Colombia was exceptional 
reimbursement of health care services […] and of course on the other hand the need to incorporate 
newly developed technologies within the benefits´ basket that for nearly 20 years was not properly 
updated, so let´s say these two issues, uhm pressured […]  the development of HTA in Colombia.” P5 
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 “[…] the current pressure, I think this will facilitate this field [HTA] […] and I think the current crisis 
within the health system is fundamental because, this pushes for exits, and this crisis well, needs an 
exit […]” P1 
The Government has taken major steps to control costs and strengthen its institutional capacity. 
Nonetheless, political instability after two attempted and failed HSRs in such a short period of time 
(2011 and 2013) is envisioned as a factor able to produce further institutional instability that may also 
have negative implications for the future development or use of HTA: 
“[...] obstacles associated with coordination within the system ought to influence IETS too, this crisis 
has affected EPS [health care insurers], IPS [health care providers] due to the financial strain, this 
uncertainty we have about the future of the Colombian health system […]” P1 
 “[...] when in crisis, you cannot plan mid or long-term to reduce the burden of disease […] this has 
made the whole system blow up […]” P3 
f) Implementation strategy: the need for an organised and well-planned HTA implementation 
strategy emerged as a “driver”. This “driver” groups not only the challenges regarding the use of 
evidence-based recommendations to inform policy, but also the expected systematic process of 
institutional (HTA related) strengthening in Colombia. This involves dissemination of results, capacity 
building, institutional strengthening, and introduction of incentives, amongst others. Regarding 
dissemination of HTA results and knowledge transfer, academics expect a systematic and well-
organised process bearing in mind the target audiences of information. 
“[...] it should have a process of communication, socialisation, call it implementation? […] well 
organised alongside each one of these products [HTA reports]  […] so if these processes, HTA reports 
or Clinical Practice Guidelines have an organised implementation plan in Colombia, they will succeed 
[…]” P1 
“I think firstly, it is important to present them [HTA results] to users in their own words, usually an HTA 
report comes out as a brick [hard to understand], and apologies for saying this, but it is intended for a 
restricted audience, so a closer communication with users […]may be hard but surely will  induce their 
further use […]”P2 
Capacity building needs to consider strengthening the skills of researchers devoted to HTA, but also 
of those in charge of using HTA as a source of information to make decisions and policies. 
Implementation strategy, in contrast to some other “drivers”, emerged more as a challenge that needs 
to be borne in mind during the operationalization of HTA policies.  Its potential impact may be bi-
directional depending on a successful or unsuccessful implementation plan. 
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 “[...] I believe the main thing [challenge] is going to be the local technical capacity being able to cope 
with demand, but let´s think it could be implemented with strategic planning and grow incrementally 
[…]” P2 
“[...] I think that if it is possible to sensitise decision-makers […] there won´t be much trouble on the 
perceived value of it [HTA] by society […]” P3 
A well-planned implementation strategy is expected to be incremental and step-by-step regarding the 
development of methods. HTA reports are expected to be available and “digestible” to a broad 
audience: 
“[…] and the other important aspects are methods [...] they could be step by step and if necessary 
adapted to our reality, so it would require awareness of our available resources and the making of 
some concessions, but to adapt our own standards for HTA […] CGPs as well.” P2 
 “[...] if it [HTA reports] becomes unintelligible to many people it will become very complicated aspect 
[...]” P4 
The recent settlement of IETS represents, according to participants’ remarks, a new opportunity to 
improve the rigour of independent HTA work and the possibility to strengthen local capacity. It raised 
great expectations; there is the expectation of hiring skilled staff which implies challenges throughout 
its implementation stage: 
“[...] the organisation created by the Government should facilitate transparency, independence of HTA 
reports on behalf of the whole society´s instead of serving some interest groups [...]” P3 
“[...] the institute [IETS] is the institutional space aimed at promoting and implementing HTA 
techniques to support evidence-based decision-making regarding technologies for health [...] second 
[key success factor] to hire competent and experienced staff […]” P5 
g) Local capacity: Local capacity emerged as a “driver” which refers to the existence or absence 
of human technical and installed capacity, infrastructure, tools, resources, and academic institutions 
in place to promote the development and use of HTA in Colombia.  Local capacity had two different 
levels of interpretation: individual and institutional. Organisational capacity referred to the 
establishment of postgraduate schools dedicated to EBM, especially of clinical epidemiology; these 
have increased the supply of skilled professionals over the last two decades: 
“[...] we provide a Master’s degree in clinical sciences, we have graduated nearly 45 clinical 
epidemiologists and within the Masters we have also introduced short courses on economic evaluation 
[…] this has been going on since 2006.” P1 
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“[...] I think in Colombia the development of clinical epidemiology has been very important […]in total 
we are three leading institutions building up capacities in the country, on the one hand Universidad 
Javeriana, and on the other Universidad Nacional and Universidad de Antioquia […] between the three 
of us easily we have graduated 200 people [...]” P1 
Organisational capacity referred also to the recent establishment of research groups, think tanks and 
institutions in charge of developing HTA work commissioned by the Government:  
“[...] generation of new institutions, and availability of financial resources, I mean in the past there was 
no way to fund them [HTA projects] […] I believe this has strengthened […]” P2 
At the individual level the number of HTA specialised professionals is still insufficient to cope with local 
demand; according to participants, Colombia has 150 clinical epidemiologist capable of conducting 
HTA (mainly clinical effectiveness requests), but the estimated number of skilled health economists 
and bio-statisticians able to conduct economic modelling and evaluation was ten times lower. The 
recent development of HTA related projects has strengthened local capacity:  
 “The group of clinical research amounts to 25 people, uhm exclusively working on CPGs or HTA around 
15.” P2 
“[…] graduated people from Javeriana we estimate 90 people, from Nacional may be 20 or 40 […]” P4 
According to participants´ remarks, skilled human resources are still scarce in some knowledge fields 
and are mostly concentrated in big urban areas:  
“Well, I haven´t mentioned the disparity of development between big cities and rural areas, we could 
be sure of technical capacity in big cities like  Barranquilla, Cali, Medellin, Bogotá, but there are so 
many places where this issue [HTA] is underdeveloped […]” P1 
“The production of a critical mass of researchers is not really big, it is partially concentrated in cities 
[...]” P3 
A perceived challenge for the stability of research groups and think tanks is the competitive local 
market for scarce HTA professionals, so far in Colombia there is no formal specialised postgraduate 
training in health economics or HTA. 
 “[...] we have no-one with formal training in HTA, but just courses, short courses […]” P2 
 “[…] with health economists there is a […] let´s call it bizarre story […] so I was about to say this staff 
is the most volatile of all […]” P4 
Infrastructure of research groups tends to be modest, more related to software and hardware and the 
availability of resources is limited and highly dependent on financial and policy support: 
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“[...] regarding infrastructure, it has always been linked to projects, it has been projects that have 
pulled out development […] and each thing [resources] has arrived associated with projects […] 
infrastructure is more related to software and hardware […]” P2 
According to participants, the need to build up local capacity goes beyond researchers’ and academics’ 
needs, and also requires raising awareness and strengthening theoretical foundations of local policy 
and decision-makers: 
“The limited stock of knowledge they have at the Ministry of Health [regarding HTA]” P4 
h) Policy and political support: policy support refers to the local social acceptance of HTA by the 
academic community and different stakeholders, and political support to the politicians’ support to 
include HTA into policy agendas. This “driver” is represented by the enactment of laws, explicit policies 
within the government or any other funding bodies regarding HTA production or use. It emerged from 
participants´ quotations, usually associated with funding. Although previous studies (Castro, 2011) 
have tracked the policy interest of Colombia to use HTA back to the early 2000s, it is only in the last 5 
years that major policy changes have boosted HTA development and use in this context. 
“[...] it has been continuous […] since 2008 with the work of CPGs […]  with stable groups working in 
HTA specific projects [...] just recently an institution has been set up with support from the Ministry of 
Health, able to pull this out [HTA] […], and this [IETS] needs to cohere different actors around an 
institutional policy [...]” P1 
Local policy support from governmental institutions such as COLCIENCIAS, the MoHSP or public 
hospitals have granted funding for HTA work and capacity building in recent times: 
“[...] our client has always been the state, our number one client of HTA [...] the Ministry of Social 
Protection, uhm […] COLCIENCIAS obviously, throughout the CPGs programme [...] the Regulatory 
Commission for Health- CRES [...]”P2 
“The Ministry of Health, the National Institute for Cancer [...] COLCIENCIAS, some of them have been 
ad hoc requirements and some others after tendering [...]” P3 
Policy and political support may have a bidirectional impact on the production or use of HTA, negative 
if it is lacking and positive if it is present. According to participants this policy/political support is still 
unstable and heavily reliant on the political environment: 
 “[…] well, provide resources that assure our sustainability, hopefully an upcoming Minister does not 
come and say “that stuff [HTA] is not relevant for me” regarding IETS resources, in that case we have 
to be sure that decision is not dependent only on Ministerial will […]” P3 
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“[...] I mean it is very volatile [funding], we need a policy, hopefully scholarships from COLCIENCIAS to 
train more people on that [HTA], it would be an opportunity, because I believe that is a major weakness 
in this country [...]” P4 
“[...] but, it will massively depend on how it is perceived by the Ministry of Health, from those leading 
it, those who should decide on its real role [HTA] [...]” P5 
Policy and political support are expected to have a broad remit that goes beyond the health sector, 
for instance to assure HTA development, policies within the Ministry of Education may enhance 
capacity building within the country. 
 “[...] a political decision is missing at the Ministry of Education, as well as at the Ministry of Health to 
promote formal education and continuous training in this field [HTA] [...]” P5 
i) Stakeholder pressure: the contested pressure among relevant actors with vested interests in 
Colombia came up as an important “driver”. This “driver” incorporates market and stakeholder 
pressure to either use or prevent the use of HTA that may, in the end, induce regulation. Among the 
stakeholders mentioned by interviewees are patients´ associations, providers, insurers, professional 
bodies, manufacturers, academics, and government bodies. Stakeholder pressure was perceived as 
mainly having a potential negative impact on both the development and use of HTA in Colombia: 
“[...] it could be a barrier again, sectional groups, physicians´ and health professionals’ associations, 
and of course the industry would be a limitation […] the neo-liberal character of Colombia […] favours 
particular interests of certain groups [...]” P1 
 “[...] pressure groups will try to influence HTA processes […] we all know that pharmaceutical labs and 
innovation tanks have huge interest, the others are patients´ groups that have tight links with labs […] 
and on the other hand insurers […]” P3 
 “[...] so let´s say there is a permanent pressure [...] when we refer to interest groups we are talking 
about those who advocate for a narrower benefits package, like health care insurers and those who 
advocate for a wider benefits plan, especially pharmaceutical and medical devices industry […]” P5 
j) Usefulness perception: usefulness perception came up as a “driver” that refers to the 
meaning and values that academics, decision and policymakers, and the whole society put into HTA 
methods as a tool to help inform health and health care decisions. An incremental shift from pure 
academic interest to a more pragmatic use of HTA as an aid to inform decision-making emerged from 
participants: 
“[…] I think it [HTA] should have a clear impact on benefits planning, service organization […] I really 
think its impact [HTA] must go beyond the academic field, definitely [...]” P2 
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“[...] basically many of them [HTA projects] were made out of academic interest, right? But many 
others were assessed aimed at informing decision-makers, which is the right thing to do, do you 
agree?” P3 
According to participants’ remarks HTA is perceived as having a role to support regulation, improve 
transparency, allocative efficiency and equity: 
 “So, I think that [HTA] regulates in a rational and conscious manner the use of resources, it also favours 
equity […] for resource-allocation and priority-setting [...]it  [HTA] allows […] the foundations and 
further construction of a more equitable, efficient, effective and safe system for Colombians.” P1 
“I think the main role [of HTA] is to inform decision-making, and to allow better planning [...] speed of 
research is very fast, so this requires drawing a line, there is always a limit to set up […] this is much 
better if done through a rational and reasoned process [HTA] […] this is much better understood by the 
people on one side or the other of that drawn line […]” P2 
“It [HTA] is an alternative available for governments aimed at improving evidence generation to inform 
more efficient decisions under current pressures for incorporating new and some times better health 
technologies [...]”P5 
This “driver” also refers to the awareness of HTA limitations and the need to incorporate additional 
values into decision-making that goes beyond HTA itself. Nonetheless, the lack of usefulness 
perception, especially among clinicians, policy and decision-makers may have a negative impact on 
the future development and use of HTA in Colombia: 
“[...] there is still a lack of knowledge about the benefits and how physicians could own this knowledge 
[HTA] to improve professional performance [...]”P1 
 “[...] it would be necessary to raise awareness among decision-makers about the importance of taking 
HTA reports into consideration [...] among decision-makers’ knowledge about these methodologies is 
weak “[...] we have to educate them and sensitise them, obviously they are not interested in being 
trained in systematic reviews, but they are willing to understand what a systematic review is [...]” P3 
 “The hardest […] for the development of HTA is the lack of knowledge among decision-makers of these 
tools, there is a big gap of information and knowledge [...] many times they mix up terms, study types, 
potential usefulness of these studies, so if there were more information on decision-makers side the 
development of HTA would have a clearer pathway in the near future […]”P5 
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DISCUSSION  
Qualitative enquiry was used in this chapter to “reach the parts other methods can´t reach” (Green 
and Thorogood, 2009). Thus semi-structured interviews with local academics devoted to HTA and 
thematic content analysis were performed as a means to answering what are the main aspects that 
may help or hinder HTA development and use in Colombia?. Although there are no mechanical 
solutions to assess the likelihood of errors in this qualitative part of the research, clear exposition of 
methods and data collection, and analysis, reflexivity and triangulation were considered by the main 
researcher for improving validity. The triangulation analysis of results is presented in a separate 
section after the empirical chapters. 
In response to the research question, ten drivers: local capacity, policy and political support, 
perceptions of its usefulness, globalisation, financial support, availability and quality of data, cultural 
aspects, implementation strategy, stakeholders´ pressure and the health system´s context emerged 
as “drivers” with the ability to prevent or induce HTA development and use in this country.  
Recent development of local capacity may have had a positive impact on HTA development, but 
human resources are still scarce in some knowledge fields such as health economics and bio- statistics 
and are mostly concentrated in big urban areas. The infrastructure of research groups is modest and 
available resources for HTA are limited and highly dependent on financial and policy and political 
support. According to participants, the need to build up local capacity extends beyond the needs of 
researchers and academics and also includes raising awareness and strengthening the theoretical 
foundations of local health care professionals and policy and decision-makers. The recent 
establishment of IETS represents a new opportunity to improve the rigour of HTA and the possibility 
of strengthening institutional capacity. This has encouraged optimism coupled with awareness of the 
challenges faced at its implementation stage.  
Policy and political support was usually associated with funding, this may also have a positive impact 
on promoting the use of HTA in Colombia. A shift from pure academic interest to a more pragmatic 
use of HTA (as an aid to inform decision-making) also emerged from participants´ remarks. This shifted 
perception of the potential usefulness of HTA was seen as a positive “driver”.  However, perceived 
lack of usefulness, especially among clinicians, policy and decision-makers, may have a negative 
impact on the future development and use of HTA. 
Most participants thought globalisation had a potential positive impact on the use of HTA, but it also 
had an impact on HTA development, especially regarding those academics who had returned after 
studying overseas to implement HTA research agendas.  
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Participants perceived international “peer pressure” to get involved in HTA. Globalisation emerged as 
an opportunity for such co-operative work and involvement in international HTA networks. It may also 
have a positive impact on both development and use of HTA.  Nevertheless globalisation could also 
have a negative impact, due to the influence and interconnectedness of countries: for instance on the 
stability of research groups. Concerns were also raised about the current asymmetry of information 
among HTA users and possible generalisation of HTA reports across borders, which would prevent de 
novo development of HTA in Colombia. A lack of confidence in HTA-related international think tanks 
emerged from the interviewees, since some participants believed that these groups have commercial 
interests and not real concerns about quality improvement or local capacity building. 
Financial support was usually associated with another “driver”, policy and political support. Financial 
support or the lack of it could have an impact on both use and development of HTA. A lack of funding 
may have a potential negative impact on the stability and continuity of research groups. The recent 
development of CPGs funded by COLCIENCIAs and the MoHSP as a policy solution to homogenise 
clinical practice has recently created some stability for HTA projects and research groups. The recent 
policy implementation of IETS is also expected to attract funding and enhance local capacity building. 
Stakeholder pressure was perceived as mainly having a potential negative impact on both the 
development and use of HTA. For instance, the contested policy pressure between those who 
advocate for a narrower benefits package (government and health care insurers), and those who 
advocate for a wider benefits plan, (pharmaceutical and medical devices industry) represents a 
challenge for HTA institutional strengthening. On the other hand, stakeholder pressure associated 
with the current context of the financial and “lack of trust” crisis within the health system could have 
a positive impact on HTA development and also on its future use, for example the Government´s 
interest in using the best available evidence for quality improvement and resource-allocation decision-
making in a transparent and systematic fashion.  
The importance of a well-planned HTA implementation strategy emerged from participant interviews. 
Also the existence of such a strategy may have an impact on the development of HTA. This “driver” 
could simultaneously have a potential impact on both development and use of HTA. According to 
participants, implementation refers to communication, dissemination of HTA evidence, as well as 
individual and institutional capacity building. 
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The health system context has pushed HTA as a possible policy solution to inform resource decision-
making in Colombia. It emerged that the current context may have an influence merely on the 
development of HTA, but also this “driver” may have an impact on its use. The current crisis within 
the system has created institutional instability that may have negative implications if instability 
extends to HTA specialised organisations and research groups. 
Cultural aspects such as resistance to change, lack of transparency for decision-making and recent 
tradition and interest of professionals´ self-regulation were identified as mostly having a potential 
negative impact on both use and development of HTA. Health care professionals in Colombia do not 
want to be told how to provide health care, and there are no clear rules from professional bodies on 
how to incorporate evidence-based information into practice.  
Finally, problems with availability and quality of data emerged as always having a potential negative 
influence, mostly on development. This may reduce the internal validity of HTA reports, with its 
subsequent negative impact on HTA as a reliable source of information which could cause doubt 
among decision-makers. However, in recent years the government has invested in improving the 
availability and quality of data essential to conduct HTA. 
All “drivers” could potentially have a positive or negative impact at specific moments in time. They 
could shift according to the dynamics of the policy process of implementing HTA in Colombia. Some 
“drivers” that in the last decade were considered as main barriers (local capacity, policy support, 
usefulness perception, globalisation and financial support), according to participant´s views have 
changed in recent years. For instance, local training and the entry of new specialists in the field in the 
last couple of years have eased HTA production, this arose from the establishment of new research 
think tanks and institutions. According to participants, the growing reputation of HTA research groups 
has gained policy, political and financial support from the government and many other funding bodies.  
Awareness of HTA usefulness and its limitations has increased over the past four to five years, boosted 
by a favourable international trend and a social mood to rely on EBM, and to prioritise and use HTA 
to inform health and health care decision-making. The establishment of CINETS, formed by three top 
ranking Universities in 2011, and the establishment of the IETS in late 2012 are tangible facilitators 
that may ease HTA in Colombia. The former was closely involved in using EBM and HTA methodologies 
in developing 24 CPGs aimed at homogenising clinical practice and improving quality of care. The latter 
is perceived by participants as a “great thing” and has given rise to expectation for methods 
development, capacity building and institutional strengthening. 
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According to participants, some “drivers” such as the financial crisis within the health system, and 
resultant lack of resources, as well as corruption and the perceived lack of transparency [cultural 
driver] have become problematic in recent years. A well-organised implementation strategy needs to 
surmount cultural aspects that resist technocratic methodologies and transparency, and the lack of 
available and valid data to populate economic models. Short-term challenges to be borne in mind to 
enhance HTA development and use in Colombia also include, insufficient local capacity, the need for 
sustained financial support, and the standardisation of HTA methods which started in 2008-2009 when 
the first methodological guidance to produce CPGs was released by COLCIENCIAS. 
According to participants, if researchers could explain the possible benefits of incorporating HTA into 
decision-making, as well as disseminating HTA results in a “digestible” manner, HTA use would succeed 
at both the individual and institutional level. They also believed that implementation strategies should 
be well planned and incentives ought to be incorporated if HTA is intended to have a bigger impact on 
policy and decision-making in Colombia.  
In recent years qualitative methods have become more commonplace in areas such as health services 
research and HTA. The status of qualitative research, like many other forms of research, depends on 
the quality of methods used (Mays and Pope, 2000). Authors like Kirk and Miller (1986) and 
Hammersley (1992) argue that there is an underlying reality which can be studied; hence the aim of 
researchers should be one of “subtle realism”, an attempt to represent that reality rather than to 
attain “the truth”. It is from this position that authors like Mays and Pope (2000) agree that it is 
possible to assess qualitative research according to two broad criteria: validity and relevance. 
Strengths and limitations 
In carrying out the research described in this chapter, the researcher sought to preserve key principles 
of qualitative research methods. Respondent validation, clear exposition of methods, reflexivity, 
attention to negative cases and fair dealing were considered to improve the validity of results. Due to 
the commitment to naturalism, in-depth semi-structured interviews were used to explore the 
experience and expectations of Colombian researchers in their natural context and in their own 
language. Perhaps a more participatory approach could have provided a different perspective of such 
a topic of interest, but time and budget constraints made the researcher opt for a thematic content 
analysis instead. 
Consistent with Morse and Field (1996) the sample approach chosen was considered appropriate and 
adequate to provide the researcher with in-depth information about the topic of interest. The 
purposive (homogeneous) sample fitted the aim of this part of the research - to help understand HTA 
development and use in Colombia. It also generated relevant information and quality data.  
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The total number of HTA specialists is limited in Colombia, and although qualitative enquiry usually 
relies on small sample sizes; the sample size and eligibility criteria were perhaps the biggest limitations 
of this part of the research. The strict eligibility criteria of inviting to participate only those leading 
researchers with 5 or more years in the field led to a sample size of only eight potential participants, 
which were restricted to five in order to avoid context duplication.  Using a bigger sample and with a 
more heterogeneous composition, the results might have been different.  
The main researcher has experience of, and is familiar with, HTA methods and processes. This enabled 
him to explore and validate the level of expertise of participants throughout the interviews. It was also 
an advantage when assessing their seniority and previous exposure to HTA work. This served to depict 
that senior experts on HTA in Colombia were more familiar and had formal training in comparative 
clinical effectiveness research than with economic evaluation methods. Nonetheless, being familiar 
with the context of interest may have shaped the process of data collection or analysis. For example, 
there was a prior assumption before data collection that barriers and facilitators for HTA in Colombia 
already existed. Although the initial assumption of the researcher was that these aspects could be 
considered as “barriers and facilitators”, participant interviews suggested these aspects were dynamic 
and highly interconnected, and more appropriately called “drivers”.  
Although the main researcher was close to the academic community, he was not as close to the 
participants as to jeopardise independence. According to Green and Thorogood (2009), “it is 
impossible to have a field for study that is untainted by values and impossible for the researcher to 
stand outside those values and subjectivities”. Nonetheless, the researcher strived to minimise 
personal values and assumptions that may “bias” findings. For instance he used a pre-determined 
interview guide to allow the exploration of the issues of interest, and maintained a non-judgemental 
attitude with flexibility to allow for any deviant cases.  
A flexible research strategy was adopted. It began with a review of the literature aimed at selecting 
the qualitative methods that best suited the research question, under time and budget constraints. 
The interview guide resulted helpful to shape discussion but also to look up for emerging themes and 
changes overtime. Purposive sampling and semi-structured interviews were selected to generate and 
collect value-rich data. As early data analysis suggested that thematic content analysis was suitable to 
allow the researcher to look at data from interview transcripts and categorise participants´ accounts 
in a way that could be summarised, this method was selected. 
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This whole process provided the researcher with an in-depth conceptual description of the context, 
conditions, and processes regarding the feasibility of producing or using HTA in Colombia.  According 
to participant responses, ten factors emerged as “drivers” with the potential to help or hinder HTA in 
Colombia. The research approach provided relevant information that moves beyond the initially 
assumed list of “barriers and facilitators”. 
The emergence of “drivers” for HTA in other contexts 
Findings from this part of research coincided with Rajan et al (2011), through an observational design 
the authors used a questionnaire aimed at analysing the motives, enablers, and barriers to promote 
or initiate HTA in different contexts. They surveyed HTA agencies of HICs and those LMICs with HTA 
agencies that were members of International Network of Agencies for Health Technology Assessment 
(INAHTA), International Information Network on New and Emerging Health Technologies (EuroScan), 
or European network for Health Technology Assessment (EUnetHTA), or belonged to the interest 
subgroup for LMICs at the Health Technology Assessment International (HTAi) which aimed to initiate 
HTA activities.  
According to this study, the top three motives for HTA initiation were the same for both HICs and 
LMICs: to support decision-making in health care and promote appropriate resource-allocation; to 
strengthen credibility, transparency and accountability of different decision-making levels; and to 
achieve better quality of health services. These motives coincided with the role or usefulness 
perceived of HTA in Colombia described in this chapter. 
The top five enablers published by Rajan were also similar in both settings and coincided with some 
of the “drivers” mentioned herein: availability of human resources to develop HTA [local capacity]; 
availability of financial resources to perform/run HTA [financial support]; existing good practices and 
examples from other countries [globalisation]; existing international networking, support and 
collaboration [globalisation]; and understanding the local needs and setting priorities [health system 
context and stakeholder pressure].  
The top five barriers described by these authors were more context specific, but also coincided with 
some of the identified “drivers”: lack of financial resources to perform/run HTA [financial support], 
resistance to change from existing practice routines and culture [cultural aspects], lack of knowledge 
about EBM and/or HTA [local capacity and usefulness perception], lack of human resources to 
perform/run HTA [local capacity]; and lack of interest in EBM and/or HTA [usefulness perception].  
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In 2011 Varela-Lema et al explored the perceptions of the use of HTA in the Galician public health 
system, identified opinions on the usefulness of the products and services developed by the regional 
Health Technology Assessment Agency (avalia-t), and determined the barriers and facilitators to the 
transfer of results to clinical practice. Through a qualitative study, based on in-depth semi-structured 
interviews with experts, some of their findings were similar to those explored in this thesis, interest in 
HTA activities was high, but participants considered these activities to be underused as a tool to aid 
decision-making in clinical practice.  
Also a series of key factors identified by these authors to enhance HTA use were similar to the 
emergent “drivers” described in this chapter. For instance, greater dissemination of HTA activities and 
availability of the results, increased involvement and communication among health care professionals 
in the selection and prioritization of relevant research, contextualization and adaptation of results to 
the local context, were similar to the implementation strategy “driver”.  Increased organizational 
support and greater financial resources resembled the “drivers” policy and financial support.  
In 2010 Silva et al conducted a systematic review which looked at the use of economic evaluation in 
decision-making at the macro-level and observed that the main facilitator to using economic 
evaluation in decision-making was governmental/institutional incentive (UK and Australia) which also 
resembled the “driver” policy/political support. According to Silva, barriers remain without apparent 
variation over time or between countries, mostly related to the accessibility and acceptability of 
economic evaluation [usefulness perception and cultural aspects].  
Pichon-Riviere et al (2009) ran a web-based auto-administered survey designed by INAHTA in 
collaboration with PAHO/WHO and mailed 242 contacts in Latin American countries. 78 complete 
surveys from nine Latin American countries were received (response rate 32%). Government support 
for HTA activities emerged as a main “driver” for HTA promotion [policy/ political support], as well as 
the use of HTA evidence [usefulness perception] and the availability of resources to develop HTA 
[financial support and local capacity]. Support from the pharmaceutical industry was considered to be 
low which coincides with the “driver” stakeholder pressure and the perceived position of participants 
regarding this interest group and HTA use as described before. 
According to Hyder et al, 2011 barriers to evidence-based policy-making included poor communication 
and dissemination, lack of technical capacity in policy processes, as well as the influence of the political 
context. All three aspects coincided with the “drivers” implementation strategy, local capacity, health 
system context and policy/political support.  
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Hyder´s study also accounts for policymakers´ recommendations for facilitating the uptake of research 
into policy. These included improving the technical capacity of policymakers, better packaging of 
research results, use of social networks, and establishment of fora and clearinghouse functions to help 
assist in evidence-based policy-making. Many of these comments emerged when coding the “driver” 
implementation strategy. 
This facet of research was considered as relevant and important since it is an attempt to add to the 
knowledge about the aspects that may enable or stifle HTA development and use in a context like 
Colombia. This country, as noted previously, is currently struggling to set priorities for health and 
health care in a more systematic and transparent manner (Castro, 2011; Caballero-Uribe, 2012 and 
Defensoría del Pueblo, 2013).  
Of worth mentioning that “drivers” such as policy/political and financial support, as well as usefulness 
perception were considered as useful information for the strategic planning of IETS during its first 
years of operation. The incremental implementation strategy of IETS has also borne in mind aspects 
like in-house and external capacity building, established links with the international academic 
community and set up a consultative committee with representatives from senior experts of HTA 
agencies around the globe, incorporated good practices of vested interest declaration and stakeholder 
engagement in order to deal with their pressure and attain legitimacy, IETS is also currently working 
on the development of guidance and manuals to improve the quality or reports and reduce 
uncertainty of estimates; all these after considering some of the emerged themes and “drivers” of this 
thesis.  
The attempt of the current government to strengthen institutional capacity has led to the 
establishment of the first HTA agency in Spanish speaking America with the purpose of informing 
resource-allocation decision-making. Hence of special interest for the government and the main 
researcher, is the uncovering of those dynamic aspects, reported as “drivers” that should be 
considered for the successful implementation of HTA in the context of interest. Although it has been 
said that the main purpose of qualitative research is not to assure external validity (generalizability or 
extrapolation), this research chapter is intended to be as detailed as possible so that readers can judge 
the applicability of its findings to similar settings. 
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SUMMARY 
This part of the research used qualitative methods to explore previous experiences of conducting HTA, 
and the perception of its role and future use in Colombia; ten potential ‘drivers’ were identified. The 
methods were chosen to pay close attention to evidence, critically approach subjective and analytic 
accounts of participants, and offer careful and rigorous analysis. After purposive homogeneous 
sampling, semi-structured interviews, rigorous transcription, and thematic content analysis, those 
aspects that may help or hinder HTA development and use in Colombia were identified. However, it 
is worth emphasising that the analysis was relatively ‘basic’ and departs from approaches of 
qualitative enquiry aimed at generating new theory such as grounded theory, phenomenology or 
ethnography. Further qualitative analyses may serve to explore in much more detail HTA development 
and use as a phenomenon in Colombia. 
Although HTA has become a tool to inform decision-making around the world, those aspects that may 
help or hinder HTA development and use in Colombia may not be generalizable to other countries. 
Nonetheless, the conceptual transferability of concepts like “drivers” with caveats may be of interest 
for similar settings trying to incorporate HTA processes and institutions into decision-making. 
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2. CHAPTER 2- A cost-utility analysis of primary prophylaxis for the treatment of severe 
haemophilia A in Colombia 
INTRODUCTION: 
Haemophilia A is a rare inherited disorder affecting the blood coagulation system, which is 
characterized by a permanent tendency to haemorrhage. Bleeding into the joints (such as knees, 
ankles and elbows) leads to articular damage (haemophilic arthropathy) which is the most frequent 
long-term complication of the disease.  The mainstay of treatment is replacement therapy with 
exogenous clotting factor VIII (FVIII). However, in some circumstances the chronic exposure to 
exogenous clotting factor leads to the onset of antibodies (inhibitors) against therapy, this is a serious 
and frequent complication of treatment.  
People with haemophilia A are categorised depending on their endogenous level of FVIII activity (LoA) 
as being either mild (LoA from 5-40% [0.05- 0.4 IU/ml]), moderate (LoA from 1-5% [0.01- 0.05 IU/ml]) 
or severe (LoA less than 1% [<0.01 IU/ml]) (White et al, 2001). For people with severe haemophilia A 
(SHA) bleeding can be spontaneous or traumatic and sometimes life threating. Of all the orphan 
conditions, haemophilia accounts for the biggest proportion of the population (approximately 1 case 
in every 5,000 people)36.  
In Colombia, haemophilia A care represents an important financial burden to the health system. The 
costs associated with clotting factor replacement for this condition were COL$140,164,400,000 
(USD$73.72 million) in 2010 37  or 0.46% 38  of the total annual spending on health while treating 
approximately 2,000-2,600 patients, 800-1,040 of whom are classified as severe cases (Colombian 
League for Haemophilia- CLH, 2011).  Indeed, health care coverage for this disease has attracted much 
media attention in recent times, but not even in the upcoming new health sector reform (HSR) has 
the issue of sustainable funding for orphan conditions been solved.   
There are two main types of FVIII treatment for people with SHA. On-demand (OD), following a bleed, 
to stop it. Or prophylaxis, when treatment is given prior to bleeding with the aim of preventing joint 
damage. ‘Primary prophylaxis’ (PP) represents treatment prior to the onset of repetitive bleeding, 
whereas ‘secondary’ prophylaxis refers to initiation of treatment sometime after this process has 
begun.  
 
                                                          
36 Orphan disease definition as per Colombia Law 1438 2011 
37 Figures published by the Colombian Medical Federation- FMC in October 2010. See http://www.observamed.org/ 
38 These costs do not include inpatient or ambulatory care arising from bleeding episodes, or their complications or the costs arising from 
the use of rFVIIa for patients with inhibitors 
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Although the prophylactic replacement of clotting factor has been recommended as the gold standard 
of care by institutions such as the World Federation of Haemophilia (WFH) and the WHO (Giangrande 
2004), in Colombia, as in many other countries, PP is provided to less than 50% of all severe 
haemophilic patients (CLH, 2011), largely because it is considered to be much more expensive than 
treatment OD. Indeed, in Colombia, there are no evidence-based clinical practice guidelines in place 
for this health condition, and haemophilic arthopathy with its subsequent negative impact on HR-QoL 
is still a frequent finding (CLH, 2011).  
Knowledge about the clinical effectiveness of haemophilia A has exponentially grown in recent 
decades. For example, a number of observational studies have shown that clinically observable signs 
of haemophilic arthropathy can be almost entirely prevented over prolonged periods (20 years) if 
exogenous replacement factor is provided early and frequently (Nilsson et al, 1992, Aznar et al, 2000, 
Coppola et al, 2008 and Berntorp 2009). However, the cost-effectiveness of PP remains a particular 
concern (Castro et al, 2012). The number of published economic evaluations for prophylaxis is very 
limited and their results are confusing. For example, while nearly a dozen studies have been published 
since 1996, they have reported results ranging from prophylaxis being “dominant” to it costing over 
€1 million per QALY gained (Miners, 2013).  
From this wide range of published results it is still unclear if this intervention has reached the point of 
being considered “good value for money”, or cost-effective. This statement is also true for Colombia, 
but no primary haemophilia-specific HTA or economic evaluation has been published in this context. 
Thus in Colombia, where the health system is facing severe financial strain, the research question of 
this chapter “what is the incremental cost-effectiveness of PP throughout life with exogenous FVIII 
compared with OD treatment for severe haemophilia A?” becomes particularly relevant.  
There are many types of economic evaluation (Drummond et al, 2005) , but in order to allow cross 
comparison of interventions a cost utility analysis (CUA) where costs are measured and expressed in 
monetary terms and outcomes stated in combined units capable of capturing morbidity and mortality 
(e.g. Quality Adjusted Life Year-QALY) was developed. This chapter presents a CUA comparing PP to 
OD treatment for severe haemophilia A. Methodological issues relating to conducting HTA through 
this economic study in Colombia are described at the end of it. A full HTA report of PP was also 
developed and presented to decision-makers in order to test the MCDA-EVIDEM in this context; this 
is described in the next thesis chapter.  
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METHODS: 
The decision problem 
The decision problem for the analysis was the choice between PP versus OD for people with SHA, from 
the health system perspective and over a lifetime horizon. This perspective was adopted because up 
to 95% of costs of long-term treatment for SHA may be associated with FVIII provision (Daliri, 2009 
and Miners, 2009). A lifetime horizon was considered as clinically relevant since SHA is a lifelong 
disease, and the long-term benefits, costs and complications of treatment are expected to occur 
throughout the life span of patients.  The analysis considered the use of plasma-derived FVIII and OD 
as current practice in Colombia. The cost of exogenous factor replacement using recombinant FVIII 
(rFVIII) is expected to be higher than for plasma-derived products, and since its use has increased in 
recent years, this was considered as an alternative in a scenario analysis.  
For the purposes of this evaluation PP is defined as treatment by intravenous injection of exogenous 
clotting factor in order to prevent bleeding in the first instance. It is assumed to begin in infancy and 
continue into adulthood. On the other hand, OD treatment was defined as FVIII administration 
whenever joint or extra-articular bleeding occurs.   
The rationale for modelling 
SHA is a chronic condition where patients are at risk of recurrent bleeding for many years, and joint 
damage is expected to develop after cumulative stress and injury within the joints. This clinical 
spectrum presented the researcher with “an unavoidable fact of life”, in order to emulate “real world” 
conditions and conduct rigorous economic evaluation it was necessary to use a modelling approach 
(Buxton et al, 1997 and Hjelmgren et al, 2001).  After reviewing the available evidence, a previous 
framework developed by Drummond et al (2009) to assess the feasibility of developing or transferring 
economic evaluations across jurisdictions was used to decide if it would be necessary to conduct de 
novo modelling or to ‘adjust’ previous cost-effectiveness information.   
Coinciding with the findings of Miners (2013), economic evaluations for haemophilia A are still very 
limited, especially CUAs. Moreover, the existing studies have adopted different perspectives, made 
different structural assumptions, used different time horizons, discount rates and sources of data. 
Figure 4 presents a modified version of the steps outlined by Drummond for determining appropriate 
methods for adjusting cost-effectiveness information, red circles account for the answers in the case 
of PP for SHA in Colombia.  
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There was limited cost-effectiveness (cost-utility) information available that adopted a broad variety 
of structural approaches and compared results of different treatment patterns. The most relevant 
studies considered the cost of rFVIII as common practice instead of FVIII which is the current case in 
Colombia, also showed model structures and results that were not transferable or adjustable to this 
setting since they analysed different prophylactic schemes, made different assumptions, adopted 
different infusion schedules and reported non-comparable treatment patterns, all these represented 
“general knock-out criteria” for transferring results. Further, since no cost-effectiveness multi-location 
trial data had included Colombia, the starting point of published economic studies was considered as 
irrelevant to the decision problem of interest.  
When considering the methodological soundness of these studies there were considerable limitations. 
Of special interest for this thesis work was the analysis of the structure, parameters and quality of the 
Miners (2009) and Colombo (2011) studies. In 2009, Miners et al updated a previous version of the 
first published CUA. In their model the prophylactic regimen treatment was not dose or time specific, 
but was set as a clinical target trough in vivo clotting factor level of 1 IU/dl, and doses required to 
reach it were calculated using pharmacokinetic principles. There was no linkage between bleeding and 
major surgery joint-related clinical status. The base case model was run from the period of treatment 
initiation (1 year of age) for 70 cycles. In their updated version costs and benefits were discounted at 
3.5%.  
A number of criticisms can be levied at this model, the sole structure could be challenged from a 
clinical standpoint since up to 10% of severe haemophiliacs with FVIII concentration of < 1IU/dl may 
not experience frequent bleeding or express the full clinical spectrum of disease (Royal et al, 2002). 
This study also uses four health states “no specific problems”, “year prior to major surgery”, “major 
surgery” and “dead” which, from a clinical perspective, are not self-explanatory.   
As mentioned by Olivieri et al (2012) who reported MRI-positive findings of joint damage in up to 19% 
of SHA patients, there is evidence of subclinical joint deterioration and the health state “no specific 
problems” may not be entirely realistic, since it is expected that the baseline disease may carriage 
morbidity for patients. 
Also not all patients would require “major surgery” throughout life and a large number of cycles need 
to be experienced for patients to move from having no problems after bleeding to the year before 
major surgery and surgery itself, especially in those with PP. Another limitation of Miners (2009) is 
that the values used to estimate outcomes OD were derived from a cross-sectional study of HCV39 
infected haemophiliacs; this may have overestimated the impact on health of PP.  
                                                          
39 HCV Hepatitis C Virus 
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Figure 4. Modified version of the steps for determining appropriate methods for adjusting cost-
effectiveness information 
 
In 2011, Colombo et al replicated Miners et al work (and perhaps some of its limitations). The authors 
used a similar model with health states: “alive”, “require major surgery”, “surgery” and “dead”, but in 
this case patients entered the model at birth. This may represent a limitation of the study since, as 
mentioned by Kurnik et al (2010), the highest risk of developing inhibitors is during the first 20 
exposure days, and it might be preferable to delay the first exposure to exogenous factors for at least 
one or two years. The model was run for 100 cycles. A 6% discount rate was used for both costs and 
outcomes. Life expectancy of severe haemophiliacs was assumed to be similar to that of the general 
North European male population (similar to Miners, 2009); this latter assumption departs from 
evidence supporting the expectation that severe cases of haemophilia may well live 15 years less than 
general population (Darby et al, 2007). The authors estimated the probability of dying after the first 
year of surgery to be equal to that of the general population, based on an Italian male life-table by 
adding a 1% that is not further explained in the publication.  
Another limitation of the Colombo study is that the utilities for the health states “alive” and “surgery” 
were derived from the Miners et al study (2009) without considering the transferability of results. The 
utility for the health state “require major surgery” was obtained from Laupacis et al (1993) who 
assumed that HR-QoL of living in such health state was equivalent to individuals with osteoarthritis.  
Another limitation is that the HR-QoL of severe patients in PP is equivalent to people with 
mild/moderate cases; this also may depart from the clinical profile of this population, since as 
mentioned before SHA patients tend to bleed even spontaneously. The Colombo study did not 
incorporate any costs other than those of clotting factor, inpatient care and surgery. 
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Context issues such as lack of local rules for conducting HTA in Colombia and the aspects of the 
published analyses that would have to be addressed before considering transfer of estimates fulfilled 
the so-called “specific knock-out criteria”, and left no other option for the researcher than considering 
other data and modelling.  
The model type and structure 
In order to compare the long-term costs and effects of OD and PP for SHA it was necessary to move 
beyond the relatively short term results of the observational and RCTs studies, and since decision 
analytic models provide the means of bringing evidence and data together in order to generate 
estimates of cost-effectiveness, it was necessary to consider the type and structure of such a new 
model.  A decision tree in this case would have become very “bushy”, with many recurring pathways 
given the long time horizon of the disease, and the recurrent nature of bleeding episodes, thus a 
Markov model was considered the most suitable structure to simulate movements between relevant 
health states over time. 
The de novo Markov model was designed and populated making use of the best available evidence; 
this was collected and gathered through two literature searches, and supplemented with ‘local’ 
evidence when necessary. Three physicians (two haematologists and a public health specialist) familiar 
with SHA participated as local clinical experts to validate, refine or estimate some of the model input 
parameters. Three third-party payer senior managers of health insurers also participated as experts 
on local costs and tariffs. This panel of experts was virtually allocated and requested to consent in at 
least two rounds of enquiry about unit consumption and costs whenever needed, participants were 
anonymous to each other. 
The model was constructed using TreeAge Pro 2013 software. The basic model logic was that fewer 
bleeding episodes leads to lower rates of joint-related complications, which in turn is assumed to lead 
to better HR-QoL. This assumption is supported by Nilsson et al (1992) who followed up 60 severe 
haemophiliacs A and B aged 3–32 years whose treatment was started at 1–2 years of age. The study 
suggested the possibility of preventing haemophilic arthropathy by giving effective continuous 
prophylaxis from an early age, by preventing clotting factor concentrations from falling below 1% of 
normal. Lalezari et al (2011) and Kempton et al (2012) have also reported similar findings.  
The model consisted of a simplified version of the natural course of the disease and considered three 
health states for each treatment branch: “Alive-no arthropathy”, “Alive-with arthropathy” and 
“Dead”.  
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The health state “Alive-no arthropathy” represented those patients with SHA without active bleeding 
that have not developed joint damage. The health state “Alive-with arthropathy” represented those 
patients with SHA without active bleeding that have already developed joint damage. Patients in the 
model could either experience active spontaneous or traumatic bleeding located within the joints 
(articular) or not into the joints (extra-articular) and the difference between the two treatments being 
the annual rate at which this occurs. In the model once bleeding has occurred, patients could die or 
recover (i.e. stop bleeding and stabilise).  
For a pictorial representation of the decision node and health states for each decision branch see 
figure 5, where the circles represent the three possible health states. All patients entered in the model 
in the health state “Alive-no arthropathy”. This initial health state coincides with the clinical spectrum 
of disease, in which patients are asymptomatic until the haemostatic system is stressed by a surgery 
or trauma, and by the fact that without joint bleeding, joint damage does not occur (White et al, 2001). 
Supporting this assumption, in 2010 Capaci et al used the radiographic Gilbert score to asses joint 
status of patients and found that in severe haemophiliacs that received prophylaxis bleeding was 
prevented and results were almost as good as those of mild cases (p <0.05). 
The primary assumption was that all severe haemophiliacs bleed at some point in life (regardless of 
the treatment option allocated), this is supported by Olivieri et al (2012) who reported MRI-positive 
findings of joint damage in 19% of asymptomatic haemophilic patients in a 10-year period of follow 
up, suggesting the substantial impact of sub-clinical bleeding within the joints and also that MRI-
positive findings may not always be clinically expressed.  
Every cycle, patients in the health state “alive-no arthropathy” bleed at a mean annual specified rate 
per-treatment option.  A proportion of these bleeds are articular, with the remainder being extra-
articular.  At this point, individuals can either die from bleeding, or recover (i.e. stay alive).  A 
proportion of patients who have experienced intra-articular bleeding and recover, develop arthrosis 
and enter the heath state “alive-with arthropathy” with the remaining proportion staying in the health 
state “alive-no arthropathy”.  
The annual probability of developing arthropathy was assumed to be constant and independent of 
the number of bleeds per cycle as this relationship is complex and not well understood.  For example, 
no published evidence documenting the cumulative probability of developing joint damage after 
repetitive bleeding within the same joint could be identified. In the base case model it was further 
assumed that once people had entered the health state “alive-with arthropathy”, they continued to 
experience an annual rate of bleeding, but that individual joints do not further degenerate. 
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It was also assumed that patients remained in the health state “alive-with arthropathy” irrespective 
of treatment, since once arthropathy has occurred it does not regress, as observed by Hilberg and 
Czepa´s 2009 in their physio-pathological description of the disease.  Eventually, throughout their life 
span, all patients without any previous joint damage who present with additional articular bleed would 
either develop arthropathy or die. 
Dying from bleeding is expected to be similar for each treatment branch; chances of dying in the model 
were considered to be associated with the promptness of access to health care, and not with the total 
number of bleeds per-cycle or the severity of haemorrhage. Although the annual probability of dying 
from bleeding of any type was likely to be relatively low,  was considered as important by the local 
clinical experts thus it was incorporated in the base case model making use of the data reported by 
Darby et al (2007). 
Figure 5. The Markov model for SHA  
 
In Colombia the probability to die from bleeding is still expected to be significant. The relevance of the 
mortality form bleeding in this context was reported by Bernal and Suarez in 2008 who estimated the 
potential years of life lost (PYLL) from haemorrhage in haemophiliacs in Colombia as 21.8 per-patient, 
the authors calculated the years lost by subtracting from life expectancy the years lost derived from 
disability and severity of disease.  Nor did this source or any other account for the frequency of deaths 
associated to bleeding in SHA patients in this country.  
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In Colombia there are still barriers to access to prompt treatment whenever bleeding occurs, also 
logistic and cultural limitations that may prevent home-based provision of FVIII such as lack of 
electricity or lack of cold-chain quality assurance, literacy, and a black market of costly medicines (CLH, 
2001 and Noticiero del llano, 2013).  
The costs and outcomes associated with each health state were expected to be different and 
associated with the treatment allocated, hence they were estimated separately. Patients entered the 
model at two years of age, taking into consideration the international recommendation deemed as 
gold standard40 (Nilsson et al, 1992, Manco-Johnson et al and Petrini et al, 2007), doses per-year were 
adjusted for weight dependence as is normal when treating with FVIII. The base case model ran for 70 
yearly cycles accounting for the life expectancy of non-HIV-positive severe type A haemophiliacs 
(Darby et al, 2007), which is expected to be 15 years less than the general population.   
In the model it was assumed that once treatment was allocated (PP or OD) patients fully complied 
with it and would not switch during their lifetime; clinical effectiveness and safety from treatment 
with either FVIII or rFVIII were expected to be similar (Mingot et al, 2009 and Gouw et al, 2013). 
Although the development of inhibitors is expected to be substantial and, according to some authors, 
may reach up to 30% of cases (Collowick et al, 2000 and Farrugia et al, 2013), there is still controversy 
in the current published evidence about the differential rates of inhibitor development among those 
receiving replacement therapy via OD versus those with prophylactic schemes (Lusher, 2000 and 
Scharrer et al, 1999 vs. Kurnik et al, 2010), hence this frequent complication was not considered in the 
model.   
Other complications from clotting factor application were assumed to be equal for PP and OD 
treatment. The number of hospitalisations whenever bleeding occurred and blood tests for diagnosis 
and inhibitor screening were expected to be similar between two groups, hence not considered, this 
is similar to the findings reported by Manco-Johnson et al in 2007.  
The probability of dying from other causes was considered similar for haemophiliacs and the general 
population for individuals borne in 2014 onwards in Colombia (5.29 per 1000 people as per DANE, 
2014), and thus not incorporated in the model. Blood-borne infections were expected to be non-
existent if proper viral attenuation methods were used or if recombinant exogenous factor was used, 
and were therefore not considered (Gringeri et al, 2011 and Darby et al, 2007).  
 
                                                          
40 Malmö protocol: treatment is started when boys are 1–2 years of age but later than 18 months of age, the regimens used being 20–40 IU 
F VIII kg  three times weekly in haemophilia-A cases (i.e. > 2000 IU kg−1 annually). 
 71 
Model Inputs 
In order to inform the decision problem of interest and gather information to populate the model, 
two literature searches were performed in 2013 to update effectiveness and cost-effectiveness 
information for PP retrieved through a preliminary search conducted by the main researcher in 2011 
(Castro et al, 2012).  
The first search assessed the clinical effectiveness of PP compared to OD treatment for SHA, and the 
second reviewed whether any previous economic model had modelled the same decision problem, 
used comparable treatment patterns or adopted a structural design that could potentially be used or 
adapted in this case study. Studies published in English and Spanish were sought from specialized 
electronic databases in medicine, health economics and health technology assessment. For details of 
the literature searches and main findings see Appendices 1 and 2. 
The first search update was performed on May 8th 2013, and aimed to identify the relevant clinical 
literature.  Using OVID browser, Journals@Ovid, LSHTM Journals@ovid, ACP Journal Club (ACP), CCTR 
(formerly Cochrane Controlled Trials Register), the Cochrane Database of Systematic Reviews (COCH), 
CAB abstracts, Econlit, Embase and Scielo were searched from their date of inception up to the above 
mentioned date. The search terms used were: [haemophilia A], [haemophilia A], [coagulation ADJ3 
disorder], [clot* ADJ3 disorder*], [clot* ADJ3 deficiency], [prophylaxis], [primary ADJ3 prophyl*], [on 
demand], [on- demand], [arthropath*], [arthrosis], [joint damage*].  These were used taking into 
account headings and sub-headings and their correspondent wording in Spanish. Boolean operators 
OR and AND were used as follows: (OR) to combine synonyms, headings and sub-headings and (AND) 
to combine different concepts. 
The inclusion criteria were: complete articles published in English or Spanish from 1970 onwards 
including systematic reviews, meta-analyses, randomized controlled trials, cohorts, case and control 
studies, case studies, full economic evaluations and review articles. 1970 was set as the start date, 
being the time when the first reports about the inception of plasma-derived clotting factors and the 
start of prophylaxis were published.  
Information on patients of all ages and from all kind of studies was sought, since SHA is a rare condition 
looking only for RCTs could severely constrained the number of studies retrieved. Only publications 
considering the clinical effectiveness of different treatment options for SHA (regardless of 
complications, age of diagnosis or time of treatment initiation) were eligible. Publications that 
described and/or compared OD versus PP for SHA were also included. Outcomes including at least one 
of the following: frequency of bleeding episodes, mortality, potential complications, quality of life and 
joint damage were considered.   
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The exclusion criteria were: publications considering patients with any coagulation disorder other than 
haemophilia A, and any stage other than severe cases (level of activity of clotting factor > 1%); 
publications addressing patients with acquired haemophilia A, clotting factor inhibitors or HIV co-
infection (due to the differences of clinical presentation, natural course of disease, co-morbidities, and 
therapeutic response to usual treatment).  
Quality control and assessment of data included extraction and a synthesis of published evidence. 
PRISMA work flow was used to systematically assess papers retrieved, control for duplication and 
assess eligibility criteria. A total of 166 articles were retrieved from the search and identified as 
potential relevant references; 25 records were added to the total number of possible articles to be 
analysed. 147 publications were recognized after controlling for duplicates, and 110 abstracts were 
screened searching for relevant data.  
After abstract screening, 41 articles were excluded because they did not specifically address the main 
topic of research; 69 full text articles that described and/or compared different treatment options for 
hemophilia A were scoped for eligibility. 13 full text articles were excluded with reasons, and finally 
56 publications were included in the analysis. Due to the heterogeneity of studies and outcomes 
reported, no studies were included in a quantitative synthesis of evidence (meta-analysis). See 
Appendix 2.1 for a detailed graphic of the PRISMA flow. 
The second search aimed to identify previously developed economic studies for SHA that compared 
the two interventions of interest.  A preliminary search of the literature carried out by Miners in 2012 
and published in 2013 was extended and updated on May 15th 2013. The following databases were 
searched: The Health Technology Assessment database, The NHS Economic Evaluation Database- 
HEED, and Ovid Medline.  
Combinations in English of the terms [haemophilia], [hemophilia], [cost], [economic-analysis], 
[economic-evaluation], [economic-study], [cost-effectiveness], [cost-benefit], [cost-utility] were used. 
These were used taking into account headings and sub-headings. Boolean operators OR and AND were 
used as follows: (OR) to combine synonyms, headings and sub-headings and (AND) to combine 
different concepts together (see Appendix 1 for the detailed search history of both searches). 
Inclusion criteria were: complete articles published in English from their date of inception.  Systematic 
reviews and full economic evaluations (i.e. those that focused on the costs and health outcomes 
associated with treatment and cost-minimization analyses) were considered. Only publications 
comparing PP versus OD treatment for SHA were eligible. Exclusion criteria were similar to those of 
the first search on the clinical effectiveness of PP.  
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Quality control and assessment of data included extraction and a narrative synthesis of published 
studies. PRISMA work flow was used to systematically assess papers retrieved, control for duplication 
and assess eligibility criteria. A total of 178 articles were retrieved from the search and identified as 
potential relevant references; no records were added to the total number of possible articles to be 
analyzed. 113 publications were recognized after controlling for duplicates; after a title search, 23 
abstracts of full economic evaluations or reviews were considered relevant and screened for 
information.  
After abstract screening, six articles were excluded because they did not specifically address the main 
topic of the research; 17 full text articles that specifically described findings of PP versus OD for severe 
hemophilia A were scoped for eligibility. Four full text articles were excluded with reasons, and finally 
a total of 13 publications were included in the qualitative analysis. (See Appendix 2.2 for a detailed 
graphic of the PRISMA flow).  
Most of the model inputs were derived from the published literature. Besides the cost of exogenous 
replacement therapy, other costs associated with the long-term treatment of severe haemophiliacs 
included were: general practitioners and specialist visits, central venous catheters and catheter 
infection treatment, conventional radiology, ultrasonography and MRI, as well as minor and major 
orthopaedic surgery, orthopaedic equipment, and physiotherapy (See Table 1 for a list of input 
parameters used for the economic model). 
FVIII dosing schedule 
The dose of PP was set based on the clinical trial of Manco-Johnson et al, (2007).  The primary outcome 
of this study was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, 
and elbows) by radiography or magnetic resonance imaging (MRI). Boys under 30 months of age were 
randomly assigned to PP (n=32) or to enhanced episodic therapy (n=33). PP dosage in the model was 
set at 25 IU/Kg three times per week for a minimum of 46 weeks per-year (3450 IU/Kg year); this 
dosing schedule represents the typical clinical approach to PP provision in Colombia.  When bleeding 
occurred during prophylaxis in Manco-Johnson’s study, patients received 40 IU/Kg of FVIII and the 
assigned prophylaxis scheme was resumed the next day; this approach was also incorporated in the 
model.  
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TABLE 1. Input parameters used for the economic model 
 
On the other hand, OD dosage in the base case departed from the enhanced episodic treatment 
presented by Manco-Johnson. In their study children were treated at the time of clinically recognised 
joint haemorrhage and received 40 IU/Kg at the time of haemorrhage, 20 IU/Kg at 24 hours and 20 
IU/Kg 72 hours after the first dose. Treatment was continued at 20 IU/Kg every other day until 
symptoms resolved, which in this study was expected to happen after week four. According to local 
experts41 (through informal consensus) recovery was assumed to happen in Colombia after two weeks 
of treatment instead of four, thus this regimen was incorporated in the model to make it more 
realistic. This equated to a total of 200 IU/Kg of FVIII per articular bleeding episode OD (form onset to 
resolution).  
Any other kind of extra-articular bleeding OD dosage (soft tissue, intra-abdominal or intra-cranial or 
post-surgery [form onset to resolution]) was estimated in 100 IU/Kg of clotting factor per-episode, this 
was transferred from Smith et al (1996) and Mannucci (2006) and validated with the local experts who 
considered it as plausible.  
The annual rate of bleeding 
There are numerous studies reporting the yearly bleeding frequency associated with PP.  For example, 
Vdovin et al (2011) evaluated three different prophylactic regimes of FVIII: 70 IU once-a-week, 30 IU 
+ 40 IU in different days per week, and 25 IU three-times-a-week (all per-Kg). It measured all bleeds 
and joint status in 32 paediatric patients, and reported that the median number of bleeds per-year in 
patients on prophylaxis ranged from 1.5-3.  
                                                          
41 Local clinical experts in haemophilia A care: two haematologists, one specialized in children and one in adult population currently working 
at two centres of excellence in central and northwest Colombia, one public health specialist familiar with heamophilia care from central 
Colombia.  
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In 2006, a study by Feldman et al compared a tailored prophylactic scheme for SHA, and showed that 
after a median follow-up time of 4.1 years 36% of patients developed target joints42. The median time 
to escalate from once to twice-weekly therapy was 3.42 years. There was an average of 1.2 joint 
bleeds per person-year. Ten subjects (40%) required central venous catheters.  
The mean estimates of bleeding episodes of Manco-Johnson et al (2007) were also considered. This 
study reported results of treatment branches PP and OD, and median values of 1.15 and 17.13 
(p<0,001) respectively. Whilst a mean value of 17.69 (CI +/-9.25) for bleeding episodes OD was very 
close to the median, a higher mean value and wider interval was presented for prophylaxis 3.27 (CI 
+/- 6.24). After looking at the mean values reported by Fischer and Van Den Berg (2003), Coppola et 
al (2008) and Vdovin (2011) in their observational studies, three bleeding episodes per-year with PP 
and 17 bleeding episodes per-year OD were selected as the input parameters for the base case model 
(close to mean estimates of Manco-Johnson et al in 2007). These seemed more realistic to clinical 
experts than more conservative estimates in the context of interest.  
Transition probabilities 
Input probabilities incorporated in the decision model included the annual probability of articular 
bleeding, the probability of extra-articular bleeding, the probability of dying from bleeding of any type, 
and the probability of developing arthropathy under each treatment branch.  
Whenever bleed occurs, the probability of it being articular was extracted from the published 
literature taking into consideration the data reported by Stachnik (2010), Wong and Vdovin et al 
(2011) and Kempton et al (2012). These authors estimated the probability a bleeding to be located in 
the joints as around 80% of all bleeding episodes, this figure was derived and validated by the panel 
of clinical experts who considered it as plausible in this context, thus incorporated in the model. The 
probability of presenting with extra-articular bleeding was calculated as the complement of the 
probability of articular bleeding.   
Data of poor quality from 2011 from the CLH was reviewed before considering other jurisdictions. 
Since in Colombia there is no available, updated and reliable data about the mortality rates and causes 
of death among SHA patients, henceforth the probability of dying from bleeding of any type was 
extracted from Darby et al (2007) which reported the life expectancy and causes of death of people 
with haemophilia A or B (non-HIV infected) in the UK from 1977 to 1999. This study reported that 145 
deaths from bleeding occurred during this 22 year period of observation.  
                                                          
42 Target joint- CDC definition MRI-positive findings after 3 bleeding episodes in the same joint over a period of 3 months 
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The study followed up 1320 severe haemophilic patients (type A and B) and reported that 81% of them 
were severe type A haemophiliacs (1069); by assuming a similar distribution among those who died 
from bleeding over the period of observation, a total of 117 deaths would have occurred from bleeding 
of any type among SHA patients (145 x 0.81). Hence the cumulative incidence over the 22 year period 
of observation was calculated as 0.109 (117/1069). This period hazard rate of dying from bleeding was 
annualized making use of the formula: 
 𝜇=
− ln[1−𝑃(𝑡)]
𝑡
   
As presented by Kuntz and Weinstein (in Drummond et al, 2001), where 𝜇 is the annual rate, P(t) the 
cumulative rate (0.109) and t the period of observation (22), it was estimated as 0.00526. By assuming 
that the annual hazard rate 𝜇  was constant over the study time horizon, the annual transition 
probability of dying from bleeding of any type was estimated as 0.00525 making use of the formula: 
 P(1)= 1- exp (−𝜇𝑡) 
Where P(1) is the annual probability and 𝜇𝑡  is the annual rate. The issue of the time difference 
between the publication of Darby´s study and this thesis was further considered before incorporating 
this data into the model; however, it was not perceived by experts as a major source of concern in the 
Colombian context.  
Similarly, the overall probability of developing arthropathy was estimated and extrapolated from the 
published evidence. No publications have reported the specific risk of developing arthropathy within 
each new bleeding episode and only two recent RCTs reported the risk rates of developing joint 
damage with PP and OD after a period of observation (Manco-Johnson et al, 2007 and Gringeri et al, 
2011). The characteristics of the dosing scheme and profile of participants in the Gringeri study limited 
extrapolation of results and left the former as the most reliable source of evidence for the model. 
Manco-Johnson et al reported that after a mean follow-up period of 49 months, 2 out of 27 patients 
(7.4%) with PP developed joint damage and for those OD, 13 out of 29 patients (44.8%) developed it 
(p=0.002). Joint damage in this study was defined as at least one joint with positive MRI findings. Using 
Miller and Homan´s (1994) approach, the monthly hazard rates of developing arthropathy with PP and 
OD were converted to monthly transition probabilities using the formula: 
 1-(1-P(t))^(1/t)  
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Where P(t) is the period rate and t the period of observation, hence monthly transition probabilities 
of 0.0120 for OD and 0.00157 for PP were calculated.  Since the decision model was expected to run 
yearly cycles, these monthly transition probabilities of developing arthropathy OD and PP were 
annualized in 0.145 and 0.0188 respectively by multiplying the monthly transition probabilities by 12 
and incorporated in the base case model.   
Other probabilities such as the annual probability of requiring a central venous access device (CVAD) 
with PP or OD and the probability of CVAD infection were not incorporated in the model. However, 
these were used to refine (weight) the annual consumption of resources to estimate “other medical 
costs”. These were also gathered from the Manco-Johnson study.  Over the follow-up period 29 
(90.62%) out of 32 patients in PP required CVAD, compared with 25 (75.75%) out of 33 OD. Among 
patients requiring a CVAD, infection occurred in 20.69% of PP cases, and 24% of OD patients. Using 
the method described before by Miller and Homan, these hazard rates were used to estimate the 
annual transition probabilities of requiring a CVAD and acquiring CVAD-associated infection among 
sub-groups. The annual probabilities of CVAD OD and PP were estimated as 0.3420 and 0.5659 
respectively; and of having CVAD infection 0.056 for OD and 0.067 for PP.  However the panel of 
experts expected the chances of CVAD infection to be similar regardless of the treatment allocated in 
Colombia, hence an average annual probability of 0.0615 was estimated to weight the annual costs of 
CVAD infection.  
Costs 
All relevant costs associated with replacement therapy with FVIII, follow up, bleeding episodes, and 
treatment of complications from chronic bleeding or joint damage were gathered from local sources. 
Costing considered the quantities of resources used per-patient per-year, as well as the local unit cost 
of health services consumed from the health system´s perspective. Besides exogenous factor 
consumption, it also calculated additional medical costs, taking into account the natural course of 
disease and local clinical standards. (See Table 2 for a detailed description of estimated costs and units 
used to populate the economic model; for the full table of input parameters see Appendix 3). 
The base case model assumed FVIII was administered at 3450 IU/Kg per-year for PP and 40 IU/Kg when 
bleeding occurred during prophylaxis, and for OD a total of 200 IU/Kg per articular bleeding and 100 
IU/Kg for any other kind of bleeding. Doses per-cycle in the model were adjusted using a table 
accounting for age-dependant weight variation of boys in the 50th percentile43; when patients reached 
adulthood all subjects were given a weight of 70 Kg in the base case model.  
                                                          
43 2 to 20 years boys chart- stature weight-for-age percentiles.  Source http://www.cdc.gov/growthcharts/data/set1clinical/cj41c021.pdf 
as per September 30th 2013. 
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The cost per IU of FVIII was estimated as COL$900 (USD$0.47)44 and the cost per IU of rFVIII COL$1450 
(USD$0.76). Prices in Colombia of FVIII and rFVIII had not been regulated or publically available at the 
time of writing up; hence a market reference of average costs per IU/Kg paid by health care insurers 
(EPS) was used to populate the model. Since the difference in costs between FVIII and rFVIII were 
substantial, a variant of the base case model was run considering the costs of rFVIII. 
Exogenous replacement therapy represented the biggest burden of resources consumed. Other 
medical costs such as number of units consumed per-year of general practitioner, haematologist and 
orthopaedist visits for both regimes, as well as MRI and radiology tests and physiotherapist sessions 
after bleeding were considered to have an annual frequency of use of more than one. Cost of services 
such as arthrocentesis, sinovectomy, arthroplasty, orthopaedic surgery devices and the use of walking 
aids OD were also included in the category of other medical cost, these were not as frequent as those 
described above, but seemed important for the accuracy of costing. For these services, unit 
consumption was expected to be less than one per-year, hence the annual frequency of use was 
proportionally adjusted making use of frequency weights informed by published data and experts´ 
input.  
Most of the data used to assign weights was gathered from cross-sectional population surveys, 
presented to the local experts who provided additional estimates used to populate the model. For 
instance, to estimate the number of ultrasonography tests and arthrocentesis (joint aspiration) OD 
per-cycle, the data reported by Manco-Johnson et al (2007) were used to inform local experts about 
the expected number of life-threatening haemorrhages among patients per-year (0.0222). Also a 
study published by Rodriguez et al in 2011 reported that in up to 50% of all cases of massive 
haemorrhage within the joints it was necessary to aspirate the blood and use ultrasonography to 
minimise scarring and injury, hence the panel agreed on using 0.0111 (0.0222 x 0.5) as a frequency 
weight to refine the annual number of units for these two interventions. 
According to Hilgartner (2002) and Windiga, et al (2005), it was estimated that up to 25% of all patients 
would require sinovectomy over their life span (65 years), hence a 0.0038 (0.25/65) frequency weight 
per-year was considered to estimate the cost of this intervention per cycle. Costs of arthroplasty and 
orthopaedic prosthesis and material needed to perform the intervention were refined in accordance 
with Windyga et al (2005), Gorina et al (2002) and Aznar et al (2000) who estimated that OD patients 
would require two major orthopaedic surgeries throughout life, by estimating an annual frequency 
weight of 0.0307 (2/65).  
                                                          
44 Currency exchange rate as per July 12th 2013. Source http://www.oanda.com/. All calculations in this thesis were developed making use 
of the same exchange rate from COL$ to USD$. 
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TABLE 2. Estimated costs, units and probabilities used for the economic model 
 
The same situation was assumed for those patients requiring walking aids OD at an expected 
frequency over a lifetime of up to 40% (Windyga et al, 2005), an annual average frequency weight of 
0.006 (0.40/65) was used to refine this cost in the model. In the case of medication, steroidal anti-
inflammatory drugs costs were based on Gorina et al’s (2002) estimations that 85% of haemophiliac 
adults had been offered medication to control swelling or haematuria at least once in their lifetime, 
hence the panel considered it adequate to multiply annual cost of medication by weighting it at a 
factor of 0.013 (0.85/65). To estimate annual weights for other medical costs the panel assumed a 
uniform distribution of resources consumed over the period of observation. All presented data were 
considered plausible in the setting of interest.  
Unit costs of central venous implantation, MRI, radiology, ultrasonography, physiotherapy sessions, 
arthrocentesis, sinovectomy, and arthroplasty per joint were estimated using the reference tariff 
manual ISS 2001 (Manual del Instituto de Seguro Social year 2001), which is widely used by insurers 
and health care providers to purchase health care services in Colombia. Unit costs of visits to general 
practitioners, haematologists and orthopaedists were also estimated using this manual. The global 
tariff was refined by informal consensus with local experts (purchasers) adding a 30% factor to control 
for inflation and regional variability of prices. 
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The costs of osteo-synthesis material for major orthopaedic surgery, central venous catheter and 
walking aids were gathered from local market reference prices collected by the researcher from a 
small sample of local retailers; cost of antibiotics to treat central catheter infection or prednisone to 
treat severe joint swelling or haematuria were gathered from SISMED 2013 (the official site of prices 
for medicines in Colombia).  Finally “other medical costs” per-cycle incorporated into the model were, 
COL$3,566,195.23 for OD no arthropathy, COL$3,852,416.35 for OD with arthropathy, 
COL$2,088,386.52 for PP no arthropathy, and COL$2,374,607.64 for PP with arthropathy. Costs are 
presented in Colombian Pesos (COL$) and corrected for inflation if not gathered for the year 2013.  
Utilities 
The further impact of chronic arthropathy, the most frequent complication of bleeds, is expected to 
have a deleterious impact on the overall HR-QoL. Collecting and gathering utilities for the health states 
incorporated into the model represented a major challenge for the researcher since no general 
instruments to assess preferences for health states have been formally applied in Colombia (either to 
patients or general population). Under these circumstances the first option to estimate utilities to 
populate the model was to look at published references. The Tufts cost-effectiveness analysis registry 
(CEA) was searched for this purpose. 
The CEA search suggested that lower utility values may be reasonable for patients with haemophilia 
who develop further complications versus those who do not, e.g. HIV co-infection 0.680 vs. 0.710 
(Lippert et al, 2005) or inhibitors 0.660 vs. 0.850 (Knight et al, 2003). Risebrough et al (2008) reported 
differential utility values for those with and without complications irrespective of the treatment 
allocated (0.920 for PP without port complications and 0.875 PP with port complications, the same for 
those OD who did not meet the target joint bleeding criteria (0.905) and those who did (0.875)), thus 
making feasible the assumption that those patients who developed further joint damage may 
experience lower HR-QoL than those who did not.   
This search also supported the preliminary aim of giving differential utility values according to the 
treatment allocated. For instance, Miners in 2002 and Colombo in 2011 reported higher utility values 
for 30-year-old HIV-negative individuals with PP compared to OD (0.87 versus 0.66 respectively). In 
2009 Miners again used differential utility values of 0.50 for OD and 0.71 for PP. In 2005 Lippert et al 
reported utility values of 0.760 for severe haemophilic patients A and B (age less than 30) on 
prophylaxis and 0.730 for those OD (age less than 30). Nonetheless, no utility values have been 
published in the literature to account for the health states described in the base case model “Alive PP 
and no arthropathy”, “Alive OD and no arthropathy”, “Alive PP and arthropathy” and “Alive OD and 
arthropathy”.  
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CEA registry findings were discussed with the panel of experts who believed the utility value of being 
treated with PP could be expected to be higher than for those OD because the positive impact of 
prophylaxis on the frequency of bleeds bears the potential of making severe cases comparable to the 
clinical profile of moderate cases of disease (Miners, 2009 and Farrugia, 2013). This view coincided 
with Risebrough´s (2008) report of 0.950 and 0.920 for those in PP (without port and with port) and 
those OD 0.905 (without target joints). Nonetheless, Risebrough´s values did not specifically address 
severe patients as was the aim of the base case model. Similarly, Lipperts´s study reported utility 
values for type A and B haemophiliacs of 0.760 for those on prophylaxis (secondary) and 0.730 for 
those OD, and also lower values (0.680 and 0.660 respectively) for older populations, which might 
represent an age-dependent disutility factor that was not considered in the base case model.  
Tufts CEA registry was also searched for utilities associated with chronic joint damage, arising from 
health conditions other than haemophilia (e.g. rheumatoid arthritis, osteo-arthritis). This latter option 
was discarded by clinical experts since the clinical spectrum and comorbidities of other diseases that 
can also lead to joint damage may clearly differ from the utility values related to haemophilia and 
haemophilic arthropathy. 
With such a shortage of published data, the second best option was to use primary or secondary 
sources of local data to populate the model. A cohort of 48 Colombian patients that had been followed 
up since 2009 served as a secondary local source to be inserted into the model.  A total of 31 severe 
haemophilic A patients (18 treated OD and 13 with PP) and their clinicians (5) participated in a recent 
survey that used the Haemophilia Joint Health Score (HJHS) questionnaire and a Spanish version of 
the EQ-5D to elicit their preferences about health states associated with haemophilia and joint 
damage.  
The HJHS (Feldman, et al 2011) is a multidimensional clinic-metric tool that is reported to be more 
sensitive than the WFH questionnaire to diagnose early joint damage among the haemophiliac 
population. HJHS evaluates 6 “index joints” (elbows, knees and ankles) using a quantitative scale from 
0 to 124 points to capture joint damage progression by a trained physiotherapist. The scale evaluates 
swelling, duration of swelling, muscle atrophy, axial alignment, and crepitus of motion, flexion loss, 
extension loss, instability, joint pain, strength and gait. HJHS also relies on a physician’s global score 
of joint health consisting of a series of six 10 cm visual analogue scales (VAS), one for each index joint, 
whereby 1 equals “no complaints, no findings” and 0 equals “continuous pain, severe limitations, 
worst damage”, and one VAS for the overall assessment of arthropathy on HR- QoL whereby 1 equals 
“no impact on life” and 0 equals “most severe impact on life”. Each yields an individual score and the 
average of the 6 joints yields the total physician’s score. 
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During February and May 2012 five clinicians in charge of the cohort were asked to complete the HJHS 
questionnaire per-patient and assess the overall impact of arthopathy on HR-QoL in the sub-groups 
treated with PP and OD. Patients were also asked to self-assess their overall HR-QoL associated with 
arthropathy using the same 10 cm VAS anchored by 1 which equals “no impact on life” and 0 equals 
“most severe impact on life”. They were also asked to answer the Spanish version of the EQ-5D. Thus 
the potential options to estimate health state preferences from this cohort were the VAS scores from 
patients and physicians and EQ-5D scores from patients. 
Various methodological limitations of VAS scores restricted its use in the base case model. For 
instance, the rating scale scores are not an interval scale of preferences (Torrance 1976, Torrance et 
al 1982, 1996 and 2001; and Robinson et al 2001), or the “end of scale” bias in which subjects tend to 
resist using the extremes of the scale, and “context” bias in which respondents tend to spread 
outcomes over the scale regardless of how good or bad those states are (Bleichrodt and Johanesson, 
1997, and Torrance et al in 2001).  
Despite its limitations, however, EQ-5D scores represent preferences gathered using a multi-attribute 
generic questionnaire where pain/discomfort and mobility are scored as separate dimensions. These 
two dimensions seemed potentially useful to populate the model since they could be relevant 
whenever assessing joint damage.  Thus, the local EQ-5D scores from patients were chosen as the best 
available source of data to estimate QALYs.  
It should be noted that in Colombia the EQ-5D 3 level questionnaire has not been formally applied to 
a random sample of population, hence the scoring function has not been measured using time trade 
off (TTO) or standard gamble (SG) techniques. Utility values for each of the four possible health states 
of interest were therefore calculated making use of the UK tariffs (Dolan et al, 1995), these were 
chosen because of the rigorous method of elicitation followed by the authors. However, from the 
above-mentioned dimensions and after further consideration, pain/discomfort was not considered as 
a reliable source to estimate utilities, since these symptoms may be unspecific and not necessarily 
joint damage-related in SHA patients according to the panel of experts´ perception. Therefore health 
states related to chronic arthropathy were assumed to be those reported in the EQ-5D 3L with a score 
of 2 or more in the mobility dimension of the questionnaire. This assumed that the main differences 
in quality of life among sub-groups were associated with joint damage and not derived from any other 
variable or comorbidity.  
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Basic statistics were performed to calculate score of tariffs per-patient, and the mean utility value for 
each one of the model health states. The utility of “Alive-no arthropathy” PP was initially calculated 
as 0.942 which was close to Noone et al´s 2011 estimates (0.930 for the Swedish population on 
prophylaxis) and Risebrough et al in 2008 (0.950); the utility of “Alive-no arthropathy” OD was 0.925 
which was close to that reported by Risebrough et al in 2008 (0.905); the utility of “Alive-with 
arthropathy” PP was 0.756, similar to that reported by Lippert el al in 2005 (0.760) for severe type A 
and B patients aged under 30; and the utility of “Alive-with arthropathy” OD was 0.679, similar to that 
reported by Lippert el al in 2005 (0.660) for severe type A and B patients.  
However, after further consideration, the uncertainty of parameters in such a small sample and 
evidence of age heterogeneity among sub-groups limited the possibility of using differential utility 
values for the before mentioned four health states of interest. For instance, of sub-groups PP versus 
OD (mean age = 8.3 versus 25.4 years respectively) and those who had developed joint damage and 
those who had not (PP mean age without arthropathy  8.0 versus 9.3 years with arthropathy; and  OD 
mean age without arthropathy 14.5 versus 28.5 years with arthropathy).   
Therefore a more conservative approach was advised for the base case model in which the same 
average utility scores were to be used, irrespective of the treatment allocated. However, since joint 
damage is expected to have a further negative impact on the overall quality of life of those who 
develop it, a lower utility value was considered for those with a score of 2 or more in the mobility 
dimension of the EQ-5D questionnaire. Making use of basic statistics an aggregated mean score of 
tariffs was estimated for those with PP and OD without joint damage and with it (scores of less than 2 
or 2 or more respectively, in the mobility dimension). The utility value was estimated as 0.937 for 
those without joint damage and as 0.639 for those with joint damage irrespective of the treatment 
allocated. The previously published utility values for haemophilia A and the VAS scores from physicians 
and patients were set as parameters to be used in the sensitivity analyses.  For all variables and health 
states half cycle correction was incorporated in the base case model.  
Table 3 shows the demographic, clinical and HR- QoL characteristics of the local sample of patients. 
There were 13 patients with PP and 18 OD, the table shows the number of patients OD and with PP 
who developed joint damage, VAS average scores gathered form examiners and patients and also the 
EQ-5D average tariffs by sub-groups, mean age and number of bleeds per-year by sub-group.  The 
utility values highlighted are those used in the base case model. (See Appendix 4 for further details of 
patient scores and demographics).  
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TABLE 3. Demographic, clinical and HR-QoL characteristics of local sample of severe haemophiliac A 
patients 
 
To account for time preference within the model, discounting rates for costs and outcomes were 
incorporated. In Colombia there is no “reference case” in place to control for structural uncertainty of 
economic evaluations, only preliminary HTA work, and a local clinical practice guidelines (CPGs) 
manual from 2010 (Ministerio de la Proteccion Social) that incorporates economic modelling suggest 
discounting both costs and outcomes at rates ranging between 0 and 5%. Recent HTA work in 
Colombia for the development of 24 CPGs published in 2013, discounted costs and effects at an 
arbitrary rate of 3% (no empirical data were used to support this figure). Since no empirical work has 
been undertaken in Colombia to estimate discounting rates, it was necessary to look at current policies 
of a relevant HTA authority such as the NICE in the UK (NICE Guidance, 2011). NICE guidance states 
that where a treatment’s effects are both substantial in restoring health and sustained over a very 
long period of time (at least 30 years) it should be applied at a rate of 1.5% for health effects and 3.5% 
for costs, thus these discounting rates were incorporated in the base case model, bearing in mind local 
guidance, the range 0 - 5% for health effects and costs was used in the sensitivity analyses.  
Analysis 
A theoretical cost-effectiveness threshold of one to three times the current Colombian gross domestic 
product (GDP) per-capita was set as the WTP decision rule, although WHO recommendations use this 
threshold as WTP for DALYs averted45, it could serve as a point of reference to inform decision-makers 
in Colombia.  
                                                          
45 Source WHO at http://www.who.int/choice/costs/CER_thresholds/en/index.html.  DALYs Disability Adjusted Life Years. The Commission 
on Macroeconomics and Health-CHOICE uses GDP as an indicator to derive three categories of cost-effectiveness: highly cost-effective (< 1 
GDP per-capita); cost-effective (1-3 times GDP per-capita); and not cost-effective (> 3 times GDP per-capita). 
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The Colombian GDP per-capita for the year 2012 was USD$8,127 (COL$15,528,700)46 47and when 
corrected for inflation for the year 2013 it reached COL$16,152,95448 (USD$8,445). Hence, if the ICER 
is up to three times the Colombian GDP per-capita 2013 (USD$25,335 or COL$48,458,861), the 
intervention is considered cost-effective  
To control for methodological, structural and parametric uncertainty, statistical methods for economic 
evaluation alongside deterministic and probabilistic sensitivity analyses were used. One-way and two-
way sensitivity analyses (SA) were conducted to check for the impact of variables considered crucial 
in the model. The variables chosen were cost of FVIII and rFVIII, utilities, probability of having an 
articular bleeding episode and of developing arthropathy, discount rates for costs and QALYs, and 
number of bleeding episodes per-year OD and with PP.  
The deterministic sensitivity analyses of costs of FVIII and rFVIII varied, assuming a hypothetical 50% 
increase and a 90% decrease in costs. Discount rate for costs and QALYs was varied according to NICE 
and local guidelines49 from 0% to a rate of 5%. The ranges for one-way sensitivity analyses were 
obtained from the literature. The number of bleeds OD varied from 8 to an upper value of 27 and for 
PP from 0 to 9 as reported by Manco-Johnson et al, 2007.   The utility values for both OD and PP were 
deterministically ranged taking in to consideration the lowest values reported by Miners in 2009 
(0.500 OD and 0.710 PP) and the highest values obtained from the local sample of patients (0.883 OD 
and 0.942 PP). The probability of articular bleeding was ranged according to Stachnik et al, 2010 and 
Kempton et al, 2012 published values (0.5-1.0). The probabilities of developing arthropathy or dying 
from bleeding were given a 50% range variation from the base case model accounting for the 
uncertainty regarding joint damage development and severity of bleeding events between the country 
of interest and the origin of data.  
Probabilistic Sensitivity Analysis (PSA) was conducted to take into consideration the uncertainty of 
parameters and structural assumptions of the model. PSA was conducted on variables such as the 
number of bleeds, utilities and the probabilities of articular bleeding, dying from bleeding, and of 
developing arthropathy with both treatment options simulating 1000 iterations. To deal with 
parameter uncertainty, distributions for the PSA were chosen according to the characteristics of each 
of the random variables.  (See Table 4 for deterministic and probabilities distributions used for the 
sensitivity analyses; see Appendix 5 for a detailed description of means, standard errors, probabilities 
and other parameters used to calculate probabilities distributions for PSA). 
                                                          
46 Report of selected countries and subjects. International Monetary Fund. Source As per 16 of May 2013 
http://www.imf.org/external/pubs/ft/weo/2012/01/weodata/weorept.aspx?   
47 Currency exchange rate as per July 12th 2013. Source http://www.oanda.com/ . All calculations from COL$ to USD$ used the same rate 
48 2013 correction inflation in Colombia 4,02% 
49 Source: http://www.pos.gov.co/Documents/GUIA%20METODOL%C3%93GICA%2023%2011%2009-1.pdf 
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TABLE 4. Sensitivity analysis of the key variables in the Markov model 
 
The number of bleeding episodes per-year with PP and OD were considered as discrete variables (3 
and 17 respectively) in the model, and since bleeding episodes occur in the model within an interval 
of one year per-cycle and always adopt values from 0 upwards, a Poisson distribution was considered 
as adequate for this purpose. Each year a “rare” event - bleeding - occurs with a probability that rapidly 
decreases over the period of observation. The distribution parameter Lambda (λ) represents the 
expected average number of events in the relevant period of time. In this case λ was 3 for PP and 17 
for OD.  
A beta distribution was selected for the utilities and probabilities of bleeding, arthropathy 
development and dying; these are all continuous variables with values lying in an interval between 0 
and 1 in a distribution with beta (β) parameters (alpha, beta). The mean probabilities and number of 
patients reported in the published sources were used to estimate α and β; in the case of utilities of 
health states, the secondary data from the local cohort of patients was used and  mean utility scores 
and standard deviations were used to estimate α and β parameters. 
RESULTS: 
Once the base case model had been rolled back, the ICER calculated for PP versus OD treatment for 
SHA using FVIII throughout life was COL$105,081,022 (USD$55,204) per QALY gained, and thus not 
considered cost-effective according to the threshold of up to three times the current Colombian GDP 
per-capita (USD$25.335 or COL$48.458.861). When PP was provided throughout life using rFVIII, 
which is much costlier than FVIII, this ICER reached COL$174,159,553 (USD$91,494) per QALY gained. 
(Table 5 shows the ICER with these two different therapeutic strategies).  
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Table 5. Results of the Cost Utility Analysis and ICERs per therapeutic approach 
 
One-way sensitivity analyses were performed to the perceived most relevant variables.  Ranging the 
probabilities of developing arthropathy with both treatment approaches at 50% intervals, did not 
show a significant impact on the final ICER, neither did ranging discount rates for QALYs and costs, 
from 0 to 5%. Only with a discounting rate of the effects very close to 0 was PP considered to be cost-
effective. 
The ICER results are sensitive to cost of FVIII, a reduction of 50% or more on the cost of FVIII would 
make PP cost-effective in Colombia (see Figure 6 for details). In the case of rFVIII only a 75% or more 
price discount would make PP cost-effective in this context.  
Figure 6. Sensitivity analysis of average (unit) cost of FVIII  
 
The model results are also sensitive to the utility values of living without arthropathy OD, varying the 
utility range of being alive without arthropathy OD from 0.5 to 0.942 does not reduce the ICER of PP 
up to a point of being considered cost-effective, this only happens with a utility of 0.2 or less in this 
health state (see figure 7). The opposite occurs with the utility of being alive with arthropathy PP, the 
higher the value of this health state the lower the ICER of PP, but not even when the utility value of 
this health state is closer to 1, PP becomes cost-effective.  
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Figure 7. Sensitivity analysis of utility OD without arthropathy 
Performing a sensitivity analysis on the number of bleeds, showed that if the number of annual bleeds 
OD reaches more than 19 episodes, PP dominates (more effective and less costly) OD treatment (see 
Figure 8); the opposite did not happen even if PP was able to reduce bleeding frequency up to 0. 
Figure 8. Sensitivity analysis of number of all bleeds OD 
 
The model results show sensitivity to the location of bleeding episode. Ranging the probability of 
having an articular bleed from 0.5 up to 1.0 shows that the higher the chance of bleeding within the 
joints, the lower the ICER of PP, making it cost-effective only above 0.95 (see Figure 9).  
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Figure 9. Sensitivity analysis of probability of articular bleeding 
 
A two-way sensitivity analysis was performed to assess the impact of total number of bleeding 
episodes on the final ICER. The total number of bleeding episodes OD had the biggest impact.  PP 
becomes cost-effective if patients OD experience more than 17 episodes per-year and if it is able to 
reduce bleeding episodes to 0. This also happens when the number of episodes per-year OD is higher 
than 19 and the bleeding pattern of patients in PP equals 9 episodes per-year (Figure 10). 
Figure 10. Two-way sensitivity analysis of number of bleeding episodes per-year OD vs. PP  
 
The Tornado diagram shows that the discounting rates for costs, cost of FVIII, number of bleeding 
episodes OD, probability of presenting with an articular bleeding, dosage/Kg per joint bleeding OD, 
probability to die from bleeding and dosage/Kg per any other bleeding OD had the biggest impact on 
the final reported ICER (Figure 11). 
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Figure 11. Tornado Diagram ICER Primary prophylaxis vs. on- demand 
 
The cost-effectiveness scatterplot (Figure 12) shows that PP is more effective, but also more costly 
than OD in almost all iterations, irrespective of the WTP.  
Figure 12. Probabilistic Sensitivity Analysis PP vs. OD CE scatterplot 
At a WTP of COL$48,458,861 (USD$25,335) the incremental cost-effectiveness scatterplot (Figure 13) 
shows PP is not considered cost-effective in any iteration when compared to OD.  
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Figure 13. Probabilistic Sensitivity Analysis PP vs. OD ICER scatterplot (WTP COL$48,458,861) 
 
 
 
The cost-effectiveness acceptability curve (Figure 14) shows that PP would only be considered as cost-
effective if the Colombian threshold were higher than COL$95,000,000 (USD$49,908). PP would be 
cost-effective at a range between COL$95,000,000 and COL$120,000,000 (USD$63,041). A formal 
willingness to pay for an additional QALY threshold does not currently exist in Colombia, but using 
WHO recommendations in all model iterations, PP was found not to be cost-effective at such a WTP. 
Figure 14. Probabilistic Sensitivity Analysis PP vs. OD- cost-effectiveness acceptability curve 
 
 
 
COL$ per additional QALY 
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DISCUSSION  
Severe haemophilia A is a life-long disease that can be highly costly to treat.  Therefore, the aim of this 
chapter was to perform a CUA of primary prophylaxis (PP) with FVIII versus treatment on-demand 
(OD) for people with severe haemophilia A in the context of interest. In answer to the research 
question: “what is the incremental cost-effectiveness of PP compared to OD treatment in 
Colombia?” the base case model showed an ICER of COL$105,081,022 (USD$55,204) per QALY gained 
whenever PP using FVIII is provided throughout life. When PP was provided throughout life using rFVIII 
(recombinant), which is much costlier than FVIII the ICER reached COL$174,159,553 (USD$91,494) per 
QALY gained. Sensitivity analysis showed that PP is more effective, but also more costly than OD in 
almost all iterations. PP would only be considered as potentially cost-effective if the Colombian 
threshold were higher than COL$95,000,000 (USD$49,908). A formal threshold does not currently 
exist in in this context, but using WHO recommendations of a threshold of up to three times the 
current Colombian GDP per-capita (USD$25.335 or COL$48.458.861) in all model iterations, PP was 
found not to be cost-effective at such a WTP. 
Only Miners has published a model structure that explicitly considered the decision problem of 
interest for this thesis, this model was later replicated by Colombo in 2011. Arguably, the structure of 
the de novo model presented in this thesis is an attempt to model in a more “clinically driven” manner 
the complexity of a long-term orphan condition, since it links joint damage with HR-QoL. For more 
than three decades the early initiation of PP in children has proven to be beneficial in preventing 
haemophilic arthropathy. However, in Colombia PP is still not usual practice and no previous HTA 
report has been produced for this health condition, the results from this CUA could perhaps be used 
to assist decision-making in this country. 
Strengths and limitations 
This economic study has attempted to add to the stock of economic evaluations for PP. Up until the 
present only one economic evaluation has been published for LMICs (Daliri et al, 2009) and no CUA 
has been published in these contexts. According to Miners (2013), studies that might be of use for this 
condition should collect utility data derived from discrete patient cohorts, link intermediate outcomes 
such as bleeds with longer term likelihood of developing arthropathy and, if necessary, gather expert 
opinion using formal elicitation methods to fill data gaps for insertion into appropriately designed 
decision models. Controvertibly, some of these methodological recommendations were considered in 
the model.  
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The main limitations of this CUA arose from the structural assumptions, methods and parameters used 
to populate the model. For instance the assumption that all severe haemophiliacs bleed at some point 
in life (spontaneously or traumatically), may not be completely accurate since according to Royal et al 
(2002), up to 10% of severe haemophiliacs have a milder bleeding pattern. The model developed 
included much uncertainty about the ability to detect subclinical spontaneous bleeding and 
subsequent joint damage, although MRI seems to be the gold standard for detecting both, the model 
did not incorporate the accuracy of diagnostics in its base case. 
The overall annual probability of developing arthropathy was adjusted in the base case after 
considering the probability of bleedings being articular (into the joints), this may have led to different 
ICER results. In the model whenever bleed occurs, the probability of it being articular was estimated 
as around 80% after looking at published observational data, although this figure was validated by the 
panel of experts, it departed form Manco-Johnson´s baseline estimations of a 48% joint bleeds rate 
per-patient per-year. This limitation was addressed by using one way sensitivity analysis, ranging the 
probability of articular bleeding up to 1. 
Haemophilic arthropathy in the model is assumed to develop at a constant pace, this assumed that 
transition probabilities did not change regardless of the cumulative effect that each new bleeding 
episode within the same joint would bring to future risk of bleeding. Instead it extrapolated the overall 
probability of developing joint damage after a 49 month period of follow up from a small RCT 
published in 2007 by Manco-Johnson. The lack of data limited the possibility of controlling for this 
“memoryless” limitation of the model by including differential transition probabilities to account for 
time dependence; this could have been attempted though, but not without introducing other sources 
of uncertainty into the model.  
In the base case, it was assumed that those patients who had recovered (stopped bleeding and 
stabilised) after having an extra-articular bleeding episode without previously having joint damage 
would always remained alive and without sequelae, this may not always be the case in real life since 
extra-articular bleeding may occur in different locations, i.e. soft tissue, intra-abdominal, intra-cranial 
or post-surgery, all these carrying important leverage in the overall quality of life. The utility of health 
states of individuals that developed joint damage remained the same throughout each cycle, this 
might not be realistic since incremental joint damage is expected to have a further deleterious impact 
on overall quality of life. 
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Complications from clotting factor application were assumed to be equal for PP and OD. Inhibitor 
development, another major complication is expected to be substantial, nonetheless chances to 
develop inhibitors were expected to be similar in both regimes and were not considered in the base 
case model, despite recent evidence that may support the effectiveness of prophylaxis in decreasing 
inhibitor incidence (Kurnik et al, 2010 and Gouw, 2013, Farrugia et al, 2013). 
The probability of dying from other causes was considered similar for haemophiliacs and the general 
population, and thus not incorporated in the model. This structural assumption may have led to 
different ICER estimations, however a scenario analysis considering  a probability of dying from other 
causes as of 0.00529 accounting for local estimations of the probability to die from all causes in general 
Colombian population resulted in an ICER per QALY gained of USD$74 lower than the one reported in 
the base case. Using a 0.0106 probability of dying from all causes as suggested by Darby in 2007 for 
SHA resulted in an ICER per QALY gained of USD$190 lower than the one reported in the base case 
scenario. 
The assumption that once treatment was commenced, patients in the model would fully comply and 
not switch between schemes throughout life may not be entirely realistic in a context like Colombia, 
or perhaps anywhere. According to Fischer et al 2008, up to 66% of patients suspend PP when they 
reach adulthood for different reasons; this was not incorporated in the base case scenario. This 
assumption coincides with the mechanistic approach of Miners´ (2009) model in that people are 
implicitly assumed to be fully adherent to treatment. Like Miners approach, the model assumes that 
people are efficient when they administer the exact dose of treatment, and no more or less than this 
amount is consumed.  
All patients entered the model at 2 years of age, although more customised protocols, depending on 
bleeding patterns and the onset of the first bleed may produce different findings. Radiological and 
follow-up costs were considered for the two treatment approaches, but additional costs of surgical 
correction of long-term joint impairment were only incorporated for OD treatment. All bleeding 
episodes were assumed to be of the same average severity (no life-threatening or minor events), and 
chronic joint damage was modelled as average clinical cases (not the mildest or the most severe). 
These assumptions may depart from the natural course of disease. 
It was assumed that up to 95% of costs of treatment were associated with exogenous factor 
replacement and although other medical cost were incorporated in the model, no further statistical 
analysis was considered to account for the uncertainty of costing. Costs were assumed to be uniformly 
distributed and non-variant over the lifespan of patients. 
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Blood-borne infections were expected to be non-existent if proper viral attenuation methods were 
used or if recombinant exogenous factor was supplied, hence they were not considered in the base 
case model, even though proper viral attenuation or recombinant FVII may not be available in all 
regions in a country like Colombia. Even if used or incorporated in a “current safe era”, uncertainty 
remains about prions or yet-to-be discovered pathogens. 
Another limitation of this study is the use of international rates for discounting costs and outcomes 
after the lack of methodological standards in Colombia. Although NICE guidance was followed in the 
analyses, the economic evaluation results should be interpreted cautiously, since applying a discount 
rate of 1.5% to the effectiveness and 3.5% to the costs may not be appropriate for the Colombian 
setting. This absence of standards leads to methodological and parametric uncertainties regarding any 
HTA results. 
To estimate utilities a Spanish version of the EQ-5D was used and health states related to chronic 
arthropathy were assumed to be those reported with a score of 2 or more in the mobility dimension 
of the questionnaire by assuming that the main differences in quality of life among sub-groups were 
associated with joint damage and not derived from any other variable or comorbidity. The average 
age among sub-groups was very different in each cohort (9.9 years PP vs. 25.1 OD), this heterogeneity 
carries uncertainty on how age difference or age-related comorbidities may have affected the mobility 
dimension as was incorporated in the analysis, although the source used was considered the best 
available evidence in this setting no sub-group analysis for age dependent heterogeneity was 
performed in the PSA. 
To estimate utilities, UK tariffs were used to calculate QALYS since no local tariffs have been estimated 
in this context. In addition to limitations from extrapolating tariffs of the EQ-5D questionnaire, this 
approach has been found to be insufficient to reflect social preferences for treating severe illness 
before less severe illness (Nord, 1996), and also to control for the ‘disability paradox’ where patients, 
as a result of adaptation, typically report greater quality of life scores than healthy individuals in similar 
circumstances (Ubel et al, 2005).   
Comparison of methodology and results with existing CUA 
Model results were within the wide range of published studies that have estimated incremental costs 
per QALYs gained. For instance, Miners in 2002 estimated an ICER of £46,500; in 2008 Risebrough 
estimated an ICER of CAN$542,938 for an escalating dose regime versus OD; in 2009 in the UK Miners 
updated his previous publication and re-calculated an ICER near £10,000 lower than his previous 
estimates. 
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In 2011 Colombo published an ICER of €40,236 in Italy and considered PP as a cost-effective 
intervention and Farrugia in 2013 stated that prophylaxis was dominant over OD treatment in the UK; 
his model resulted in an ICER of USD$68,000 within the range of treatments reimbursed in the USA, 
and of SEK1.1 million in Sweden, which was also within the range of reimbursed treatments in that 
country.  
It is interesting to note how ICER results in this study are much higher than those reported by other 
authors that have also modelled treatment with rFVIII throughout life and from a similar perspective 
(COL$174,159,553 or USD$91,494 per QALY gained) versus Miners in 2009 (£38,000 or 
[COL$144,586,669 or USD$60,970 50 ]), Colombo et al in 2011 (€40,236 [COL$111,676,372 or 
USD$62,970]), and Farrugia et al, 2013 (USD$68,000 or COL$129,931,000), all these also per QALY 
gained. This may reflect the substantial influence of the unit cost of clotting factors in unregulated 
prices settings like Colombia.  
As in other publications, the results of the base case model were sensitive to input parameters. The 
model dosage schedules for PP considered the Mälmo protocol´s recommendations of 25 IU/per Kg 
for 46 weeks at minimum. This schedule was lower than that used by Colombo (2011) who used 30 
IU/Kg every other day, and similar to Farrugia´s (2013) who also used 25 IU/Kg every other day; but it 
clearly departed from the Miners (2009) approach who used an in vivo clotting factor threshold of 1 
IU/dl as the clinical target to achieve.  
The model also included a lower dose regime than that presented by Manco-Johnson, in the case of 
bleeding OD 200 IU/Kg were to be administered in the base case model instead of 320 IU/Kg as per 
the enhanced approach. The different approaches adopted by each author to assess clinical 
effectiveness of PP may explain the difference in results.  The scarceness of published data and 
variability of methods makes validation of consistency of results from this study more difficult. 
The number of bleeding episodes per-year in the base case model with PP was similar to that used by 
Colombo (2.5- 5.4) and identical to Farrugia (3), but much lower for OD than that reported by these 
same authors (33.7-36.9 vs. 36 respectively). Other input parameters also differed from previously 
published studies. For instance, discounting rates of the model were within the range of published 
studies from 3.5-6% for costs (Risebrough et al, 2008 and Miners et al 2009 vs. Colombo et al, 2011) 
and from 1.5- 6% for QALYs (Miners et al, 2002 and Farrugia et al, 2013 vs. Colombo et al, 2011). 
Nonetheless the base case model used the lowest rates reported in the literature. This wide range of 
input parameters may well also explain the variability of published data. 
                                                          
50 Currency Exchange rate at http://www.oanda.com/ as per July 15th 2009 and corrected for inflation to COL$ at present value (Nov 2013). 
Source of inflation rates 2009-2013 http://www.dane.gov.co/index.php/indices-de-precios-y-costos/indice-de-precios-al-consumidor-ipc 
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Many of the major limitations of this work lay in the assumptions made for modelling, like all 
previously published studies on haemophilia have done. For instance, in 2009 Miners assumed that 
life expectancy for individuals with severe hemophilia was equivalent to that of the general regional 
male population, whilst this population is expected to live at least 15 years less (Darby, 2007); the 
present study was no exception and also assumed that life expectancy for patients with SHA in 
Colombia was similar to those of HICs. 
Miners also assumed that HR-QoL of those on PP was equivalent to people with mild/moderate 
haemophilia, this coincides with Farrugia (2013), although no clinical metric publication comparison 
of different health states has backed such assumption. Departing from this, this study assumed a 
milder clinical profile for those who have not developed arthropathy irrespective of treatment 
allocated. In the publication by Miners (2009) values used to estimate likely outcomes OD were 
derived from a cross-sectional study of HCV infected haemophiliacs, on its part the HR-QoL 
estimations of this study where gathered from a small sample of patients using a non-validated (in 
Colombia) Spanish version of the EQ-5D questionnaire. 
In 2011 Colombo developed a model where patients started prophylaxis at birth which does not seem 
clinically realistic according to bleeding patterns and the natural course of disease. This author 
obtained the utility of the health state “requires major surgery” from Laupacis (1993) who assumed 
that all individuals in that state suffered from a painful condition similar to that of individuals with 
post-surgery osteoarthritis, which is not accurate from a clinical standpoint. This same approach was 
initially considered but later precluded after further consideration by the panel of local experts.  
Lippert et al in 2005 assigned differential utility values for OD and prophylaxis. Also Miners (2009) and 
Risebrough (2008) used 0.5-0.905 and 0.71-0.95 for OD and PP respectively. Initially the model 
attempted to estimate differential utility values for all health states of interest but after further 
consideration about the limited size of the sample and evidence of heterogeneity among sub-groups, 
an average utility estimate was used for those without joint damage (0.937) and for those with it 
(0.639) irrespective of treatment allocated. This latter assumption however is more conservative and 
may have led to different results from using differential utility values for each health state in the 
model. This estimation of utilities probably represented the major limitation of this part of the study 
since the health states preferences to estimate QALYS were gathered from a local cohort of only 31 
patients. 
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Issues for conducting HTA by making use of economic models in the case of SHA in Colombia 
Haemophilia itself, as a topic of interest, represented a challenge. It was a challenge to deal with the 
limited number of RCTs comparing PP versus OD for SHA. The rareness of this disease, the potential 
ethical limitations for conducting new interventional research and the fact that most of the published 
evidence on the average effect of PP has been produced in HICs, impose additional methodological 
constraints for researchers conducting economic evaluation not only in Colombia, but also elsewhere 
in LMICs.  
Economic studies comparing PP versus OD treatment were also very limited. Only six CUAs have been 
published and some of these took different perspectives to that of the health system, as adopted in 
the case study or modelled short time horizons. Three of the publications adopted a similar standpoint 
that of this thesis and just two of them specifically modelled the costs and effects of the problem of 
interest and adopted the same perspective (Miners 2009, Colombo 2011).  
The Drummond et al (2009) framework helped the researcher to identify the main issues that 
prevented the transferability or adaptation of HTA results from other jurisdictions (“general and 
specific knock out criteria”), but also served to identify methodological factors that may make HTA 
work difficult in this context.  
When referring to the issues for conducting HTA depicted in this case of study in Colombia, it is worth 
mentioning that although there is an incipient health information system, the methodological 
challenge of modelling presented the researcher with information constraints about costs and quality 
of life to fill in the gaps within the base case. Data on costs were fragmented and came from a broad 
array of sources ranging from tariffs that have regional variations, market reference prices subject to 
hidden extra loads resulting from intermediation, and variability in the units of consumption resulting 
from heterogeneous clinical approaches in a context which lacks of CPGs for this condition, especially 
in the case of treating OD bleeding episodes.  
In the case of health states-related quality of life information, utilities were estimated using a small 
sample of local patients’ data, and the researcher was forced to make some strong assumptions in 
order to simplify the intricate and long-term natural history of disease. The severe shortness of local 
data about disease-specific or general health preferences (specifically addressing haemophilia A joint 
damage) was probably the biggest methodological concern for modelling. These contextual data 
constraints may represent major hurdles to producing quality HTA in this country. It is worth noticing 
that besides costs and utility data, virtually none of the other parameters were gathered from Latin 
American sources.   
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There are some other methodological factors that may make HTA work difficult in Colombia, especially 
dealing with uncertainty. As noted before there is no “reference case in place”, hence the perspective 
to be adopted by the local HTA authority is not yet clear, no outcome measure to combine quality and 
quantity of life like (QALYs or DALYs) has officially been adopted and no local discounting rates based 
on empirical estimations are in use at the moment. The lack of methodological standards in Colombia 
prompted the researcher to look for standards used in other jurisdictions like the UK. To reach a final 
decision it was necessary to set up a hypothetical WTP or threshold by looking at international 
standards such as those of WHO, although with caveats. 
According to ICER results, PP would not be cost-effective in Colombia, although the publication of a 
high cost per QALY is just one input parameter into decision-making, and any drastic change from the 
clinical standpoint in health policy towards preventing patients from gold standard care could only be 
envisioned by decreasing the quality of health care. It is worth mentioning that besides the benefit of 
haemophilic arthropathy prevention from prophylaxis, a marked reduction of intracranial and life-
threatening haemorrhages, lower muscular-skeletal pain, lower rates of inpatient admissions and 
average of stay, improved school and work attendance and improved academic achievement have 
been reported in the literature (Berntorp et al, 2003 and Carcao et al, 2007), nonetheless this variables 
were not considered in the model. 
Of worth noting that although a willingness to pay (WTP) threshold of up to three times the Colombian 
GDP per capita was set as the decision rule, and although WHO recommendations use this threshold 
as WTP for DALYs averted, it was considered that it could serve as a point of reference to inform 
decision-makers in Colombia.   In Latin America other countries such as Brazil, Mexico and Chile are 
currently using similar approaches as decision-making rules. In fact IETS is currently working on 
producing its first “reference case manual” supported by international experts and since there are 
considerable limitations to empirically estimate an opportunity cost threshold there is a high chance 
that this “rule of thumb” threshold is the one to be used in the near future in this context. Of worth 
noting that PP was always way off this range of 1-3 times the Colombian GDP per capita.  
There is a lack of consensus about the exact time to initiate PP or the need to continue it into adult 
years (Berntorp et al, 2003). Up to 10% of SHA patients do not bleed as frequently as expected and 
two thirds of them suspend PP when they reach adulthood for different reasons. In Colombia, as in 
other countries, patient compliance with the infusion regimens is not universal (Carcao et al, 2010). 
Hence differential initiation schemes, mixed patient preferences and reduced compliance should be 
incorporated into more realistic decision modelling in future research.  
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According to Farrugia (2013) the current era of safe treatment creates the option for LMICs to 
exchange exogenous supply of recombinant factors for less costly plasma derived options.  Therefore, 
the findings from this report are just the starting point to inform decision-making in a more systematic 
and transparent manner in this context. However, the scarceness of published data and variability of 
published approaches makes validation of consistency of results from this study much more difficult. 
There is still the probability that even after robust sensitivity analyses had been conducted, the ICER 
estimates in the case of SHA in Colombia would not be completely credible. Alternative approaches 
able to incorporate other and wider relevant criteria into decision-making may be of use in this 
context. This may also be the case of other rare diseases that compete for public resources, but face 
similar methodological limitations than SHA derived from limited data. This may also be an 
opportunity in this context to develop policy frameworks able to produce and incorporate HTA 
information, bearing in mind the difficulties and challenges imposed by infrequent and costly 
conditions. 
Colombia is currently strengthening its institutional capacity for HTA.  The recent establishment of 
IETS is an opportunity to standardise methods and methodologies, the ability to strengthen local 
capacity and standards may ease the issues for conducting rigorous HTA in the near future. IETS is 
currently working on establishing a “reference case” and methods manuals which are expected to be 
publicly released in 2014. There is also a project sponsored by this institution to elicit societal 
preferences using the EQ-5D questionnaireThe “general and specific knock-out criteria” (Drummond 
et al, 2009) described before, may prevent researchers from adjusting international results to 
Colombia, but create a propitious environment for de novo development of HTA processes, methods 
standards and evaluations in this context.   
 
SUMMARY 
 
This study showed that the incremental cost effectiveness ratio (ICER) of PP compared to OD 
treatment in Colombia for severe haemophilia A using FVIII was COL$105,081,022 (USD$55,204) per 
QALY gained, and thus not considered cost-effective according to the threshold of up to three times 
the current Colombian GDP per-capita (USD$25.335 or COL$48.458.861). When PP was provided 
throughout life using rFVIII, which is much costlier than FVIII, this ICER reached COL$174,159,553 
(USD$91,494) per QALY gained.  Moreover, this overall conclusion did not change after conducting 
extensive sensitivity analysis. 
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This part of the research adds to the wider understanding of economic issues regarding PP since it 
attempts to move beyond the usual clinical parameter - joint bleeds - to a long-term frequent 
consequence-joint damage HR-QoL. Limitations aside, it has attempted to adhere to established good 
practice at all times and to report its methods and limitations in a clear and transparent manner. 
Nevertheless, further studies are needed to confirm the assumptions and findings of this model.  
Although, early initiation of PP in children has proven beneficial in preventing joint damage, there is a 
lack of consensus about the need to continue it into adulthood (Berntorp et al, 2003). The publication 
of a high cost per QALY is just one input parameter into decision-making, and changes in health policy 
towards preventing patients from accessing gold standard care from a clinical standpoint could only 
be envisioned by decreasing the quality of health care. 
Some of the main methodological factors that may hinder HTA work in Colombia arising from this CUA 
relate to the availability of data and structural uncertainty. The recent establishment of IETS provides 
an opportunity to standardise methods and methodologies, and conduct HR-QoL research that may 
reduce these uncertainties. 
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CHAPTER 3- Testing the MCDA-EVIDEM and the use of HTA for resource-allocation decision-making 
in Colombia 
INTRODUCTION: 
Decision-making in health care is a process that moves from evidence generation to deliberation and 
communication of the decision made (Goetghebeur et al, 2008).  HTA is only a part of this process 
whereby the best available evidence is assessed with the aim of informing decision-makers about the 
most efficient use of resources under conditions of uncertainty. Besides the assessment, 
reimbursement decision-making also involves appraising the available evidence, while bearing in mind 
societal values and ethical considerations (Miot et al, 2012). 
While multiple studies and publications have examined the role of HTA through the collection of data 
(Heyse et al, 2001, Briggs, 2001, Briggs et al, 2002, Hoch et al, 2002), there is still limited knowledge 
of the perceived needs and expectations of decision-makers regarding its use as a source of evidence, 
as well as the challenge of incorporating other broader criteria in an explicit manner. For example, 
Drummond in 2009 suggested a “divorce” of the evidence produced and decision-making process, 
since many economic evaluations published in the literature have been performed with no specific 
decision-maker in mind. 
In 2000, Zwart-van Rijkom et al investigated the differences in attitudes, knowledge and actual use of 
economic evaluations in different groups of decision-makers. They compared results from the 
Netherlands with the overall regional results of the European Network on Methodology and 
Application of Economic Evaluation Techniques (EUROMET). The authors found that most decision-
makers do not want to base their decisions strictly on cost-effectiveness rankings; this was similar to 
the rest of Europe. According to Miot et al, 2012, systematic and transparent approaches to priority-
setting are needed to produce decisions that are sound and acceptable to stakeholders.  
Country-specific HTA health organizations and processes for priority setting have emerged and 
principles such as transparency, robust and appropriate methods for combining costs and benefits, 
explicit characterization of uncertainty and active engagement with stakeholders have been 
associated with the robust operation of HTA programmes and institutions (Drummond et al, 2008 and 
Chalkidou et al, 2009). Nonetheless, according to Pichon-Riviere et al (2010) in Latin America, including 
Colombia, “the current level of application [of these principles] is considered uniformly poor”.  
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All health systems face the challenge of managing finite resources to address unlimited demand for 
services (Glassman et al, 2012).  Moreover, it is worth noting that even after robust HTA has been 
conducted, transparent and systematic decision-making is not guaranteed. Rational decision-making 
requires an efficient and explicit process to ensure transparency and consistency of factors considered 
(Goetghebeur et al, 2012).  
Countries such as England have institutionalised the use of HTA to turn evidence into policy and 
practice. Under the NICE system for example, clinical recommendations are partly legitimised by the 
fact that appraisals are conducted by independent committees with close stakeholder engagement. 
Indeed, NICE’s ability to establish a transparent review process to determine the clinical and cost-
effectiveness of health care interventions for the NHS51 continues to attract interest across the world. 
It is also the case that NICE Technology Appraisal recommendations carry significant weight because 
the NHS is legally compelled to implement them.  
Even in countries where formal HTA activities are ongoing, and in most LMICs, rationing still occurs as 
an ad hoc, haphazard series of non-transparent choices that reflect the competing interests of 
governments, donors and other stakeholders (Glassman et al, 2012) – suggesting that the results of 
research are not being used appropriately.  In the case of Colombia, the Regulatory Commission for 
Health (CRES) was established in 2007 as a decision-making body, nonetheless HTA had played a 
limited role in this context in terms of providing information to set priorities, allocate resources or 
formulate evidence-based policies for health and health care.  Five years later, in September 2012 IETS 
was established aimed at informing CRES about the clinical and cost-effectiveness of interventions, 
but a few months later CRES was disbanded because of a lack of ‘legitimacy’ and the MoHSP regained 
reimbursement decision-making responsibilities.  This institutional instability has created the 
opportunity for the development of a more transparent and systematic priority setting process in this 
context. 
There are a number of different methods for attempting to convert HTA reports into 
recommendations. For instance Culyer and Bombard (2012) proposed a framework targeted to 
advisory bodies aimed at improving their assessment process, from how they receive their terms of 
reference; scope the agenda prior to topic selection; prepare background briefing for decision-makers; 
and help to structure the discussion and composition of stakeholders throughout the process. 
However, although useful, this framework does not really address the issue of pragmatically 
converting HTA into evidence based decisions.   
                                                          
51 NHS National Health System England and Wales 
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Another possible approach is to use multi criteria decision analysis (MCDA), which has been widely 
used in supporting decisions in transport, agriculture, marketing and environmental engineering, and 
more recently it has emerged as a tool to support decision-making in health care (Miot et al, 2012). 
Multi-criteria methods are designed to help people make ‘better’ choices when facing complex 
decisions involving multiple dimensions (Goetghebeur et al, 2008). In theory, MCDA allows a 
structured and objective consideration of factors that are both measurable and value-based in an 
open and transparent manner (Baltussen et al, 2006).  It has been said that “MCDA’s are especially 
helpful when there is a need to combine ‘hard data’ with subjective preferences or to make trade- 
offs that involve multiple decision-makers” (Dolan, 2010). 
In MCDA, the decision problem (e.g. the choice of intervention) is analysed to identify all the factors 
(i.e. criteria) that may affect its use, and thus develop ex-ante for any evaluation, a full set of decision 
criteria. A major part of the process is to ask decision-makers to make their values and objectives 
explicit by assigning weights to each stated criterion. They then score the performance of each 
intervention of interest with respect to each criterion. This step is designed to prompt explicit 
consideration of the advantages and disadvantages of each option and to foster discussion within the 
relevant decision-making group (Goetghebeur, 2012).  This forces decision-makers to think hard about 
what they value, why they value it, and how they value it in a specific context (Goetghebeur, 2012). 
By combining weights and scores an aggregated measure of each intervention of interest can be 
produced. Completeness, non-redundancy, mutual independence and operationality of criteria are 
aspects to take into account to fulfil the MCDA methodological approach.  
The EVIDEM framework 
In 2008 Goetghebeur et al conducted extensive analyses of the literature and documented decision-
making processes worldwide. After this preparatory work, the authors developed a MCDA framework 
known as Evidence and Value: Impact on Decision-Making (EVIDEM). The framework was intended to 
help judge the value of interventions from two perspectives: the value system of the evaluator 
(decision-maker) with regard to the importance of each component (weights) and the actual 
performance of an intervention according to pre-selected decision-making criteria (scores).   
EVIDEM includes 15 core quantifiable components that are currently considered important in 
decision-making (Tony et al, 2011), these criteria are grouped into six clusters (disease impact, context 
of intervention, intervention outcomes, type of benefit, economics and quality of evidence). See 
Appendix 6 for details.  
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The original EVIDEM criteria included: disease severity, size of population affected by a disease, clinical 
guidelines for intervention, comparative intervention limitations, improvement of efficacy/ 
effectiveness, improvement of safety and tolerability, improvement of patient-reported outcomes, 
public health interest, type of medical service, budget impact on health plan, cost-effectiveness of 
intervention, impact on other spending, adherence to requirements of decision-making body, 
completeness and consistency of reporting evidence, and relevance and validity of evidence. 
The framework also includes detailed protocols for the collection, analysis, assessment, synthesis and 
presentation of evidence for each decision criterion (HTA module). It also includes a template to 
synthesise the HTA evidence needed to assess each criterion which is known as the ‘by-criterion HTA 
report’. Results of the EVIDEM MCDA module can be used to rank health care interventions for 
reimbursement decisions/prioritisation. Each appraised intervention receives an aggregated MCDA 
value ranging between 0 and 1 (scores of 0 and 1 indicating lowest and highest priority respectively) 
which in turn allows for cross comparison of health care interventions.  
Modified versions of the EVIDEM framework have allowed for the incorporation of additional criteria 
considered relevant for the context of interest, and have been tested for clinical and resource-
allocation decision-making in developed and developing countries including Canada, the US, Nepal 
and, more recently, South Africa (Goetghebeur et al, 2010 and 2012, Tony et al, 2011 and Miot et al, 
2012).  
The overall aim of this chapter was to assess the feasibility and usefulness of using and incorporating 
HTA to inform resource-allocation decision-making in Colombia by using EVIDEM, since it has not 
previously been tested in this context.  A second objective was as to whether the use of primary 
prophylaxis should be prioritised over three other chosen health care technologies. 
METHODS 
The general methodological approach taken in this chapter is similar to the steps followed by Miot et 
al (2012) when they field tested EVIDEM in South Africa, and by Goetghebeur et al (2012) who also 
tested EVIDEM for formulary decision-making in Canada. Both studies followed a similar pathway that 
included a preparatory stage in which the investigators conducted literature searches and produced 
HTA reports for each one of the interventions of interest, followed by a panel session with decision-
makers that included four steps: 1- contextualisation of the broader criteria to be used for decision-
making, 2- establishing a panel perspective (weighting of the criteria), 3- appraising the value of the 
intervention(s) of interest (scoring each criteria) and, 4- discussion of the results. For a graphic 
representation of this scheme of work when piloting EVIDEM see Figure 15. 
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Miot el al´s work consisted of field-testing EVIDEM using the example of liquid-based cytology (LBC) 
for cervical cancer in South Africa, and included a panel of 12 local experts. The authors first invited 
the panel to contextualise the decision criteria they considered as relevant, hence the four steps 
described before were undertaken in a panel session. On the other hand, Goetghebeur et al piloted 
EVIDEM for formulary decision-making using the 15 core criteria with a pan-Canadian panel of 13 
health care stakeholders who were asked to appraise 10 medicines; in this case no contextualisation 
of the criteria was performed.  
Figure 15. Scheme of work for piloting EVIDEM 
 
The initial research plan for this thesis chapter was to conduct the initial preparatory stage and follow 
the four steps reported by Miot et al at the panel stage, test the MCDA value of four interventions of 
interest (including the economic evaluation of primary prophylaxis for haemophilia conducted in the 
previous chapter) in order to inform/help the Colombian MoHSP in establishing a more systematic 
and transparent process for updating the publically financed benefits package content (POS). 
However, during October and November 2012 the preliminary objectives had to change when the 
former Regulatory Commission for Health (CRES) of Colombia led an independent initiative aimed at 
selecting broader criteria for reimbursement decision-making to update the POS content, in order to 
comply with the constitutional court´s mandate of transparently updating and equalizing its content 
for both the subsidiary and contributory regimes as soon as possible. 
Literature review of intervention(s) of interest
 Published sources, public domain and other information
Source: adapted from Goetghebeur et al (2012)
HTA report for each intervention of interest
 Synthesised data organised into MCDA matrix
Contextualisation of decision-making criteria
 Adopt or adapt EVIDEM core criteria
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 Feedback on process, policy implications
Preparatory stage
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The preliminary work developed by CRES consisted of three workshops with 11 senior decision-makers 
(academics, researchers and civil servants) with broad experience of working in the context of the 
Colombian health system, and high visibility among stakeholders. The main researcher was invited to 
participate in the panel as part of the discussion during all three workshops. As in step 1 of Miot´s 
work, participants were asked to nominate a list of additional contextual aspects they considered 
relevant for resource-allocation decision-making in Colombia. After three voting rounds in two 
nominal group sessions a final list with 15 criteria was produced, 13 of these criteria belonged to the 
EVIDEM core model criteria (one criterion less than Miot´s publication), and two added contextual 
criteria. See Table 6 for the final list of criteria and weights selected for Colombia, those highlighted 
are the two added contextual criteria to the original EVIDEM framework. 
Table 6. Final list of criteria and weights for Colombian-modified version of the EVIDEM:  
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The final 15 criteria considered for Colombia were: completeness and consistency of reporting 
evidence; relevance and validity of evidence; disease severity; size of population affected by disease; 
current clinical guidelines; current intervention limitations; improvement of efficacy/effectiveness; 
improvement of safety and tolerability; improvement of patient-reported outcomes; public health 
interest; type of medical service; budget impact on health plan; cost-effectiveness of intervention, 
attention to vulnerable groups of population; and attention to differential needs for health/health 
care. This first part of CRES work closely resembled Miot´s step 1 of panel stage (contextualisation of 
criteria). For a detailed description of CRES work and criteria definitions see Appendix 7. 
Once the panel had agreed on the final criteria and their definitions, participants were asked to weight 
each criterion irrespective of any health care intervention of interest (step 2: panel perspective).  CRES 
delivered further consensus meetings with different stakeholders around the country to disseminate 
the selected list of criteria and ask further participants to weight them. A total of 201 citizens voted 
on their level of agreement and preferences regarding each of the 15 criteria (CRES, 2012).  The list of 
voting participants included the academics on the same panel, patients’ associations, citizen´s councils 
and representatives from the medical societies. Despite all the above, in December 2012 CRES was 
dissolved by Ministerial/Presidential Decree 2560 before appraising the value of any intervention 
(step 3) or discussing the MCDA results with decision-makers (step 4).  This thesis chapter completes 
these final two steps. 
To test the overall feasibility and usefulness of EVIDEM, the rest of this chapter takes the following 
approach.  First, a preparatory stage consisting of a synthesis of existing HTA data into MCDA matrices 
of a) PP with FVIII for SHA throughout life (incorporating the CUA presented in chapter b) zinc supply 
for diarrhoea prevention, c) anastrozole for breast cancer and d) ticagrelor for acute coronary 
syndrome. 
Since the pilot to test EVIDEM was also intended to inform the MoHSP on how to design a process to 
update POS in Colombia, two different approaches to incorporate HTA results into decision-making 
were considered in this ‘synthesis stage’.  One was the EVIDEM ‘by-criterion’ framework with the 15 
contextualized and weighted criteria for Colombia as it stands and the other a much simpler narrative 
HTA synthesis of evidence containing the same information as per the by-criterion report, but not 
summarized into components, and supplemented by a comprehensive budget impact analysis (BIA).  
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The latter approach took into consideration the MoHSP´s request to incorporate BIA alongside HTA 
data in a narrative format since this was the previous approach used in 2011 to update POS content 
by former CRES.  Previous attempts to estimate budget impact of technologies into POS have 
calculated the average cost per-year per-technology per-person, instead of the overall aggregated cost 
of technologies for the overall population exposed to such technology. The aim of incorporating a 
comprehensive BIA was to properly test it as a source of information for coverage decision-making. 
Using this second format means that only an aggregate score would be assigned per- per-technology, 
rather than summed by criterion. 
The starting point for the work presented in this thesis chapter follows on from steps 1 and 2 that had 
already been developed by CRES prior to its dissolution.  Specifically, this required the scoring of each 
HTA summary by relevant decision makers (step 3) and a discussion regarding the policy implications 
of the along with feedback on the usefulness of the EVIDEM framework as a whole (step 4).  Note that 
although the CRES work partially departed from the original voting system used by Miot and 
Goetghebeur in 2012 to select and weight criteria, it was considered that it sufficiently emulated steps 
1 and 2 of Miot et al´s work, therefore could serve as starting basis for the research presented in this 
chapter. 
A focus group approach was considered to be the most suitable approach to fulfil the aims of this 
chapter (Green and Thorogood, 2009). Focus groups are useful to test, evaluate or conduct 
programme reviews, especially when participants’ reasoning behind their views is of interest, they can 
also obtain input from individuals and interest groups, obtain detailed reaction and input from 
stakeholders to preliminary proposals or options, collect information on the needs of stakeholders 
surrounding a particular issue (as in the case of resource-allocation decision-making), determine what 
additional information or modification may be needed to develop consultation or issues for further 
discussion (Elliott et al, 2005). 
Focus group planning 
One focus group was organised as a mock reimbursement decision committee with individuals with 
potential decision-making responsibilities or academic interest in this field.  Three people were 
assigned roles during the meeting: the moderator/facilitator (the main researcher) would lead a semi-
structured discussion to draw out and summarise the views of all participants, a second person would 
record the session and take informed consent and conflict of interest declarations, and a third person 
would time the scoring criteria and conduct estimates of the MCDA value of each intervention. The 
two supporting roles were assigned to technical staff from IETS. 
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The focus group was planned to last for two hours and follow a pre-determined set of topics including 
the aims of the meeting, background about deliberation for decision-making, an introduction to the 
four technologies to be appraised, methods overview, and voting. The feasibility of using and 
incorporating HTA to inform resource-allocation decision-making and their perception of EVIDEM was 
planned to be explored during the meeting through a set of open-ended questions to allow 
participants to guide the discussion, and to diverge if necessary in order to address ideas and concepts 
not anticipated by the moderator (Britten, 1995). 
Selection of the four competing technologies  
The list of technologies to be valued during the focus group included PP throughout life for SHA, as 
well as three other non-haemophilia health technologies; zinc supply for diarrhoea prevention, 
anastrozole as first line therapy for hormone-receptor-positive postmenopausal women with 
metastatic breast cancer, and ticagrelor + acetylsalicylic acid (ASA) for patients with acute coronary 
syndrome (ACS) without ST elevation and moderate to high cardiovascular risk. The three ‘competing’ 
non-haemophilia health care technologies were chosen because they created an opportunity to 
contrast the features of an intervention aimed at treating an orphan disease with others intended for 
wider populations.  
However, technology selection was also partly based on convenience because over the past two years 
local HTA summaries following good HTA practice for these interventions had been published. In 
addition, all three non-haemophilia-related technologies were considered as potentially cost-effective 
whilst prophylaxis was not. Nonetheless, at the time of writing this thesis, no reimbursement decision 
had been made as to whether they would be listed in the POS.  The HTA report of PP for SHA was an 
extension of the CUA presented in Chapter 2, a brief summary of evidence of the three non-
haemophilia technologies is provided below (for the detailed by-criterion HTA report in Spanish and 
sources of data of all four interventions see Appendix 8):  
a. Zinc supply:  Acute diarrheal infection (ADI) occurs at any age, but toddlers and children 
aged less than 5 are at higher risk of complications such as sepsis, dehydration and death. 
In 2006, 336 children died in Colombia due to ADI and 374 due to malnourishment. Recent 
studies suggest that zinc supply may reduce the prevalence of ADI and pneumonia 
responsible of many deaths per-year globally, improve prognostics and reduce in-patient 
stay. ICER of prophylactic zinc supply in Colombia was COL$2,022,322 (USD$1,011.16) per 
ADI averted for malnourished children less than 5 years old. It was considered as cost-
effective at a WTP threshold of up to three times the Colombian GDP per-capita. 
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b. Anastrozole as first line therapy for hormone-receptor-positive postmenopausal women 
with metastatic breast cancer (BC): BC is the most frequent type of cancer in women, 
there are around 1.38 million new cases per-year in the world in 2008; BC is the most 
common cause of cancer deaths in females (in LMICs 269,000 deaths per-year).  The 
natural course of disease and severity varies according to type and location. In Colombia 
from 2002-2006, annual incidence rate was estimated in 32.6 per 100,000 women. 
Anastrozole has proven superior to tamoxifen on tumour response to treatment, mainly 
in terms of time free of disease progression. The ICER of anastrozole was 6,173,144 
(USD$3,087) per DALY averted, hence considered as cost-effective at a WTP threshold of 
up to three times the Colombian GDP per-capita. 
 
c. Ticagrelor for patients with Acute Coronary Syndrome (ACS) without ST elevation and 
moderate to high risk of cardiovascular disease (CVD): CVD is the most common cause of 
death in Latin America. In Colombia CVD is the main cause of all deaths for people aged 
more than 45 years.  82,293 of ACS would be expected per-year in Colombia. Ticagrelor is 
an antiplatelet drug that has proven a major and faster effect when compared with 
common practice (clopidogrel). Ticagrelor reduced deaths from all cardiovascular causes 
when compared to clopidogrel. The ICER of ticagrelor was $28,411,503 (USD$14,205) per 
QALY gained, hence considered as cost-effective at a WTP threshold of up to three times 
the Colombian GDP per-capita. 
Assembling the HTA evidence for the focus group 
The EVIDEM framework collaboration group has developed a standard protocol for the search and 
analysis of data to be synthesised and used for appraising the MCDA value of the technologies of 
interest.  However, this was not used as recent local HTA reports following what is deemed good 
international practice were available. The clinical practice guidelines by Perry et al in 2012 (BC), Florez 
et al (ADI) and Senior et al (CVD) in 2013 were used to produce the HTA reports. In the case of PP, the 
HTA was based on the CUA described in chapter 2 and complemented from the searches by Castro et 
al (2012), public domain information of the CLH and the MoHSP, and refined with information from 
local experts when needed. 
Two different formats were used and tested to present HTA results to participants. The first format 
used the EVIDEM by-criterion modified MCDA matrix to assemble the HTA information of the four 
technologies in Spanish. All reports contained the relevant information organised as per each of the 
15 weighted criteria by CRES in 2012.  
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However, since the pilot was also aimed at informing the MoHSP on how to design a process to update 
the POS, a second format to be tested included a narrative HTA summary containing the same 
information, for the same technologies and from the same published sources, nonetheless this time 
it was not assembled into components as in the by-criterion EVIDEM template. HTA information for 
this second approach was supplemented with a comprehensive budget impact analyses (BIA) taking 
into consideration the MoHSP´s request of incorporating the previously used formats in Colombia 
when POS content was lastly updated by CRES in 2011.   
Of worth noting that although EVIDEM includes ‘budget impact on health plan’ as a relevant criterion, 
the BIA information traditionally used in Colombia for coverage decision-making was not 
comprehensive and only estimated individual average cost of technologies per-year. The 
comprehensive budget impact analyses of the four competing technologies were developed by 
technical staff from IETS. These were prepared presenting the result of subtracting the average annual 
cost of a new scenario (new intervention) from the annual cost of the current scenario (current 
practice). Each scenario accounted for the quantities and estimated cost per-year of the interventions 
if they were incorporated into POS package for the first year only.   
Identifying the decision-makers 
The aim of the focus group was to gather a group of individuals able to represent different 
stakeholders within the Colombian health system with decision-making responsibilities; hence a 
convenience purposive sample was used in this part of the research. Sampling was judgemental and 
involved the conscious selection of participants to be included in the study (Crookes and Davis, 1998). 
The focus group was designed in essence to mimic a resource-allocation decision-making committee.  
Relevant eligibility characteristics were established before sampling started, a total of twelve 
organisations were identified as containing potential sources of participants (government, insurers, 
providers, patients groups, academics, health care professionals, people´s advocates and lay 
members). Senior policymakers and ‘visible’ individuals were to be chosen to assure legitimacy and 
“buy in” of the pilot. In the case of the lay member it was considered that any available citizen not 
familiar with health or health care would suit the purpose of the study. Since traditionally resource-
allocation decision-making occurs as a centralised process in Colombia, all eligible participants were 
expected to be located in Bogotá.  
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The scoring system 
To appraise the health care interventions of interest using (method 1), respondents were presented 
with a synthesised report of the evidence needed for each component of the MCDA (EVIDEM by-
criterion HTA summary). They were asked to use the EVIDEM matrix containing the 15 criteria 
contextualised by CRES, and score each individually on a 4-point scale (0-3), where 3 represents the 
highest level of fulfilment of each decision criterion and 0 the lowest (as per Miot and Goetghebeur´s 
work). The calculation of the MCDA value estimates as per the EVIDEM approach was done through a 
linear model. A linear model is a statistical model in which the value of a parameter for a given value 
of a factor is assumed to be equal to a+ bx, where a is a constant, and b is the coefficient on variable 
x. In this case b is the weight of each criterion and x the score by-criterion, and a is the aggregated 
weighted score of any previous criterion.  
The weights were normalised by distributing them across the 15 criteria to sum up to 1 for each 
participant, scores were also standardised by dividing them by the maximum possible score of 3 (all 
as per the EVIDEM approach). Hence the MCDA estimated values would lay between 0 and 1 as a sum 
of combined weights and scores for all decision criteria.  Where 1 is the highest value of an 
intervention (perceived as an ‘ideal’ intervention according to criteria) and 0 the lowest. Once weights 
and scores were obtained, they were tabulated using Excel software and descriptive statistics were 
used to calculate the mean values. Results were presented to participants only after testing the 
alternative approach requested by the MoHSP to assist decision-making at the end of the second part 
of the session. 
The second approach (method 2) to appraise the value of interventions consisted of presenting 
participants with four mini HTA narrative reports for the technologies of interest.  This time instead of 
using a by-criterion format, the same information was presented to participants but not separated 
into EVIDEM components. Detailed budget impact analyses (BIA) considered the potential cost 
implications for POS after the first year of incorporation of technologies. To appraise the value of the 
competing health care interventions with this method, respondents were asked this time to 
individually rank each intervention on a scale from 1 to 4 based on the merits of the narrative 
description and BIA, where 1 represented the highest priority intervention and 4 the lowest.  
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When using the ranking scheme, the number of points given to each technology depended on the 
total number of technologies being considered; since there were four technologies, each time a 
technology was ranked as first it obtained 4 points and the one that was ranked as fourth was assigned 
1 point, and so on. This approach is known as the Borda count 52 and was the traditionally used 
approach for ranking technologies by CRES up to its abolishment.  
The aggregated value of interventions was obtained by adding the individual ranking scores of each 
participant, this according to the original authors seems to be more sensitive than estimating ordinal 
average scores. According to this system, ranking first would mean the technology with the highest 
value and thus higher priority of reimbursement; the opposite would be true for ranking fourth. Using 
this second format an aggregated score per-person per-technology, rather than by-criterion was 
assigned. In order to identify any substantial differences in level of difficulty when scoring using the 
two methods, average times of assessment per-technology and per-participant were measured.  
Promoting discussion 
On August 30th, 2013 a two-hour focus group was held in the conference room of IETS to evaluate the 
usefulness of the EVIDEM framework. All participants were asked to consent to participate and to be 
recorded throughout the meeting, also to declare any conflicts of interest. As consent was given by 
all, the meeting was recorded for transcription. 
The moderator welcomed the group and provided general background to participants, as well as the 
outlines and ground rules. The fact that no names were to be used in the final report was emphasised 
and open participation of all attendees was encouraged. The moderator advised participants on the 
intended use of the focus group results and what form the data would take. He also explained the 
scoring mechanism for each approach to be used. 
The last part of the focus group was aimed at discussing the results and their policy implications. To 
promote discussion, participants were presented with a hypothetical scenario where only those two 
technologies with the highest scores were to be reimbursed by the health system regardless of the 
format used to present HTA information.  
 
 
 
                                                          
52  In Borda count the voter ranks the list of candidates in order of preference. Named after the French mathematician and political 
scientist Jean-Charles de Borda, who devised the system in 1770, It is also known as the ranked voting system, 
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The following questions were posed to participants in order to gather their inputs, concerns and 
expectations about EVIDEM, for example: was there enough information to make resource allocation 
decisions in Colombia?, should the use of PP be prioritised over the three other non-haemophilia 
health care technologies?; participants were also asked about which of the methods of presenting 
HTA information they preferred and what changes or improvements could be added to the processes 
and methods presented in the pilot for future implementation.  At the conclusion of the meeting, the 
main points of view of participants were summarised, validated for accuracy and group members were 
thanked for their participation. 
Analysis of data 
The focus group was recorded and once finished transcribed verbatim by an independent transcriber. 
After transcription, the document was uploaded to ATLAS- ti7 to assist content analysis. In order to 
interpret emerging data rather than simply describing it, no preliminary hypothesis was considered. 
Labels such as sufficiency of information, methods concerns, methods comparison, validity of 
information, incorporation of HTA into decision-making, and the specific value of each intervention 
were predefined as the relevant categories that may serve to inform the aims of this chapter.  
Uncertainty about valuation, level of difficulty, specific criterion issues, opportunities for 
improvement, preferred method, as well as change in final decision to be made and perceived benefits 
of using HTA were added to the initial list of labels for data analysis. A detailed description of 
participants´ profiles, MCDA value of interventions and emergent themes during the focus group are 
given in the results section of this chapter.  
RESULTS: 
Seven people out of twelve accepted and attended the invitation to participate in the focus group (the 
remaining five had accepted the invitation but were unable to attend). Participants represented a 
broad range of stakeholders within the Colombian health system, from members of the MoHSP, 
academics, insurers, patients and professional associations to lay members of society.  
All participants were skilled workers with a graduate and at least one postgraduate degree. All of them 
declared vested interests, and two had potential conflicts of interest with the technologies to be 
appraised. Six participants were currently working in the health sector and one was retired.  Figure 16 
shows a detailed profile of participants.  No representatives from hospitals or people´s advocates 
participated in the meeting, although they were formally invited to attend. Six out of seven 
participants were health professionals, and four were physicians; four were women.  
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Figure 16. Profile of participants (Focus group) 
 
All participants valued the interventions using the two alternative methods presented. According to 
observations after scoring the four technologies of interest using the EVIDEM by-criterion was more 
time consuming than ranking technologies. The former took an average of 11.15 minutes (ranging 
from 7-18 minutes) per-health care technology-per-participant and the latter 9.14 minutes (ranging 
from 7-15 minutes).  
The value of interventions 
After calculating the relevant EVIDEM scores (method 1), PP for SHA was third out of four with an 
average weighted score of 0.794 when compared with zinc (0.904), anastrozole (0.822) and ticagrelor 
(0.708).  MCDA estimates of perceived value of PP varied widely from 0.595 to 0.977, but also for all 
other technologies, zinc (0.782-0.986), anastrozole (0.698-0.934) and ticagrelol (0.449-0.945) 
reflecting the diverse perspective of participants. Table 7 shows the detailed results of the EVIDEM 
comparative value of all four interventions, each row represents the average weighted score by-
criterion by-technology and the last row the average weighted MCDA score by-technology. 
PP performed particularly ‘well’ when the criteria disease severity, improvement of 
efficacy/effectiveness, improvement of safety and tolerability, current intervention limitations and 
attention to vulnerable groups of population were scored. Scoring of participants was consistent and 
almost all scored PP with a score of 3 in these dimensions. The existence of clinical guidelines, public 
health interest and cost-effectiveness of intervention were the least scored criteria for PP.  
 
 
 
PARTICIPANT 1 PARTICIPANT 2 PARTICIPANT 3 PARTICIPANT 4 PARTICIPANT 5 PARTICIPANT 6 PARTICIPANT 7
Gender Male Male Female Female Female Male Female
Profession Medical Doctor Medical Doctor Medical Doctor Nutritionist Lawyer Medical Doctor Nurse
Affiliation
Colombian 
Association of 
Scientific Societies 
National 
Academy of 
Medicine
Ministry of 
Health & Social 
Protection
Association of 
insurers from the 
subsidiary 
scheme
Lay member Public University
Association of 
high cost diseases 
at a public insurer
Postgraduate 
studies
Specialist in intern 
medicine, 
cardiology and 
electrophysiology, 
MSc in clinical 
epidemiology
Specialist in ear, 
nose & throat. 
Former director 
of a public 
hospital 
Specialist in 
economics and 
health 
management
Specialist in 
social security 
and health
Specialist in 
administration 
law & in public 
contractual 
affairs
Specialist in 
anaesthesiology 
MSc in clinical 
epidemiology & 
MSc in University 
management
MSc in education, 
research & 
lecturing
Current 
experience
Works at a private 
healthcare 
institution
Retired professor
Works at the 
directory of 
technologies and 
medicines
Works as 
coordinator of 
insurance
Works at the 
contractual 
office of a NGO
Works at a 
directory position 
Works as lecturer
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Table 7. Results of the EVIDEM comparative value of interventions by-criterion (method 1) 
  
Table 8 presents detailed results of the EVIDEM-MCDA value estimations of PP showing where the 
variation across participants lies. Each column reflects the minimum and maximum scores by-
criterion, and each row the MCDA average weighted value of PP by-criterion. The scores of existence 
of clinical guidelines ranged from 0 to 3, with five out of seven participants scoring this criterion with 
0. The cost-effectiveness of PP was also scored in a range from 0 to 3, and of worth noticing that 
although it was not considered as being cost-effective two participants scored this criterion with 3 and 
three with 2.  
Table 8. Results of the EVIDEM-MCDA value of primary prophylaxis  
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This wide variability of result among respondents was also a common finding for all the other criteria. 
For instance when valuing the criterion size of population affected only one individual considered SHA 
as an infrequent condition whilst the other six considered the number of patients affected by this 
disease as substantial.  Using method 1 (the EVIDEM approach) and assuming a scenario where only 
the two interventions with the highest scores would be incorporated in to POS, PP would not be 
reimbursed in Colombia. 
Using the second format (method 2) an aggregated score was assigned per-person per-technology, 
rather than by criterion, using this ranking system does not allow to assess how each technology 
performed by-criterion or to compare by-criterion results across interventions. When the ranking 
system was used, PP for SHA was ranked last after ticagrelor, zinc and anastrozole. In this ranking 
system being first represents the preferred option and fourth the least preferred one. Ticagrelor was 
ranked first with an overall score of 24, zinc placed second with an aggregated score of 19, anastrozole 
ranked third scoring 17 and PP placed last with a score of 10. Thus after using method 2 and under the 
assumption that only the top two ranking interventions would be incorporated in POS, PP would not 
be reimbursed in Colombia. See Table 9 for detailed results of the ranking value of all interventions.  
Table 9. Results of the ranking value of interventions (method 2) 
 
It should be noted that PP was always placed at the bottom positions using either method, it placed 
third out of four with method 1 and last with method 2. It is also noteworthy that ticagrelor, which 
was at the bottom of the list when using EVIDEM, climbed to the top after using the ranking system. 
Participants’ input, concerns and expectations 
In order to assess the feasibility of using and incorporating HTA into resource-allocation decision-
making, as well as to explore participants´ perception of EVIDEM as a tool to assist decision-making, a 
set of open-ended questions was presented to guide the discussion as much as possible. The findings 
that emerged from these research questions are presented in this section.  
To the question, ‘was there enough information to make resource-allocation decisions?’ participants´ 
perceptions diverged. Some considered the information insufficient, because of gaps or 
heterogeneous quality of reporting; others thought it was sufficient: 
P1 P2 P3 P4 P5 P6 P7
Ticagrelor 3 2 1 1 2 1 1 24 1st 
Zinc 1 3 3 4 1 2 2 19 2nd
Anastrozole 2 1 2 2 4 3 4 17 3rd
Primary prophylaxis FVIII 4 4 4 3 3 4 3 10 4th
Total score Final rankCRITERION
INDIVIDUAL RANKING REPORT
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“Well no, some cells […] missed information […]” P6  
“[…] many descriptions […] well yes, they provided very complete information, but some others let´s 
say not that much […] it should be as homogeneous and complete as possible”. P4 
Some specific criteria emerged as creating more difficulties for interpretation and valuation than 
others. For instance, according to participants, the existence of CPGs was not considered as sufficient 
reason to value one intervention higher than other, the financial impact of interventions should be 
better explained beforehand in order to avoid any potential confusion; clarification as to whether 
higher weight should be assigned to a costlier or a less costly intervention would be appreciated, also 
vulnerability as a decision-making criterion should be better defined.  
“[…] the existence of a guideline should not be a criterion to determine value […]” P3 
“[…] economic impact needs to be clear if three means that it should be favoured and a score of one 
should not, […] what should the direction of valuing this criterion be […]” P1 
“[…] vulnerability of population, is not that clear” P2 
According to participant valuation of technologies, the response to the question: ‘should the use of 
PP be prioritised over three other non-haemophilia health care technologies? It appears to be no, 
since it placed at the bottom of priorities with both methods used. Nonetheless, it seems that the final 
valuation of technologies was associated with the methods and criteria used to assist decision-making 
not only in the case of PP, but also for all other technologies; for instance ticagrelor moved from the 
bottom to the top of the list.  
“At first zinc seemed to me as an economic alternative during the first exercise [EVIDEM template], […] 
they were kids, whatever; but when I go and look in detail at the budgetary impact [method two] and 
realize that I have to pay that much money for that benefit, my final decision ought to change”. P3 
“[…] the health technology for Acute Coronary Syndrome [ticagrelor], did not find a real benefit versus 
current practice [clopidogrel], but when I go and look at the budget impact analysis of method two 
and find out that new technology is cost-saving […] realized that is worth doing […]” P3 
Participants also considered that decision-making in Colombia should go beyond the use of 
incremental cost effectiveness ratios (ICERs). 
 “And then one realizes that it [coverage decision-making] goes beyond ICERs, and takes into account 
equity […]” P2 
 120 
“[…] cost effectiveness (RATIO) is superior to our ability to pay, but might not be the only element to 
make a decision, well yes it might not be cost-effective […] but if I only have ten patients countrywide 
[…] it may not be that much […]” P6 
There was extensive discussion among participants to reach an agreement on their preferences about 
methods. Participants found the EVIDEM by-criterion HTA summary useful and comprehensive to 
inform their preferences, but also considered a detailed budget impact analysis a useful tool to assist 
coverage decisions. Of worth noting that the budget impact of interventions has been traditionally 
been estimated in Colombia individually instead of globally as it was presented in this pilot. One 
method without the other was perceived as incomplete and prone to decision-making bias. 
Participants came to a final agreement that a mixed methods approach including a by-criterion HTA 
report, supplemented by a detailed budget impact analysis, would be ideal.  
“[…] if I am interested in looking at an HTA summary, either method is useful, but if it is about coverage 
decision-making […]  it is mandatory for decision-makers to bear in mind and take into account the 
budget implications, so in my view method number one [EVIDEM] should be supplemented with 
detailed budget impact information” P4 
“Uhm, I just would like to say that in my experience the budget analysis was very important for me to 
be able to rank from one to four” P3 
“[…] method one [EVIDEM] […] makes one think about each criterion whenever valuing them, whilst in 
method two [narrative + BIA] although information is visible there, probably one might not 
comprehensively value each criterion at a time […] obviously valuation would be biased towards 
budget impact, but if you assess each item separately incorporating the budget analysis according to 
its weight, possibly it might be better” P6 
“We could try a mixed methodology which includes method one [EVIDEM] and the detailed budget 
impact of method two, […] it would be a genius idea” P3 
In answer to the question, ‘What changes or improvements could be added to the processes and 
methods presented in the pilot for future implementation?’ participants answered that more 
explanation should be provided before voting on each technology and criterion, especially regarding 
grading criteria. Also that information should be as complete, homogeneous and coherent as possible, 
in order to reduce quality and parametric uncertainty among decision-makers. 
“[…] I think at the very beginning some more explanation should be provided, […] regarding the 
methodology […]” P7 
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“Whoever is voting should feel comfortable and with no doubts, right? […] Not everyone is familiarised, 
it requires a level of training of those in charge of decision-making […]” P4 
Some concerns and considerations emerged among participants about the methods used to conduct 
the HTAs; for instance the use of QALYs when conducting CUA, or the reliance on the ICER alone to 
inform decision-making, and also regarding the validity of data used to estimate both aggregated 
measures. 
“Yes, because here we do not operate with QALYs, no methodology for QALYs has been developed 
here.” P6 
 “[…] what should really be important is the bibliography supporting the assessment, […] if assessment 
is solid then decision-making is much easier.”P2 
Some methodological considerations also emerged about the use of EVIDEM; in particular, cost 
implications represented a challenge for participants who had doubts when independently valuing 
this criterion. 
“[…] methods, uhm all the time I doubted, if scoring should regard the consistency of information or 
about my subjective perception of it […]” P7 
“[…] I doubted […] uhm because sometimes I had no idea if I was valuing the importance of a criterion 
or the information about such criterion” P4 
“[…] regarding cost, […] of importance to clarify what a score of three means, if such a therapy benefits 
the system or represents a burden […]” P1 
Concerns aside, participants considered HTA and EVIDEM as useful tools to assist decision-making. 
HTA is perceived as an approach able to incorporate efficacy, effectiveness and cost-utility 
information. 
“Because when you refer to cost-effectiveness it implies efficacy has been assessed, effectiveness has 
been assessed, utility has been assessed, hence if Health Technology Assessment is understood […] 
hence eventually no scientist should think that such a big decision has been made only based on 
economic grounds […]” P1 
EVIDEM served as a means to incorporate HTA into decision-making, but also to prioritise different 
health interventions for decision-making. According to participants’ responses regardless of the 
number of technologies to be appraised systematic priority-setting should take place in Colombia.  
 122 
“[…] different priorities, but the interesting part about this is that they can be reconciled […], I think it 
[EVIDEM] is a good methodology, for creating a ranking and deliberating, but it is important to have 
experts participation” P2 
“It does not matter if they are one or one hundred [health technologies] we need a filter for final 
comparison” P1 
DISCUSSION: 
The aim of this chapter was to assess the feasibility of incorporating HTA to inform resource-allocation 
decision-making in Colombia. In answer to the research question: can EVIDEM be used in Colombia 
to assist resource-allocation decision-making? Although they identified limitations, participants 
found EVIDEM was a means of incorporating HTA into decision-making, and also of prioritising 
different health interventions for resource-allocation.  
Participant perceptions differed as to the adequacy of information presented in the EVIDEM summary. 
Some specific criteria represented more challenges for interpretation and valuation by participants 
than others. Some concerns and considerations emerged from participants of the methods used to 
conduct HTA in Colombia, but also on how to incorporate its results into decision-making; for instance 
of validity of data used for modelling, the use of QALYs when conducting CUA, or reliance on ICERs 
alone to inform decision-making.  
Extensive discussion took place on methodological preferences; participants found the EVIDEM by-
criterion HTA summary useful and comprehensive to inform their preferences, but thought a detailed 
budget impact analysis would be an important piece of information for coverage decision-making. The 
final consensus of participants was that a mixed methods approach including a by-criterion HTA report 
and a detailed budget impact analysis would be ideal for Colombia. It appears from these findings that 
EVIDEM can be used in Colombia for assisting more systematic and transparent processes for coverage 
decisions. 
After testing EVIDEM, and in a hypothetical scenario that only two out of the four technologies were 
to be reimbursed, PP for SHA was ranked third of the list compared with three competing non-
haemophilia health care priorities. The answer to the question, ‘Should the use of primary 
prophylaxis be prioritised over three other non- haemophilia health care technologies?’ is that 
regardless of the method used in the pilot, the final coverage decision about PP for severe haemophilia 
A care would not potentially change; it should not be prioritised given the options presented.  
 
 123 
The final valuation of technologies nonetheless was sensitive to the methods and criteria used to assist 
decision-making not only in the case of PP, but also for all other technologies tested in this pilot.  For 
instance, ticagrelor from being last when using the EVIDEM approach moved to the top of the ranking 
after method 2 was applied. Perhaps the fact of being the only technology considered as cost-saving 
may have impacted participants’ preferences after using this approach, as one participant referred to 
BIA information: “obviously valuation would be biased towards budget impact”, however the 
weighting system itself and the fact that the pilot was run with only 7 participants may have also 
impacted final results.   
It is noteworthy that the comprehensive BIA was the only additional piece of information presented 
to participants when testing this latter approach. The other three competing technologies were 
displaced one position by ticagrelor in the ranking format, but since the aggregated score of this 
system did not make explicit consideration of preferences by-component it made it difficult to depict 
other variables that may have impacted prioritisation when using this format.  
Strengths and limitations 
This part of the study sought to preserve key principles of qualitative research. Data were collected 
through a focus group with relevant stakeholders resembling a decision-making body (Elliot et al, 
2005). It was able to capture the nature and intensity of stakeholders´ concerns and values, and also 
to obtain a snapshot of their opinions and reactions about the methods presented, also to collect 
details of their needs relating to information.  
The focus group comprised seven participants with decision-making roles or interest in this field, 
however a total of twelve individuals were initially invited to attend. The limited number of 
participants who finally attended the focus group may well represent a limitation of the study, 
although this number was similar to the number and composition of panel members of the previous 
EVIDEM pilots published by Miot and Goetghebeur (2012). The profile of participants was very broad, 
as was their familiarity with HTA and decision-making methods, this heterogeneity of knowledge may 
have had an impact on their ability to participate.  
The research processes aimed to minimise the values and assumptions of the moderator that could 
bias findings. Although the main researcher is now the CEO of IETS, the “distance” between him and 
participants was not as close or personal as to jeopardise independence; for instance he broadly knew 
three of the participants. A non-judgemental attitude, no help in valuing each technology and no 
guidance as to participants’ responses to research questions served this purpose.   
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Nonetheless, as noted by Green and Thorogood, 2009, whenever conducting qualitative enquiry “it is 
impossible to have a field for study that is untainted by values and impossible for the researcher to 
stand outside those values and subjectivities”. Therefore the venue (IETS) and moderator (CEO of IETS) 
may have had an impact on the ability of participants to be open and spontaneous. Since participants 
were aware that the focus group would also serve as a pilot to inform the Colombian MoHSP on how 
to establish a more transparent process to update POS, this may have impacted their responses and 
overall expectations.  
One limitation of this part of the research relates to language differences between the original EVIDEM 
tools used (matrix and by-criterion), published in English and the non-validated Spanish versions 
presented to participants. According to participants, more explanation should be provided before 
voting on technologies and criteria, especially grading criteria and directionality of scoring, this was 
similar to the finding reported by Goetghebeur in Canada in 2012, regarding questions of participants 
as to which perspective should they adopt for weighting and scoring, and whether the same set of 
weights and scores shall be used for all types of interventions.  Some doubts emerged when 
independently valuing each criterion, especially cost, which represented a challenge for participants. 
In this part of research, no strategy was considered to consistently synthesise HTA evidence or avoid 
double counting (consideration of the same evidence in multiple criteria). This limitation of the current 
research is being addressed by the original framework developers, who have incorporated a list 
(Hailey, 2003) that aims to improve transparency and consistency of HTA reports. Nonetheless this 
HTA module was still under development at the time of testing EVIDEM in Colombia (Goetghebeur et 
al 2012). Provision of complete information, together with homogeneity and coherence of reports to 
reduce uncertainty among decision-makers were considered as opportunities of improvement to be 
added to the processes and methods presented in this pilot.  
It is worth noting that although recent economic evaluations were available for each of these four 
technologies, in the case of zinc researchers had published results of a CEA reporting outcomes in 
“natural units” i.e. acute episodes of diarrhoea averted.  In the cases of PP, ticagrelor and anastrozole 
the authors had conducted CUAs, but for anastrozole the ICER was expressed in terms of DALYs 
averted and only in the former two cases QALYs gained were used in the ICER denominators. Although 
it is quite clear that cross comparison of interventions is only possible if researchers have estimated 
health outcomes in the same units, it was considered that in a context with no methodological 
standards in place to conduct an economic evaluation, a broad variety of results should be expected. 
Since EVIDEM considers cost-effectiveness of interventions as one separate criterion for each 
intervention and does not cross compare, these technologies and ICER results were considered as 
suitable for the purpose of this chapter.  
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Most of the limitations of this part of the research were associated with the methods used to test 
EVIDEM, not only during the focus group, but also before. Of special consideration is the work 
developed by CRES, which did not fully comply with the methodological requirements of non-
redundancy and mutual interdependence of criteria, since the two added contextual criteria were 
both associated with vertical equity (treating different people differently).  
CRES work also departed from the qualitative approach to contextualise criteria and the 0-5 scale 
presented by the original EVIDEM authors for weighting; the Delphi approach used to select the 
contextual criteria and the Borda count used for weighting may have had an impact on selected 
criteria, final weights and MCDA value of interventions by making respondents to shy away from 
extremes as it happens with other rating scales (Robinson et al 2001). 
There were also limitations in the focus groups related to tools and processes. For instance, the 
EVIDEM by criterion template presented was a modified version of the original and did not include a 
directionality guide to assist participants with valuation. Due to time constraints, the explanation of 
grading criteria was not exhaustive, and since only one of the participants was familiar with EVIDEM 
and the preliminary work of CRES (in Miot´s work the same participants weighted and valued the 
intervention of interest), a more detailed explanation or a preparatory workshop would have helped 
valuation, and perhaps produced different results. 
One major limitation of this study is the fact that participants had already read the relevant HTA 
information when they were presented with method 2 (narrative HTA + BIA), thus presenting a second 
approach after having read a previous report, may not really make it a ‘fair’ comparison. Hence 
average times of assessment with each format and the final impact of the comprehensive BIA on the 
final ranking with method 2 should be interpreted cautiously. Nonetheless since method 2 does not 
make explicit account of factors, this latter statement carries substantial uncertainty. 
The focus group was recorded and transcribed by an independent transcriber to facilitate analysis. 
Unfortunately the meeting venue was large and the recording machine was not sufficiently sensitive 
to capture all the comments, this made transcription more complicated. No full description of 
bibliographic references was presented to participants during the meeting creating further 
uncertainty about validity and consistency of data. 
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MCDA methodological concerns reported by the original authors are also applicable to this research, 
these are related to methodological requirements of completeness, non-redundancy, mutual 
independence and operationality. For instance the criterion cost-effectiveness is problematic since it 
includes other considered criteria such as improvement in efficacy/effectiveness, improvement in 
safety and tolerability, patient-reported outcomes, impact on other spending, and budget impact on 
health plan.   
Goetghebeur et al (2012) have even proposed the removal of cost-effectiveness from this framework 
or to make it optional, nonetheless this latter statement probably needs further consideration since 
the results of a robust ICER after economic modelling may be preferable than presenting 
disaggregated information about the incremental costs and benefits of interventions without explicit 
consideration of uncertainty of parameters and results. 
Besides the described benefits of MCDA approaches (such as EVIDEM): adaptable to specific contexts, 
provide the means to reveal the perspectives of decision-makers and facilitate discussion and 
consensus seeking on recommendations and decisions, there is an issue of consistency of the 
estimated MCDA value of interventions. Coinciding with Goetghebeur (2012) rankings should never 
be used as formulaic rules, but as a basis to promote deliberation and explicit consideration of relevant 
aspects into decision-making. As stated by this same author, MCDA value estimates are committee 
and context specific and should be interpreted cautiously for coverage decision-making. Although 
consistent application of a MCDA model by a stable decision-making committee could produce a more 
robust ranking of interventions. 
Under a different context (a softer constraint or other competing technologies) PP could have had a 
different chance of being prioritised. In this case methods used to incorporate HTA also seemed to 
have an impact on the final preference of participants.  Although EVIDEM weights and scores using 
simple linear scales may have drawbacks (low discriminatory power or non-linear performance), the 
whole idea of the framework is to make it simple, intuitive and easy to use (Goetghebeur, 2012).  
Methodological concerns aside, participants appeared to consider HTA and EVIDEM as useful tools to 
assist health care decision-making in Colombia. They were perceived as capable of incorporating 
efficacy, effectiveness and cost-effectiveness. EVIDEM is a way of prioritising different health 
interventions for decision-making. According to participants’ responses, regardless of the number of 
technologies, systematic priority-setting should take place in Colombia.  
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It seems after testing EVIDEM as it stands and an alternative approach using a narrative HTA summary 
plus a comprehensive BIA, that EVIDEM is superior since it makes explicit consideration of relevant 
aspects into decision-making.  Using a ranking system may limit deliberation since it does not force 
decision-makers to think hard about what they value, why they value it, and in what context they 
value it. Nonetheless, when deciding on resource-allocation BIA placed an important role and seemed 
illustrative to participants. According to participants remarks a MCDA with a comprehensive BIA could 
be ‘ideal’ in Colombia (either as a single criteria as in the EVIDEM or as a separate piece of 
information). 
These findings coincide with those of Tanios et al (2013) on decision-makers’ perceptions of the 
relevance of a core set of criteria and on the need to consider a wider range of criteria to assist 
decision-making, and also Guindo et al (2012) on the perceived importance of considering both 
normative and feasibility criteria for fair allocation of resources and optimised decision-making. 
According to these authors sound multi-criteria approaches may be useful to enlighten health care 
decision-makers and priority setters.  
The merit of this part of the research is the relevance of its findings.  The use of HTA as a tool to assist 
decision-making in Colombia is feasible. Structured and objective consideration of the factors that are 
both measurable and value-based in an open and transparent manner may be feasible through the 
use of MCDA approaches. This chapter attempts to add to the knowledge about the decision-making 
process, expand the scope of EVIDEM regarding context and health care intervention, and pilot its use 
to serve the interest of the MoHSP of Colombia in setting up a more robust process for resource-
allocation decision-making. As stated by Goetghebeur et al in 2012, further testing and validation are 
needed to advance MCDA approaches into health care decision-making.  
SUMMARY 
 
In August 2013 a two hour focus group comprising seven participants, was held to assess the feasibility 
of HTA to be used to support decision-making.  The MCDA EVIDEM framework was tested and 
preferred by participants than an alternative format including a narrative HTA report and 
comprehensive BIA in the case of four competing health care interventions of interest (including PP 
for severe haemophilia A).  
Participants considered HTA and EVIDEM useful tools to assist decision-making that could be used in 
Colombia. HTA is perceived capable of incorporating efficacy, effectiveness and cost-utility that will 
be focused on assessing marginal benefits of health care interventions. EVIDEM can value and 
prioritise different health interventions for decision-making. Participants believed that systematic 
priority setting should take place in Colombia, regardless of the number of competing technologies.  
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After testing EVIDEM and according to its MCDA value, and also after using an alternative preference 
ranking upon the MoHSP request, PP for severe haemophilia A in Colombia was not prioritised over 
the other competing technologies. Nonetheless the final valuation of technologies was sensitive to 
the methods and criteria used to assist decision-making, not only in the case of PP, but also for other 
tested technologies. 
This part of the research attempted to add to the knowledge about the decision-making process, 
expand the scope of EVIDEM regarding context and health care intervention, and pilot its use to serve 
the interest of the MoHSP of Colombia on setting up a more systematic and transparent process of 
resource allocation decision- making.  
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IV. CONVERGENT, DIVERGENT AND CONTRADICTORY FINDINGS 
As stated by Mays and Pope (2000) there are not mechanical solutions to limit the likelihood that there 
will be errors in qualitative research. Various ways have been informed for improving the validity of 
results (i.e. triangulation, respondent validation, clear exposition of methods and analysis, reflexivity, 
attention to negative cases, and fair dealing amongst others). Triangulation compares the results of 
two or more methods of data collection or sources of data as a way of ensuring comprehensiveness 
and encouraging more reflective analysis. Findings from each chapter were triangulated to improve 
the validity of research. Results from interviews from chapter one, practical observation after 
conducting economic evaluation from chapter two, and findings of the focus group from chapter three 
helped to identify convergent, divergent and contradictory findings regarding the feasibility of 
producing and using HTA in Colombia.  
Triangulation was made by listing all salient findings from each empirical chapter separately, then 
cross-comparison of findings served to classify as coincident those aspects that were similar in at least 
two of the three empirical chapters.  Divergence occurred when a finding from any chapter was not 
coincident with any other chapter, and contradiction was assumed if either within a chapter or 
amongst them findings took opposite directions. After considering these aspects, a template was 
developed to look for patterns of convergence in order to strengthen interpretation of findings, and 
as a way of ensuring comprehensiveness and more reflective analysis. A traffic light system helped to 
represent highly convergent findings as green, moderate convergent findings as yellow and divergent 
findings as red (see figure 17 for a graphic representation of convergent and divergent findings). 
In chapter one ten drivers emerged with the potential ability to influence HTA development and use: 
availability and quality of data, implementation strategy, cultural aspects, local capacity, financial 
support, policy/ political support, globalisation, stakeholders´ pressure, health system context and 
usefulness perception.  
In chapter two, after conducting economic evaluation for PP those methodological aspects that may 
make HTA difficult in this context were identified: data constraints about the clinical and cost-
effectiveness of PP, a fragmented information system, uncertainty about costs and frequency of 
services consumed to populate the model, lack of methodical standards (no reference case), the need 
to transfer international standards, and the recent establishment of a local HTA-IETS were described 
as aspects to consider.  
 
 130 
Figure 17. Convergent and divergent findings regarding the feasibility of HTA being produced and 
used in Colombia  
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Finally, in chapter three it emerged that the main expectations for the use of HTA relate to adequacy 
of information for decision-making, methods used to incorporate HTA into decision-making, criteria 
used for decision-making, concerns about reimbursement decision-making, and the need for 
explanation or capacity building for decision-makers. MCDA and particularly EVIDEM emerged as a 
tool capable of combining efficacy, effectiveness and cost-utility information useful to value and 
prioritise different health interventions. 
Concerns about the availability and quality of data converged with data constraints of the clinical 
effectiveness, cost-effectiveness, costs, quality of life amongst others; all these emerged as potential 
hindrances to better informed decision-making in Colombia. Academics, the main researcher and 
decision-makers considered information about costs (prices and quantities) and health state 
preferences the most important of the needs to conduct robust HTA reports and use them in decision 
making.  
The lack of methodological standards and the absence of a “reference case” converged from all 
methods as a source of structural uncertainty for HTA to be incorporated and used to inform decision-
making. The perspective to be adopted, discounting rates for costs and effects, the use of combined 
measures for quantity and quality of life gained (or lost) and the use of a cost-effectiveness threshold 
were listed in two of the chapters as sources of concern to be considered in Colombia. All these as 
well as the need to strengthen the current incipient information system should be borne in mind in a 
well-planned implementation strategy 
It also emerged from all the component studies that there are local capacity constraints that may limit 
the production and quality of HTAs; capacity building and institutional strengthening of those devoted 
to HTA like IETS was seen as an opportunity to build capacity not only for HTA work, but also for 
incorporating its results into broader criteria for decision-making. There was also convergence on the 
need to develop local capacity among those who will produce HTA, but also among those who will use 
it for resource-allocation decision-making.  
Globalisation emerged as a convergent finding that brought the global trend to institutionalise HTA to 
Colombia, and EVIDEM as a disposable tool able to incorporate social values and hard criteria into 
decision-making. Under the current health system´s context, both HTA and EVIDEM are perceived as 
opportunities to restore trust; these are being considered for the establishment of a more transparent 
and systematic resource allocation decision-making process. 
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Another convergent finding was the need for policy formulation about HTA methods guidance in order 
to avoid transferring methods and standards from other jurisdictions (such as NICE or WHO), as well 
as promoting local research and a robust information system, thus avoiding the need to rely on data 
that may not be generalizable to a local population or subject to vested interests (such costs or prices). 
As stated by Pluye et al, 2009, mixing qualitative and quantitative methods may reveal some form of 
divergence and as proposed by these authors, taking divergence into consideration is a key issue for 
triangulation. Four strategies have been used to take account of divergence of results: reconciliation, 
initiation, bracketing and exclusion. Conflicting findings between qualitative and quantitative 
approaches often lead researchers to dismiss or ignore qualitative findings (Patton, 2002).  
In this case divergence was considered when findings from one chapter did not coincide with findings 
from other chapters, reconciliation of findings was used to deal with divergence (results interpretation 
in a sense-making plausible manner) (Trend, 1978). For instance, cultural aspects and financial 
support, although considered as potential “drivers” with the ability to help or hinder HTA production 
and use in Colombia in chapter one, did not coincide with the findings of other chapters.  
“Cultural aspects” referred to the social conceptions determined by local custom, meaning, and beliefs 
in Colombia with the potential to influence the development or use of HTA. These were considered in 
chapter one as a “driver”, and although were not directly explored when conducting economic 
evaluation for SHA or piloting EVIDEM, it became apparent that such a lack of tradition of HTA 
methods, priority-setting and planning had methodological implications for the development of HTA 
in a context without a “reference case” or a transparent decision-making process in place. Even the 
current financial and “trust” crisis within the health sector may be a result of these so-called cultural 
aspects. 
Similarly the “driver” financial support was explored and emerged from the participant interviews 
described in chapter one, but was not addressed or re-explored when conducting economic evaluation 
or when testing haemophilia HTA results for decision-making. Nonetheless, financial support was 
associated with resources devoted to HTA research, meaning the need of funding to strengthen 
groups and institutions, but also to strengthen information systems as sources of reliable data for 
economic modelling.  
 
 
 
 133 
The strategies of exclusion (not taking into consideration conflicting data), bracketing (used when 
qualitative and quantitative data are irreconcilable) and initiation (which requires asking new research 
questions and collecting and analysing new data from a different perspective) were not used to deal 
with divergence. Divergence was considered relative, and other indirect findings supported the view 
that cultural aspects and financial support had the ability to influence the feasibility of conducting and 
using HTA in Colombia. 
No findings were considered as consistently contradictory, although aspects like globalisation 
emerged as having a broad range of influence on HTA use and development in Colombia. On the one 
hand, globalisation has enabled Colombian staff and students to study HTA methods overseas in 
world-class universities, brought renowned HTA representatives and granted access to HTA guidance 
from consolidated institutions (such as NICE or WHO). In chapter one, academics perceived 
globalisation as creating “peer pressure” to produce HTA but also representing an opportunity to 
create networks of cooperation. 
On the other hand, globalisation creates technological pressure with new and costly technologies that 
may create further financial strain within the health system, and a risk of “brain drain” of skilled HTA 
experts. In chapter three participants’ concerns emerged about the potential ability of globalisation 
to promote the use of methods or the use of controversial decision-making criteria without the 
accuracy of locally-produced data (e.g. QALYs, ICERs, cost-effectiveness thresholds).  
There were some contradictory findings about the adequacy of information for resource-allocation 
decision-making; some participants considered it adequate and others did not. Views of participants 
on the use of the ICER were also contradictory. Some considered HTA and economic modelling as 
comprehensive tools able to incorporate efficacy, effectiveness and cost implications into a single 
measure to assist decision-making whilst others thought decision-making criteria should go beyond 
ICERs.  
Reflexivity, positionality and power relations in the process of data collection and interpretation 
As mentioned before, throughout the process of conducting research on HTA and priority setting in 
Colombia the researcher adopted multiple identities, this may have shaped the process of data 
collection and interpretation. For instance, during the OPA at NICE international the researcher 
preliminary explored how HTA has been used to assist resource allocation decisions in different 
contexts; he also interviewed as part of the consultancy project relevant stakeholders in Colombia, 
this may have shaped his vision on the feasibility of HTA in this country, but also provided him with 
preliminary insights that were useful to design the questionnaire to be used during the interviews.  
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By the time of data collection for Chapter 1, the main researcher was a consultant at the MoHSP, 
perhaps the power relations between him and interviewees were expected to change as he was 
working for the Minister, nonetheless adopting a flexible approach during the interviews and selecting 
neutral venues agreed with participants may have reduced this risk of bias, also since he was 
presented to participants just as “a researcher”. The development of the economic evaluation for SHA 
and the pilot to test EVIDEM (Chapters 2 and 3) were conducted after the main researcher had already 
been appointed as CEO of IETS, the latter rather than the former may had been subjected to the 
influence of the power position of the researcher who acted as moderator during the focus group, 
also  the venue (IETS) for gathering insights when testing the MCDA approach may have had an impact 
on the ability of participants to be open and spontaneous. The fact that participants were informed 
that the pilot would also serve to inform the MoSHP interest on developing a more transparent 
decision-making process may have also shaped their expectations and answers.  
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V. OVERALL DISCUSION AND CONCLUSIONS 
 
The challenge of allocating finite health care resources is a problem common to all health systems.  
Decision-making in health care requires the consideration of scientific, medical, economic, social and 
ethical aspects and calls for objective-scientific and value judgment (Goetghebeur et al, 2012). HTA is 
a part of the process where the consequences of the application of health technologies are examined 
with the aim of better informing decision-makers. In recent decades different countries have 
established specialised HTA organisations; in September 2012 Colombia established IETS.  
In most LMICs decision-making for health care occurs as an ad hoc and non-transparent process.  The 
level of application of HTA procedural principles, such as transparency, robust and appropriate 
methods for combining costs and benefits, as well as the explicit characterization of uncertainty and 
active engagement with stakeholders, are often limited in these contexts. This was the case in 
Colombia where until the establishment of IETS HTA had played a limited role. 
Since the 1993 health sector reform in Colombia, the health system has reached almost universal 
coverage (96%); nonetheless, the country still struggles to set priorities and allocate resources for 
health care in an efficient manner. By late 2009 a COL$2 Billion  (USD$ 1.045 billion) deficit in the total 
health budget was announced by the government. At the peak of the crisis, the constitutional court 
mandated the government to equalise the publicly financed benefits package (POS) for the entire 
population, and update its content as soon as possible. All these represent an additional financial 
burden to the system. This financial crisis within the health sector has led to new legislation and a new 
health sector reform that is on its way in the Congress. 
The interest of the Colombian government in relying on scientific evidence to better inform health 
policies began in the mid-2000s, but it has only been in the last three years that policymakers have 
paid attention to the methods and processes for assessing and appraising the evidence used in other 
countries. However, some of these processes, methods and methodologies may not be applicable to 
a setting like Colombia. For instance there are substantial differences in the architectural 
arrangements and roles played by institutions in countries, as well as differences in the involvement 
of stakeholders in decision-making. 
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As an example, NICE in England and Wales has operated since 1999 as an institution responsible for 
appraising evidence and formulating recommendations, supported by independent appraisal 
committees. In Colombia, however, IETS has been established just recently, and is expected to assess 
the evidence, but the MoHSP remains the organisation responsible for appraising it and making 
coverage decisions. It is worth noting that the UK has a relatively long tradition of performing and 
using the results from economic evaluations, applying WTP thresholds and including stakeholders 
throughout assessment processes. In Colombia, on the other hand, stakeholder engagement or the 
consideration of societal values are not current practice and the institutional arrangements for 
reimbursement decision-making and communicating of decisions to the general public are yet to be 
implemented.  
The current government in Colombia has taken incremental steps to control costs and strengthen its 
institutional capacity. Besides creating IETS, it disbanded CRES in December 2012 and re-assumed its 
role of resource-allocation decision-maker. Since in Colombia there is no systematic process in place 
to set priorities or transparently and actively engage with stakeholders, nor is there a “reference case” 
to standardise methods or methodologies to produce HTA, the case of PP for SHA perhaps serves as 
an example of how the progressive adoption of newly developed health care technologies can 
dramatically change the natural course of a disease while challenging the financial sustainability of 
health systems. 
In Colombia there may be potential for the use of alternative processes, methods and methodological 
approaches to incorporate HTA into decision-making moving beyond appraisal committees and the 
use of ICERs, such as MCDA to assess the value of new interventions. Given this context, the aim of 
this thesis was to assess the feasibility of conducting and using HTA to inform decision-making in 
Colombia.  The main questions of interest were: 
 What are the main aspects that may help or hinder HTA development and use in Colombia? 
  What is the incremental cost-effectiveness of primary prophylaxis compared to on-demand 
treatment in Colombia?  
 Can EVIDEM be used in Colombia to assist resource-allocation decision-making, and should 
the use of primary prophylaxis be prioritised over three other non-haemophilia health care 
technologies?  
These questions were addressed using a mixed methods approach in three different empirical 
chapters.  
 137 
The issues around previous HTA work in Colombia were studied through a qualitative approach 
presented in the first empirical chapter. The aim of this first empirical chapter was to explore previous 
experiences of conducting HTA and perceptions of its role and future use in Colombia. A qualitative 
methodology that included purposive homogeneous sampling, semi-structured interviews, rigorous 
transcription, and thematic content analysis was used.  
Historically HTA has been developed in Colombia by research groups mostly motivated by academic 
interest, and interviews confirmed it was advanced in Colombia in the early 1990s by academics who 
returned from overseas studies and started using methods related to those used by EBM and HTA. 
From 2010-2011 onwards this research interest converged with political support to use HTA as a tool 
to inform decision-making.  
Chapter 1 identified ten potential “drivers” that may help or hinder HTA activities in Colombia. 
However, findings from this project are the result of an in-depth exploration of the topic of interest in 
a particular setting and thus these “drivers” may not be generalizable to other countries. Nevertheless, 
the conceptual transferability of the term “drivers” although with caveats, may be of interest for 
similar settings trying to incorporate HTA processes and institutions into decision-making. 
The case of primary prophylaxis (PP) versus on-demand (OD) treatment with FVIII for severe 
haemophilia A (SHA) was chosen as a case study because in recent decades PP has proven to be 
superior to OD treatment in preventing bleeding, but much more costly to provide. Despite much 
media attention to SHA in Colombia, no HTA work for this health condition has been developed so far. 
A CUA was developed to assess the feasibility of conducting economic evaluation in this setting and 
the incremental cost per QALY gained of PP using FVIII versus OD throughout life for severe cases 
following what is deemed good practice. A Markov model was designed from the local health system 
perspective and populated making use of the best available evidence, and completed and refined with 
local sources when necessary.  
The results from the CUA presented in chapter 2, strongly suggest PP is not cost-effective if a 
willingness to pay for an additional QALY threshold of up to three times the current Colombian GDP 
per-capita is used, and that there is relatively little uncertainty around this conclusion despite the 
overall paucity of underpinning clinical evidence. This finding is broadly in line with the results of 
existing literature. This work additionally served to identify some methodological factors that may 
hamper HTA activities in Colombia such as the availability of local data and structural uncertainties. 
Although IETS is working on establishing a “reference case” and methods manuals for Colombia, there 
are currently no methodological standards in place to minimise uncertainty in HTA results.  
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To assess the feasibility of using HTA as a tool to assist decision-making in Colombia and answer the 
third set of questions, a focus group resembling a decision-making panel was held. This served to 
assess local decision-makers’ views of the potential use of HTA to inform resource-allocation decision-
making for health, and to test EVIDEM in the case of PP for SHA, comparing it with zinc supply for 
diarrhoea prevention, anastrozole for breast cancer and ticagrelor for acute coronary syndrome.  
The results presented in chapter 3 suggest that EVIDEM could be used in Colombia to incorporate HTA 
and assist resource-allocation decision-making. Participants considered HTA and EVIDEM useful to 
assist decision-making. HTA is perceived as capable of incorporating efficacy, effectiveness and cost-
utility information. EVIDEM may serve to value, cross compare and prioritise different health 
interventions for decision-making. According to the MCDA-EVIDEM valuation of PP for SHA, it would 
not be prioritised, nonetheless it should also be noted that the final valuation of technologies was 
sensitive to the methods and criteria used to make these judgements. Besides the methodological 
limitations of the tools and linear scoring system used by EVIDEM, it appears that the MCDA value of 
interventions are also committee and context specific, hence results for coverage decision-making 
should be interpreted cautiously. Participants also believed that regardless of the number of 
technologies, transparent and systematic priority-setting should take place in Colombia.  
EVIDEM may offer a way to incorporate cost implications and societal values to rank health care 
interventions and develop “league tables”, departing from the “hard” methodological constraints 
imposed by unmeasured opportunity costs.   This represents an opportunity for prioritising 
interventions departing from ICERs in severely data and resource constrained settings, such as 
Colombia.  This framework is a pragmatic step adaptable to specific contexts with the ability to reveal 
the different perspectives of decision-makers, facilitating discussion and consensus seeking on both 
recommendations and decisions (Goetghebeur et al, 2010).  Nonetheless, it still requires further 
testing and development in order to advance the integration of MCDA and HTA for more effective and 
transparent evidence-informed policies and practice. 
After triangulating results from all chapters, most findings converged. For instance the adequacy of 
information, lack of methodological standards, the need to develop capacity, the impact of 
globalisation, and the need for policy formulation on HTA. Divergence occurred and was dealt using 
reconciliation of findings, such as cultural aspects and financial support. No findings were considered 
as consistently contradictory. Nonetheless, aspects such as globalisation emerged as having a broad 
range of influences on HTA use and development in Colombia. There were also contradictory findings 
in reference to the preferred method for incorporating HTA into coverage decision-making. However, 
there was a final convergence that a mixed approach of MCDA-EVIDEM criteria supplemented by a 
comprehensive budget impact analysis could be the preferred process looking forward. 
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This thesis (limitations notwithstanding) has described factors that may enable or hinder the use of 
HTA in Colombia which are particularly relevant for the current implementation stage of HTA that is 
being led by IETS.  It has also added to the existing evidence base about the cost-effectiveness of 
primary prophylaxis for severe haemophilia A, especially in LMICs where no CUA has been published 
for this health condition so far.  This thesis also contains  information of MCDA (EVIDEM) as a tool for 
decision-making that may serve as a starting point to assist the Colombian MoHSP on its interest of 
setting up a more robust and transparent priority-setting process. 
There are three models for HTA promotion and initiation (Rajan et al, 2011), top-down whenever HTA 
is initiated from political interest, bottom-up whenever HTA is initiated and promoted from academic 
or research interest, and converging that combines both the political and academic/research interests. 
In Colombia, although academic interest in HTA started in the 1990s as a bottom-up initiative, it is only 
in recent years that HTA has attracted the attention of policymakers and been top-down formulated 
as a policy solution. Both bottom-up and top-down interests converged with the enactment of Law 
1438 of 2011 that enabled the establishment of IETS, thus HTA formal initiation could be considered 
as converging in this country.  
According to focus group participants decision-making criteria should go beyond ICERs in Colombia, 
coinciding with the views of Zwart-van Rijkom et al (2000), also in agreement with Oliver et al (2001) 
participants in both the semi-structured interviews described in chapter 1 and the focus group 
described in chapter 3 considered that cultural aspects and a need for skills development amongst 
consumers of HTA were to be borne in mind for its successful implementation in this context.  
Performing rigorous HTA in LMICs may be challenging in the short-term, but may also help local 
researchers identify the methodological aspects that need to be considered or strengthened to follow 
what is deemed “good practice”. In these contexts where scarcity of all types of data is common, 
transferability of HTA results from other jurisdictions may be seen as an option, but factors that may 
preclude transferability (“specific knockout criteria”) and aspects of analysis that need to be addressed 
before transferring estimates should be borne in mind whenever conducting HTA in these 
jurisdictions. All these aspects may prevent researchers from adjusting international results to 
Colombia, but create a propitious environment for the development of HTA processes, methods 
standards and evaluations in such context.  Conducting HTA for SHA as a case study could have 
therefore provided the framing to address some of these methodological concerns.  
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There is still limited knowledge of the needs and preferences of decision-makers regarding broader 
criteria for decision-making and this work has attempted to explore them. As stated by Kanavos and 
Angelis (2013), “a new approach is needed for assessing the value of new medical technologies that 
takes into account a more comprehensive set of parameters than just the incremental cost-per-unit 
of additional therapeutic benefit”. MCDA may be able to link through weighting and scoring the 
multiple considerations affecting decisions by making them explicit and creating a clear link between 
HTA and health care decision-making, hence the use of alternative methodological approaches like 
MCDA as described by Baltussen et al (2007) and Miot (2012) could be an important step towards 
rational priority-setting in developing countries.  
The aim of this thesis was to assess the feasibility of conducting and using HTA to inform decision 
making in Colombia where there is limited capacity, data and resources to conduct it, as well as a very 
recent a tradition and interest in using it as a tool to support decision-making. It seems from the 
findings of this project that HTA development and use is feasible. HTA has incrementally gained space 
in policy making in this country.  
Resource-allocation decisions about haemophilia care and many other health conditions in Colombia 
so far have been made without enough evidence-based information. Institutional efforts aside, the 
Colombian system´s allocation of health care resources is still far from efficient and equitable. It also 
lacks transparency and “buy in”. The use of HTA has increased in recent years and although, the 
country faces some contextual constraints, there are many opportunities to further assess the aspects 
that may help or hinder its use and institutionalisation.  
This thesis has attempted to add to existing knowledge about the decision-making process by making 
explicit the processes and factors considered for health care decision-making. It expanded the scope 
of EVIDEM regarding context and health care intervention, and pilot its use for the MoHSP of 
Colombia. Although EVIDEM allows for incorporation of additional contextual criteria considered 
relevant, concerns arise on the possibility of double counting when assessing criteria such as cost-
effectiveness or the two contextually added criteria for Colombia; hence further research should focus 
on testing the validity and consistency of the reported MCDA-EVIDEM values of interventions.  
Lessons learnt, steps forward and further research on HTA and priority setting in Colombia 
Throughout the process of conducting research on priority setting in Colombia the researcher has 
adopted multiple identities. During the preparatory stage of this thesis and being a consultant at NICE 
international (as part of the OPA) the main lessons learnt were, that there is a global trend to use or 
institutionalise HTA in many countries and that decision making is an intricate and incremental process 
whereby the use of evidence is just a part of it.  
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At the first stages of research (being a consultant at the MoHSP of Colombia), especially when 
conducting semi-structured interviews and developing de novo economic evaluation, it became 
apparent that that there are relevant aspects and a contested scenario that need to be considered for 
the successful introduction of HTA in a context like Colombia. After conducting a focus group to assess 
the feasibility to implement HTA into decision-making it emerged that decision-making criteria should 
go beyond ICERs and HTA in order to capture other relevant aspects that these methods are incapable 
of, this in order to reach sustainable, but also fair resource allocation. Finally after being appointed 
CEO of IETS the importance of bridging the gap between research and policy and practice was of 
unsurmountable value since all findings from this thesis have nurtured and shaped the development 
of IETS in Colombia. 
In order to establish a more systematic and transparent priority setting process in Colombia 
establishing IETS could be considered as step number one, but institutions such as the regulatory 
agency (INVIMA) and the MoHSP itself need to be strengthened as well.  Aspects such as comparative 
efficacy and safety for market authorization or managed entry agreements could be incorporated in 
this country. The restitution of a decision-making body with the ability to appraise the HTA evidence 
produced by IETS and transparently engage with stakeholders and reflect their values and preferences 
would be another step forward on the attempt to establish a more transparent and systematic 
process. Under such an ideal institutional arrangement INVIMA, IETS and the MoHSP shall consider 
different frameworks for producing and incorporating HTA results for coverage decision-making for 
frequent and infrequent disorders. 
Future research agendas for HTA and priority setting in this setting shall focus on strengthening the 
methods and methodologies for HTA (i.e. societal elicitation of health state preferences or empirical 
estimation of thresholds), but also on the incorporation of wider aspects and broader criteria into 
decision making in order to reach sustainable universal health coverage, especially under the current 
context of the new enacted statutory law which upgraded health as a fundamental constitutional right 
to all citizens. 
 It is hoped that the results of this doctoral research project could be of significant value to the field 
of public health and policy since non-explicit priority-setting processes, poor information, lack of policy 
on HTA, barriers to implementation, political agendas and limited resources are common findings in 
developing countries (Youngkong et al, 2009), the final results from this research may be applicable 
to a wider context than Colombia, SHA and the competing technologies chosen for the pilot.  
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VI. APPENDICES 
APPENDIX 1. SEARCH HISTORY AND TERMS  
APPENDIX 1.1 SEARCH HISTORY SYSTEMATIC SEARCH OF CLINICAL EFFECTIVENESS (Primary 
prophylaxis vs. on- demand) SEVERE HEMOPHILIA A-May 8th 2013 
 
1. hemophilia A.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
2. haemophilia A.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
3. (coagulation adj3 disorder*).mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, 
dv, kw] 
4. (clot* adj3 deficiency).mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
5. (clot* adj3 disorder*).mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
6. 1 or 2 or 3 or 4 or 5 
7. prophylaxis.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
8. (primary adj3 prophyl*).mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, 
kw] 
9. on demand.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
10. on- demand.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
11. arthropath*.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
12. arthrosis.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
13. joint damage*.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, tx, sh, ct, tn, dm, mf, dv, kw] 
14. 7 or 8 
15. 9 or 10 
16. 11 or 12 or 13 
17. 6 and 14 and 15 and 16 
18. remove duplicates from 17 
 
APPENDIX 1.2 SEARCH HISTORY SYSTEMATIC SEARCH OF ECONOMIC STUDIES OF SEVERE 
HEMOPHILIA A (Primary prophylaxis vs. on- demand)- May 15th 2013  
1. hemophilia.m_titl. 
2. haemophilia.m_titl. 
3. 1 or 2 
4. cost.m_titl. 
5. economic- analysis.m_titl. 
6. economic- evaluation.m_titl. 
7. economic- study.m_titl. 
8. cost-effectiveness.m_titl. 
9. cost-utility.m_titl. 
10. cost- benefit.m_titl. 
11. 4 or 5 or 6 or 7 or 8 or 9 or 10 
12. 3 and 11 
13. remove duplicates from 12 
 
 
 
 143 
APPENDIX 2. PROCESS AND SUMMARY OF FINDINGS OF SYSTEMATIC SEARCHES OF CLINICAL 
EFFECTIVENESS AND ECONOMIC STUDIES OF SEVERE HEMOPHILIA A 
The summary of evidence retrieved on the clinical effectiveness of treatments for SHA showed that 
although there is a growing stock of knowledge about the benefits of prophylaxis, most of it is derived 
from observational studies. From the 56 eligible publications, only two were systematic reviews - one 
of which was narrative (Castro, 2012) and the other a partial meta-analysis (Lorio, 2011); three RCTs 
were retrieved.  All retrieved studies were considered as important sources of information of the 
natural course of disease and estimates that may of use to inform the decision problem of interest. 
The systematic review by Lorio et al (2011) compared previous results of six RCTs studies of 
prophylaxis in people with haemophilia A and B (including 142 participants). Pooled results from two 
of these studies (Manco-Johnson et al, 2007 and Gringeri et al, 2011) showed a RR of 0.30 (95% CI; 
0.12 to 0.76; p=0.012) for all bleeds and 0.22 (95% CI; 0.08 to 0.63; p=0.005) for joint bleeds favouring 
prophylaxis (three-times-a-week) with OD in children with haemophilia. Nonetheless, results for the 
number of patients with preserved joints after three to seven years of follow-up were not pooled due 
to significant heterogeneity of dosing regimens.  
Three of the remaining four studies evaluated haemophilia A alone (Aronstam et al, 1996 and 1977) 
or compared different prophylaxis regimens (Carlsson et al, 1997). However, they did not present 
results of patients exposed to PP at early ages and stages of the disease hence were not considered 
as relevant to the decision problem of interest. A fourth study by Morfini et al (1976) evaluated 
hemophilia B, which was not the primary aim of this research. 
Of interest for the case of study was a study by Manco-Johnson et al (2007) that randomly assigned 
young boys with SHA to regular infusions of rFVIII (PP) at doses of 25 IU/Kg every other day or to an 
enhanced OD schedule (40 IU/Kg)  at the time of a joint haemorrhage. The primary outcome of the 
study was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and 
elbows) by radiography or magnetic resonance imaging (MRI). Boys under 30 months of age were 
randomly assigned to PP (n=32) or to enhanced episodic therapy (n=33). When the boys reached 6 
years of age, 93% of those in PP and 55% of those in OD were considered to have a normal index-joint 
structure on MRI (p=0.006).  
Many observational studies retrieved were considered as additional sources of information regarding 
the decision problem of interest. In 2007, Darby et al reported the mortality rates, life expectancy, 
and causes of death in people with haemophilia A or B in the UK who were not infected with HIV over 
a 22 year period of observation (from the late 1970s to late 1990s).  
 144 
Mingot et al in 2009 reported that after following for 31 months, 22 haemophilia A patients treated 
with FVIII who switched to another plasma derived FVIII or rFVIII  both FVIII and rFVIII are safe and 
effective products, with similar recovery and adverse events rates. Another cohort study published by 
Kurnik et al (2010) showed that the highest risk of developing inhibitors is during the first 20 exposure 
days, and that minimizing exposure to exogenous FVIII by using low dose prophylactic schemes during 
the early ages of life may reduce the risk of inhibitor formation. 
Saulyte et al (2010) showed the utility of using the Haemophilia Joint Health Score (HJHS) for assessing 
early joint damage in a cohort of SHA and B patients in Lithuania. It was also assumed that FVIII and 
rFVII are interchangeable, in 2013 Gouw et al reported that after evaluating 574 patients treated with 
recombinant and plasma-derived clotting products both conferred similar risks of inhibitor 
development. In such cases the chances to develop inhibitors were expected to be similar in both 
regimes and thus this complication was not considered in the base case model.  
It is worth noting that most retrieved publications were cross-sectional studies, historic or narrative 
reviews, and just a few of them economic studies. A remarkable finding from this search was the 
limited number of RCTs for SHA, perhaps owing to the fact that it is a rare lifelong disease and ethical 
limitations of randomization after observational designs in the late 1970s suggested that prophylaxis 
was clinically effective.  
Institutions like the WFH, the US National Foundation of Haemophilia and WHO recommend 
continuing prophylaxis in adulthood, because adults remain at risk of developing joint or other kinds 
of bleeding, and no publication was found that supported the interruption of prophylaxis in adulthood. 
Of all interventional studies only the one by Manco-Johnson et al was considered relevant to the 
decision problem of interest since it exactly compared the two approaches of interest and presented 
results of joint outcomes associated to chronic bleeding.  
On the other hand, the summary of the evidence of economic evaluations retrieved showed that since 
1996 only 12 economic studies have been published assessing PP versus OD treatment for 
haemophilia A (one more than the number reported by Miners in 2013); five of these (Smith 1996, 
Szucs 1996, Bohn 1998, Miners 1998 and Daliri 2009) were cost-effectiveness analyses (CEA), one a 
cost-benefit analysis (Steen-Carlsson 2004), and six were CUA (Miners 2002 and 2009, Lippert 2005, 
Risebrough 2008, Colombo 2011, and Farrugia 2013) all showing a broad variety of results and 
structural approaches.  
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All reported studies accounted for information from HICs, except that by Daliri et al (2009), which 
reported information from a CEA in Iran. Only five of these CUA specifically compared PP with OD 
treatment (Miners et al, 2002 and 2009, Risebrough et al, 2008, Colombo et al, 2011 and Farrugia et 
al, 2013). Of these, only four (Miners 2009, Daliri 2009, Colombo 2011 and Farrugia 2013) adopted a 
health system perspective, and only three of these had modelled the costs and effects of treatment 
throughout life using QALYs (Miners 2009, Colombo, 2011 and Farrugia 2013). Of these, only Miners 
and Colombo had modelled the disutility associated with joint outcomes.  
Coinciding with Miners findings (2013), a number of these publications have estimated high 
incremental cost-effectiveness ratios (ICERs) for PP. For instance, a study in Canada by Risebrough et 
al (2008) reported ICERs per QALY gained of CAN$500,000 for an escalated prophylactic scheme and 
CAN$1 million for a fixed PP scheme when compared to OD provision of clotting factor. UK estimates 
revealed £46,500 per QALY gained in 2002 (Miners et al) and after refining some methodological 
aspects more recently (Miners 2009) this figure was rounded to £38,000 per QALY gained which, 
although still above the threshold used for reimbursement decision-making by the UK NHS, is 
somewhat closer.   
The Italian study by Colombo et al (2011) considered prophylaxis to be cost-effective and showed 
ICERs per QALY gained of €40,229 to €40,236 for individuals with haemophilia A who receive primary 
and secondary prophylaxis respectively, versus OD. Of worth noting that no explicit CE threshold was 
formally in operation as a decision rule in this context, nonetheless the Italian Health Economics 
Association had recommended a threshold between €25,000 and €40,000 which would mean that PP 
is still above such threshold. A cost benefit analysis by Steen-Carlsson et al (2004) in Sweden concluded 
that prophylaxis was cost-effective. However, total costs of treating patients were divided by the 
national general population and monetary benefits subtracted were based on the mean WTP per 
patient, which do not really represent the monetary benefit for this population. 
In 2013, Farrugia et al reported PP to be dominant (lower cost and higher QALYs) from a UK 
perspective, and cost-effective in the USA with an ICER of USD $68,000 per QALY gained and in Sweden 
with SEK 1.1 million per QALY gained; both figures within the range of treatments reimbursed in these 
countries. The authors conducted a CUA modelling PP versus OD throughout life using a health care 
perspective, but using inhibitor development instead of arthropathy as the relevant outcome 
associated with QALYs. All published results were sensitive to the unit cost of clotting FVIII, frequency 
of bleeding and discounting rates (See appendix 2.4 for a narrative synthesis of published economic 
studies).   
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APPENDIX 2.1 - PRISMA FLOW DIAGRAM OF SYSTEMATIC SEARCH OF CLINICAL EFFECTIVENESS OF 
PRIMARY PROPHYLAXIS VS. ON- DEMAND HEMOPHILIA A- May 8th 2013  
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APPENDIX 2.2 - PRISMA FLOW DIAGRAM OF SYSTEMATIC SEARCH OF ECONOMIC STUDIES OF 
SEVERE HEMOPHILIA A (Primary prophylaxis vs. on- demand)- May 15th 2013  
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APPENDIX 2.3 NARRATIVE SYNTHESIS OF PUBLISHED STUDIES AND QUALITATIVE ASSESSMENT 
MATRIX 
 
 
Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
2008 
Haemophilia. 
2008. Sep; 
14(5):923-30. 
EPub 2008 Jul 14. 
The Use of 
Prophylaxis in 2663 
Children and Adults 
with Haemophilia: 
Results of the 2006 
Canadian National 
Haemophilia 
Prophylaxis Survey.  
Biss TT, Chan AK, Blanchette VS, 
Iwenofu LN, Mclimont M, Carcao MD. 
Association of Haemophilia Clinic 
Directors of Canada (AHCDC); 
Canadian Association of Nurses In 
Haemophilia Care (CANHC).  
 
Data on 2663 individuals (2161 haemophilia A; 
502 haemophilia B), were returned by 22 /25 
Canadian haemophilia treatment centres. 
Represented 98% of Canadian haemophilia 
population. Among individuals with severe HA, 
the frequency of prophylaxis use was 84% in 
children (</=18 years) and 55% in adults (>18 
years). Prophylaxis is no longer confined to 
children with severe haemophilia A. 
Prophylaxis is being started earlier in boys with 
severe haemophilia A. 
Observational 
Cross 
sectional 
 
+ 
2002 
Haemophilia. 8 
(6) (pp 745-752) 
 
Prophylactic versus 
on-demand 
treatment strategies 
for severe 
haemophilia: A 
comparison of costs 
and long-term 
outcome.   
Fischer K., Van Der Bom J.G., Molho 
P., Negrier C., Mauser-Bunschoten P., 
Roosendaal G., De Kleijn P., Grobbee 
D.E., Van den Berg H.M.   
49 Dutch patients with PP compared with 106 
French patients OD. Median bleeds py PP 2,8 
OD 11,5. Less arthropathy PP.  
Observational 
Cohort  
 
 
+ 
2002 
Haemophilia. 8 
(SUPPL. 2) (pp 38-
42), 
Results of an 
orthopaedic survey in 
young patients with 
severe haemophilia in 
Spain  
 
Gorina E., Alberca I., Aznar J.A., Garcia 
Talavera J., Gutierrez R., Lucia F., 
Magallon M., Moreno M., Paloma I., 
Querol F., Quintana M., Rodriguez-
Pinto C., Sedano C., Tusell J.M., 
Uranga M.  
70 Spanish patients from 11 hospitals 
receiving OD or secondary prophylaxis. Mean 
age 21,6 y.o. Articular complaints in 84,3% to 
85,7% of patients  
Observational 
Cross 
sectional 
+ 
2007 
Haemophilia.  
13(4):345-50 
RCTs and 
observational studies 
to determine the 
effect of prophylaxis 
in severe 
haemophilia.  
Fischer K.  Grobbee DE.  Van den Berg 
HM.  
 
Several valid observational studies comparing 
prophylaxis and OD have reported both a short 
term reduction of 75%- 90% in bleeding 
frequency, and significant improvement in 
arthropathy, QoL and socio-economical 
parameters after more than 20 years of 
prophylaxis 
Review article 
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2005 
Haemophilia.  
11(5):438-43 
Variability in clinical 
phenotype of severe 
haemophilia: the role 
of the first joint 
bleed.  
 
Van Dijk K,  Fischer K,  Van der Bom 
JG,  Grobbee DE,  Van den Berg HM 
171 severe HA patients. Age at first joint bleed 
0,2 to 5,8 years. The onset of bleeding is 
inversely related with treatment requirement 
and arthropathy 
Observational  
Cohort 
 
++ 
2003 
Haemophilia  
9(4):376-81 
Prophylaxis for 
severe haemophilia: 
clinical and 
economical issues.  
 
 
Fischer K.  Van Den Berg M.  
 
3 cohorts of patients with severe HA were 
compared. 106 French OD, 49 Dutch 
intermediate dose PP and 24 Swedish high 
dose PP. PP reduced bleeds and arthropathy. 
For high dose PP the frequency of bleeds /year 
were 0,5. The cost of PP is twofold higher than 
OD.  
Observational 
Cohort 
 
+ 
 
2009 
International 
Journal of 
Technology 
Assessment in 
Health Care, 
25(4): p. 584-587. 
 
Cost-effectiveness of 
prophylaxis against 
on-demand 
treatment in boys 
with severe 
hemophilia A in Iran 
Daliri AA, Haghparast H, and 
Mamikhani J.  
A retrospective chart review of twenty-five 
type A haemophiliacs who were treated in 
three haemophilia treatment centres was 
conducted. Data were extracted during a 
period of approximately 6 months. The 
patients receiving prophylactic treatment had 
fewer bleeding events each month (mean, 
0.26 versus 2.74) but used more concentrate 
(225.31 versus 87.20 units/kg per month). 
Average monthly cost per patient in the 
prophylaxis group was approximately 1.9 
times higher than in the on-demand group. 
Compared with on-demand infusion, 
prophylaxis costs 3,201,656 Rials (euro213.45) 
per bleeding event prevented. 
Observational 
Cross 
sectional 
Cost study 
      0 
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Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
      
2012 
Haemophilia 
18(2):152-157 
Health technology 
assessment and 
haemophilia. 
Farrugia A, O'Mahony B, Cassar J.  
 
In this review comments principles utilized in a 
recent systematic review of the use of 
haemophilia products carried out in Sweden as 
part of an HTA. Authors suggest that ranking 
haemophilia related interventions with the 
standard interventions of therapeutics and 
public health in CUA comparisons is 
inappropriate and suggest that haemophilia 
therapies should be assessed differently from 
mainstream interventions. 
 
Review article                 0 
2013 
Haemophilia. 18 
(5) (pp 828-829). 
Treatment for life for 
severe haemophilia 
A– A cost-utility 
model for prophylaxis 
vs. on-demand 
treatment. 
Farrugia A., Cassar J., Kimber M.C., 
Bansal M., Balboni S.  
 
A Markov model was applied to a single 
provider national health system exemplified 
by the United Kingdom’s National Health 
Service and a third party provider in the United 
States. The incremental cost- effective ness 
ratio (ICER) was estimated and compared to 
threshold values used by payer agencies to 
guide reimbursement decisions. A cost per 
quality-adjusted life year (QALY) was also 
estimated for Sweden. 
Prophylaxis was dominant over OD treatment 
in the UK. The model resulted in an ICER – $68 
000 –within the range of treatments 
reimbursed in the USA. In Sweden, a 
cost/QALY of SEK 1.1 million was also within 
the range of reimbursed treatments in that 
country. Dosage- and treatment-induced 
inhibitor incidence were the most important 
variables in the model. Subject to continuing 
clinical evidence of the effectiveness of 
pharmacokinetic dosage and the role of 
prophylaxis in decreasing inhibitor incidence, 
treatment for life with prophylaxis is a cost-
effective therapy, using current criteria for the 
reimbursement of health care technologies in 
a number of countries. 
 
Economic 
Evaluation 
CUA 
++ 
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2001 
Haemophilia.  
7(5):446-52 
Changes in treatment 
strategies for severe 
haemophilia over the 
last 3 decades: effects 
on clotting factor 
consumption and 
arthropathy. 
Fischer K, Van der Bom JG, Mauser-
Bunschoten EP, Roosendaal G.  Prejs 
R, Grobbee DE, Van den Berg HM.  
 
Cohort of 214 patients with severe HA. Median 
follow up 17 years. Over 3 decades clotting 
factor consumption per Kg increased 260%. CF 
consumption stabilized in adulthood for those 
who received intensive treatment 
Observational 
Cohort 
 
            ++ 
2000 
Haemophilia.  
(3):170-6. 
 
The orthopaedic 
status of severe 
haemophiliacs in 
Spain 
Aznar JA, Magallon M, Querol F, 
Gorina E, and Tusell JM.  
Cross- sectional study aimed at assessing 
orthopaedic complications of young severe 
haemophiliacs (A and B). Eleven Spanish 
hospitals participated. 70 patients on- demand 
348 bleeding episodes  per patient  year (mean 
16,1) 
Observational 
Cross 
sectional 
+ 
2012 
Indian Journal of 
Hematology and 
Blood 
Transfusion. 
November 2012.  
 
 
The History and 
Evolution of the 
Clinical Effectiveness 
of Haemophilia Type 
A Treatment: A 
Systematic Review.  
Castro HE, Briceño MF, Casas C and 
Rueda JD.  
A systematic search of the literature aimed at 
assessing the evidence of different treatment 
options for haemophilia type A over the past 
four decades. The introduction of prophylactic 
schemes during the 1970s have proved to be 
more effective that the classic on-demand 
replacement of clotting factors, Main concerns 
for haemophilia healthcare are shifting from 
clinical aspects to the economic 
considerations of long-term replacement 
therapy.  
Systematic 
review 
+ 
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Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
      
2012 
Haemophilia. 18 
(5) (pp 738-742) 
Is on-demand 
treatment effective in 
patients with severe 
haemophilia? 
Aznar J.A., Marco A., Jimenez-Yuste 
V., Fernandez-Fontecha E., Perez R., 
Soto I., Parra R., Moreno M., Mingot 
M.E., Moret A.  
167 patients from 37 centres (92% HA). OD 
and short term prophylaxis. 13% of biologically 
severe patients had no bleeding phenotype. 
OD therapy not effective in preventing 
arthropathy. 
Observational  
Cross 
sectional 
+ 
2012 
Haemophilia.  
18  (pp 143), 2012  
Association of 
prophylaxis regimen 
with FVIII and 
treatment outcomes 
in Latin America 
patients with severe 
hemophilia A.  
 
Perez Bianco P., Berges A., Soto V., 
Linares A., Krishnan S., Xiong Y., 
Aguilar L., Gomez J., Arvizu J., Brabata 
C 
444 patients from Argentina, Chile, Colombia 
and Mexico. 53,4% patients OD. PP 68,7 % 
reduction in total number of bleeds, and 
82,6% reduction in joint bleeds per year (p< 
0.00001). Odds of having limited ROM 4.42 for 
OD vs. PP 
Observational 
Cross 
sectional 
 
+ 
2012 
Haemophilia. 18 
(pp 124-125). 
 
Diagnostic, cross-
sectional evaluation 
of joint status using 
magnetic resonance 
imaging in patients 
with severe 
hemophilia a: 
Biomarker analysis. 
Oldenburg J., Zimmermann R., 
Katsarou O., Theodossiades G., Zanon 
E., Niemann B., Kellermann E., Lundin 
B.  
Multiple schemes of prophylaxis and on- 
demand. MRI performed on 4 index joints (2 
ankles and 2 knees). MRI vs physical 
examination (Gilbert score). MRI is highly 
sensitive to detect joint damage. Prophylaxis 
beneficial vs. OD. 
Observational 
Cross 
sectional  
 
+ 
2012 
Haemophilia. ). 18  
(pp 25) 
Regional differences 
in baseline patient-
reported outcomes in 
a randomized, 
controlled, 
prospective trial of 
secondary 
prophylaxis VS on-
demand treatment in 
patients with severe 
hemophilia A.  
Kempton C., Valluri S., Reding M., 
Lissitchkov T., Goranov S., Gercheva 
L., Rusen L., Ghinea M., Uscatescu V., 
Rescia V., Hong W., Manco-Johnson 
M.  
 
3 year RCT Argentina, Bulgaria, Romania and 
US. PRO EQ-5D, VAS, Hemo- QoL- A. 84 
patients. US scores 0,84, non- US 0,78 EQ-5D 
(p< 0.04)and 0,81, non- US 0.68 VAS (p<0.001) 
Interventional 
RCT 
 
+ 
APPENDIX 3. TABLE OF EVIDENCE AND GRADING CRITERIA 
 
2004 
Biodrugs; 18 (4): 
225-234 
 
Blood Products for 
Haemophilia Past, 
Present and Future.  
Giangrande, PLF.  Cryoprecipitate still the mainstay of therapy in 
many developing countries. Many patients were 
infected with hepatitis and/or HIV through the 
use of coagulation factor concentrates before the 
introduction of physical methods of viral 
inactivation in the mid-1980s. Coagulation factor 
concentrates are expensive, and cost-benefit and 
quality-of-life studies will assume an increasing 
importance in guiding the selection of products. 
Looking to the future, genetic engineering offers 
the potential to create coagulation factors with 
enhanced properties, such as reduced 
immunogenicity and prolonged half-life.  
Review Article  0 
2012 
Haemophilia. 18 
(3) (pp 369-374) 
Identification and long-
term observation of 
early joint damage by 
magnetic resonance 
imaging in clinically 
asymptomatic joints in 
patients with 
haemophilia A or B 
despite prophylaxis.  
Olivieri M., Kurnik K., Pfluger T., 
Bidlingmaier C.  
 
Single- centre retrospective cohort study, MRI 
performed in symptomatic and asymptomatic 
ankles in haemophiliac A and B patients in 
prophylaxis. Since 2000, 38 MRIs performed in 26 
patients. 5 of 26 patients worsened MRI findings 
without joint bleed. Early morphological changes 
in asymptomatic ankles detected with MRI in 
patients with prophylaxis. 
Observational 
Cohort  
+ 
2013 
N Engl J 
Med. 368(3):231-9 
 
PedNet and RODIN 
Study Group. Factor 
VIII products and 
inhibitor development 
in severe hemophilia A  
Gouw SC, van der Bom JG, Ljung 
R, Escuriola C, Cid AR, Claeyssens-
Donadel S, van Geet C, Kenet 
G, Mäkipernaa A, Molinari AC, Muntean 
W, Kobelt R,Rivard G, Santagostino 
E, Thomas A, van den Berg HM; .  
Evaluated 574 patients with severe haemophilia 
A born between 2000 and 2010 and collected 
data on all clotting-factor administration for up to 
75 exposure days. Inhibitory antibodies 
developed in 177 of the 574 children (cumulative 
incidence, 32.4%); 116 patients had a high-titre 
inhibitory antibody, defined as a peak titre of at 
least 5 Bethesda units per millilitre (cumulative 
incidence, 22.4%). Plasma-derived products 
conferred a risk of inhibitor development that 
was similar to the risk with recombinant products 
(adjusted hazard ratio as compared with 
recombinant products, 0.96; 95% confidence 
interval [CI], 0.62 to 1.49). Recombinant and 
plasma-derived factor VIII products conferred 
similar risks of inhibitor development. 
Observational 
Cohort 
 
+ 
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Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
      
2011 
Cochrane 
database of 
systematic 
reviews (Online). 
9  (pp CD003429) 
 
Clotting factor 
concentrates given to 
prevent bleeding and 
bleeding-related 
complications in 
people with 
hemophilia A or B 
Lorio A., Marchesini E., Marcucci M., 
Stobart K., Chan A.K. 
SLR of six studies (142 participants). PP 
compared with OD. RR of 0,3 (95% CI; 0,12- 
0,76) for all bleedings and 0,22 (95% CI; 0,08- 
0,63) for joint bleeds favouring prophylaxis. 
Non-significant increases in both inhibitors 
and infectious complications OD vs. PP, except 
for PP when using long term venous access. 
Systematic 
review 
++ 
2011 
Haemophilia. 17 
(SUPPL. 2) (pp 1-
23) 
Joint protection in 
haemophilia.  
 
Rodriguez-Merchan E.C., Jimenez-
Yuste V., Aznar J.A., Hedner U., 
Knobe K., Lee C.A., Ljung R., Querol 
F., Santagostino E., Valentino L.A., 
Caffarini A.  
 
Joint aspiration plays a roles in acute and 
profuse haemarthroses. Ultra-sonography is 
appropriate diagnostic technique to assess 
evolution of bleeding. 
Review article 
 
0 
2011 
ClinicoEconomics 
and Outcomes 
Research. 3 (1) 
(pp 55-61) 
Cost-utility analysis of 
prophylaxis versus 
treatment on 
demand in severe 
hemophilia A.  
 
Colombo G.L., di Matteo S., Elisa 
Mancuso M., Santagostino E.  
 
CUA of hybrid prophylaxis, OD, PP and 
secondary prophylaxis. Showed that PP is cost- 
effective with and ICER €40.229 per QALY 
gained compared to OD, results sensitive to 
unit cost of FVIII, bleeding frequency, 
discounting rates.  
Economic 
evaluation 
 
+ 
2011 
Arthritis & 
care.Vol 63 No 2. 
Pp 223- 30 
Validation of the new 
pediatric joint scoring 
system from the 
international 
haemophilia  
prophylaxis study 
group: validity of the 
heamophilia joint 
health score. 
Feldman B, Funk S, Bergstrom BM, 
Zourikian N, Hilliard P, Van der Net J, 
Engelbert R, Petrini P, Van der berg H, 
Manco M, Rivard G, Abad A  
 
HJHS was developed to be more sensitive for 
detecting arthropathy than WFH. Validity 
compared in 226 boys with mild, moderate 
and severe haemophilia in 5 centres. HJHS is 
97% more efficient than WFH at differentiating 
mild from moderate haemophilia, and 74% 
from differentiated those OD vs. prophylaxis. 
Both HJHS and WFH showed strong construct 
validity. HJHS more sensitive for mild 
arthropathy 
Diagnostics ++ 
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2011 
Journal of 
Thrombosis and 
Haemostasis. 9  (pp 
694 
Mild vs. severe 
haemophilia A: The 
dilemma of an 
underestimated 
disease  
Bidlingmaier C., Knorr S., Olivieri M., 
Kurnik K.  
 
42 mild and moderate patients with haemophilia 
compared to 46 birth matched severe patients. 
Reasons for diagnosis bleeding vs. family history 
Observational 
Cross sectional 
+ 
2011 
Journal of 
Thrombosis and 
Haemostasis. 9  (pp 
373) 
Subgroup analyses of 
annualized number of 
bleeds with three-
times-per-week 
prophylaxis with rFVIII-
FS. 
Lalezari S., Coppola A., Lin J., Enriquez 
M.M.  
 
LIPLONG study, RCT, randomized, double blind, 
non-inferiority of 52 wks. Compared prophylaxis 
1 x wk vs. 3 times x wk previously treated 
patients. Number of bleeds per year prophylaxis 
1,4 (CI 0- 20,9) p= 0,6152. Number bleeds and 
presence of target joints determined rate of 
response to prophylaxis.  
Interventional  
RCT 
 
++ 
 
2011 
Haemophilia. 17 
(2) (pp 360). 
The Russian children 
study: A prospective 
study to evaluate the 
effect of rFVIII-fs in 
different prophylactic 
regimens on frequency 
of bleeding events and 
development of 
arthropathy in a 
previously treated and 
minimally treated 
haemophilia A 
paediatric population.  
Vdovin V.V., Andreeva T.A., Chernova 
T.A., Perina F.G., Maasenriquez M., 
Rauchensteiner S. Haemophilia.  
 
Non randomized open- label study evaluated 3 
different prophylactic regimes: 70 IU 1x w/ 30+ 40 
IU x w/ 25 IU 3x w. Joint bleeds, all bleeds, joint 
status in 32 paediatric patients. Median number 
of bleeds per year ranged 1,5- 3. #x w prophylaxis 
safely and effectively decreases overall bleedings 
and prevents subsequent joint damage. 
Interventional 
non- 
randomized  
 
+ 
 152 
  
 
 
Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
2010 
Journal of 
Rheumatology 
and Medical 
Rehabilitation. 21 
(2) (pp 29-36) 
Outcome of joint 
functions in 
hemophilic patients: 
A twelve year 
retrospective study.  
 
Capaci K., Balkan C., Yilmaz D., Yilmaz 
A.Y., Kirazli Y., Durmaz B., Kavakli K.  
 
31 patients after 12 year follow up. Gilbert 
score was used to assess joint status. Grouped 
by severity of disease. Joint assessment results 
in patients with severe haemophilia that 
received prophylaxis were almost as good as 
those of mild cases. (p< 0,05) 
Observational 
Cohort 
+ 
2010 
Haemophilia; 16: 
256–62 
New early 
prophylaxis regimen 
that avoids 
immunological 
danger signals can 
reduce FVIII inhibitor 
development. 
Kurnik K, Bidlingmaier C, Engl W, 
Chehadeh H, Reipert B, Auerswald G.. 
 
The highest risk of developing inhibitors is 
during the first 20 exposure days (EDs). 
Developed a prophylaxis regimen for the first 
20-50 EDs specifically designed to induce 
tolerance to the administered FVIII and to 
minimize inhibitor development by avoiding 
immunological danger signals. Twenty-six 
consecutive previously untreated patients 
(PUPs) with severe haemophilia A were 
treated with the new prophylaxis regimen and 
the incidence of inhibitor development in this 
group was compared with that in a historical 
control group of 30 consecutive PUPs treated 
with a standard joint protection prophylaxis 
regimen (40-50 IU kg(-1), three times a week). 
There were no significant differences between 
the study and control groups. Our results 
indicate that minimizing danger signals during 
the first 20 EDs with FVIII may reduce the risk 
of inhibitor formation. These results should be 
confirmed in a larger prospective clinical 
study. 
Observational 
Cohort 
+ 
2010 
Haemophilia. 16 
(3) (pp 479-486), 
2010 
 
Utility of the 
Haemophilia Joint 
Health Score in study 
of episodically 
treated boys with 
severe haemophilia A 
and B in Lithuania.  
 
Saulyte Trakymiene S., Ingerslev J., 
Rageliene L.  
 
Lithuanian patients 4- 17 years with SH A and 
B, no inhibitors and OD. Grouped by age 
HJHS, most affected joints ankles. HJHS useful 
in evaluating musculoskeletal outcome in 
patients OD 
Observational 
Cohort 
 
+ 
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2010 
Value in Health. 13 
(3 SUPPL. 3) (pp 
A216). 
US cost effectiveness 
analysis of primary 
prophylaxis versus on-
demand treatment in 
hemophilia: Design 
and rationale of a 
comprehensive model.  
Boer R., Lalla A., Mathew P., Preblick R., 
Pocoski J.  
 
Lifetime Markov model compared PP vs. OD, took 
into account the probability of inhibitor 
development, use of central catheter, and total 
bleeding risk. Prophylaxis assumed to be from 
birth to 16 years of age. ICER results not available 
Economic 
evaluation 
Gray literature 
 
0 
 
2009 
Hamostaseologie. 
29 Suppl 1  (pp 
S77-79),  
Cross sectional study to 
investigate the 
influence of treatment 
regimens on the 
development of 
haemophilic 
arthropathy 
Hilberg T., Czepa D Only a small amount and a short exposure to 
blood in vitro are able to induce impairment of 
joint cartilage. Bone and cartilage damage are 
induce by macrophages and monocytes, 
cytokines and inflammatory processes, at worst H 
arthropathy occurs reducing QoL. No consensus 
on treatment of adult population 
Observational 
Cross sectional 
+ 
2009 
Haemophilia 15.6: 
1219-27 
Joint outcomes in 
patients with 
haemophilia: the 
importance of 
adherence to 
preventive regimens.  
Berntorp, E. 
 
Early evidence from Sweden suggested that 
prophylaxis improved patient outcomes, this has 
been proven by recent RCTs. This applies for HA 
and HB. Barriers to prophylaxis: cost, venous 
access difficulties, time required for infusions 
Review article 0 
2005 
Coagulation and 
Fibrinolysis, 16(7): 
p. 477-485 
 
Cost effectiveness of 
haemophilia 
treatment: A cross-
national assessment. 
Lippert, B., Berger, K., Berntorp, E., 
Giangrande, P., Van Den Berg, M., 
Schramm, W. and Siebert, U. Blood  
The aim was to assess the ICER of on-demand 
versus prophylactic haemophilia therapy in 
Germany, Sweden, the United Kingdom and The 
Netherlands from the third-party payers' 
perspective. Using a decision tree model, based 
on decision analysis, the use of prophylactic 
treatment was overall more effective than on-
demand therapy in young haemophiliacs, but at 
extremely high cost. 
Economic 
Evaluation 
+ 
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Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
2007 
Br J Haematology; 
138: 580–6. 
 
The Risk Associated 
With Indwelling 
Catheters In Children 
With Haemophilia.  
.  
 
Ljung R.  
 
Infections most frequent complication of use 
of CVL in haemophiliac patients. 0,2- 0,3 
infections per 1000 catheter days, some other 
studies 1- 2/ 1000 CD. Despite risks are useful. 
 
Review article 
 
0 
2002 
PharmacoEconom
ics; 20 (11) (pp 
759-774).  
 
Cost-utility analysis of 
primary prophylaxis 
versus treatment on-
demand for 
individuals with 
severe haemophilia.  
Miners A, Sabin C, Tolley K, Lee C.  CUA analysis with primary data and modelling. 
Societal perspective, lifetime horizon. Primary 
prophylaxis ICER £46.500 per QALY gained 
Economic 
Evaluation 
 
CUA 
+ 
2009 
Journal of 
Thrombosis and 
Haemostasis. 7 
(S2) (pp 1124) 
Impact of FVIII 
product change in 
severe haemophilia A 
patients previously 
treated with plasma-
derived FVIII.  
 
Mingot M.E., Heiniger A.I., Garcia M., 
Fernandez J.A.  
 
22 HA patients treated with pdFVIII switched 
to another pdFVIII or rFVIII. Median follow up 
of 31 +/- 9 months. Both pdFVIII and rFVIII are 
safe and effective products, similar recoveries 
and no adverse events. 
Observational 
Cohort 
 
+ 
2013 
Haemophilia. 
19(2):174-180,  
 
Economic evaluations 
of prophylaxis with 
clotting factor for 
people with severe 
haemophilia: why do 
the results vary so 
much? 
Miners A H.  Review of literature, 11 economic evaluations 
identified. ICERs reported ranging from 
prophylaxis being cost saving to over € 1 
million per QALY gained. Differences in 
structural design as well as parametric 
variability explain reasons. Concerns about 
appropriate methodology. 
Review article 
 
0 
2008 
Blood 
Transfusion. 6 
(SUPPL. 2) (pp s4-
s11),  
Primary prophylaxis 
in children with 
haemophilia.  
 
Coppola A., Di Capua M., De Simone 
C.  
  
 
This review summarizes available data from 
which current clinical practice of primary (and 
early secondary) prophylaxis in children with 
severe haemophilia was drawn. Observational 
studies clearly established the superiority of 
prophylaxis over on-demand treatment in 
reducing the risk of arthropathy, also showing 
that starting prophylaxis earlier in life and 
after very few joint bleeds was associated with 
better joint outcomes, and led to the current 
definitions of primary (started before the age 
of 2 yrs and after no more than one joint 
bleed) and secondary prophylaxis. More 
recently, evidences from randomized trials, 
which were previously lacking in this setting, 
were also provided.  
Review article 
 
0 
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2008 
Haemophilia. 14 
(4) (pp 743-752), 
2008 
Cost-utility analysis of 
Canadian tailored 
prophylaxis, primary 
prophylaxis and on-
demand therapy in 
young children with 
severe haemophilia A.  
Risebrough N., Oh P., Blanchette V., 
Curtin J., Hitzler J., Feldman B.M.  
 
From a societal perspective, this study compared 
the incremental cost per joint-haemorrhage that 
is avoided and quality-adjusted-life-year (QALY) 
gained of SP and EscDose to on-demand 
(Demand) therapy in severe haemophilia A boys 
treated to age 6 using a decision analytic model. 
Costs included factor VIII (FVIII), professional 
visits and tests, central venous 
placement/complications, hospitalization, home 
programmes and parents' lost work-days. 
Resource utilization was estimated by surveying 
17 Canadian clinics. The natural history of 
bleeding and other probabilities were 
determined from a longitudinal chart review (n = 
24) and published literature. EscDose costs an 
additional $3192 per joint-haemorrhage that was 
avoided compared with Demand whereas SP 
costs an additional $9046 per joint-haemorrhage 
that was avoided compared with EscDose. Clinic 
costs and lost wages were reduced by 60-80% for 
EscDose and SP compared with Demand. EscDose 
attained more QALYs than SP and Demand on 
account of less bleeding than Demand and lower 
need for ports than SP. The incremental cost per 
QALY for EscDose vs. Demand was $542938. 
EscDose was less expensive with similar QALYs 
compared to SP. Sensitivity analysis showed the 
model was sensitive to the cost of FVIII and the SP 
and target joint utilities. In conclusion, 
prophylaxis will substantially improve clinical 
outcomes and quality of life compared to 
Demand treatment, but with substantial cost 
Economic 
evaluation  
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Year of 
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Title Author Summary Type of 
publication 
Score 
      
1992 
Journal of Internal 
Medicine, 232(1): 
p. 25-32. 
 
Twenty-five years' 
experience of 
prophylactic 
treatment in severe 
haemophilia A and B.  
Nilsson M, Berntorp E, Lofqvist T, and 
Pettersson H.  
Population consisted of 60 severe 
haemophiliacs (52 A, 8 B), aged 3–32 years. 
Treatment is started when the boys are 1–2 
years of age, the regimens used being 24–40 
IU F VIII kg−1 three times weekly in 
haemophilia-A cases (i.e. > 2000 IU 
kg−1 annually) and 25–40 IU F IX kg−1 twice 
weekly in haemophilia-B cases. The 
orthopaedic and radiological joint scores 
(maximum scores of 90 and 78, respectively) 
are evaluated as recommended by the World 
Federation of Haemophilia. Of those subjects 
aged 3–17 years, 29 out of 35 individuals had 
joint scores of zero. The oldest group had only 
minor joint defects. The VIII:C and IX:C 
concentrations had usually not fallen below 
1% of normal. All 60 patients are able to lead 
normal lives. In conclusion, it appears to be 
possible to prevent haemophilic arthropathy 
by giving effective continuous prophylaxis 
from an early age, and preventing the VIII:C or 
IX:C concentration from falling below 1% of 
normal. 
Observational 
Cohort 
++ 
 
2008 
Haemophilia. 14 
(SUPPL. 3) (pp 
196-201) 
Prophylaxis for 
severe haemophilia: 
Clinical challenges in 
the absence as well as 
in the presence of 
inhibitors.  
 
Fischer K., Valentino L., Ljung R., 
Blanchette V.  
 
Extensive data from observational studies and 
a recent randomized controlled trial (have 
established that early prophylactic treatment 
prevents bleeds and arthropathy in boys with 
severe haemophilia. The initiation of 
prophylaxis in young children remains 
challenging. To prevent arthropathy, 
prophylaxis should be started early, before the 
onset of joint damage. Alternative strategies 
of starting include starting before the age of 2 
years, or starting before the third joint bleed. 
Dose and frequency vary between the original 
Swedish regime of 20-40 IU kg(-1) three times 
per week and lower dosed and step up 
regimes starting with 50 IU kg(-1) once weekly 
and rapidly increasing dose and frequency in 
case of bleeds. The third decade of life often 
represents a change in lifestyle. Patients may 
get a job and periods of physical activity may 
be more confined. About two thirds of 
patients experiment with discontinuing 
prophylaxis in their early twenties, and 20-30% 
with mild bleeding patterns switch to on-
demand treatment for prolonged periods or 
Review article 0 
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2011 
Haemophilia, 1-2  
 
A survey of the 
outcome of 
prophylaxis, on-
demand or combined 
treatment in 20-35 
year old men with 
severe haemophilia in 
four European 
countries. 
Noone D,  Mahony O and Prihodova L.  This study was carried out to examine the long-
term effects of prophylaxis and the continuing 
benefit of the therapy in adulthood. National 
Haemophilia patient organizations in Ireland, UK, 
France and Sweden were asked to participate by 
randomly selecting 20 severe haemophilia 
patients between 20 and 35 years from their 
database. Overall, on-demand treatment results 
in a lower utility value in relation to quality-of-life 
for people with severe haemophilia. Prophylaxis 
started at an early age and continued into 
adulthood results in less bleeding, less damage to 
joints and less time missed at work. Prophylaxis 
increases mobility and the ability to do everyday 
activities and improves the health-related quality 
of life of people with severe haemophilia.  
 
Observational 
Cross sectional 
+ 
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Year of 
Publication 
Title Author Summary Type of 
publication 
Score 
      
1996. 
Journal of 
Pediatrics, 129(3): 
p. 424-431 
 
Episodic versus 
prophylactic infusions 
for hemophilia A: a 
cost-effectiveness 
analysis. 
Smith, P.S., Teutsch, S.M., Shaffer, 
P.A., Rolka, H. and Evatt, B.  
A random sample of patients from 11 
haemophilia treatment centres receiving 
episodic care and prophylactic care were 
included in the study. The final sample size 
comprised 117 boys. Of these, 90 were treated 
episodically (control) and 27 prophylactically 
(intervention). No power calculations were 
undertaken to determine an appropriate 
sample size. A model was used to estimate 
both costs and benefits. The model comprised 
three hypothetical cohorts of patients (aged 3 
to 50 years) who were receiving either 
episodic or one of two types of prophylactic 
treatment. In the first model of prophylaxis, 
treatment begins at the age of three (when 
regular bleeding usually begins) and continues 
until the age of 50. In the second model, 
prophylaxis is administered from the age of 
three to 20 years only (when the frequency of 
regular bleeding begins to decline). The total 
direct medical costs to treat prophylactically 
were increased approximately threefold, from 
$23,435 to $75,574 (p<0.005). 
 
 
Economic 
evaluation 
CEA 
0 
2004. 
Haemophilia, 
10(5): p. 527-541 
Willingness to pay for 
on-demand and 
prophylactic 
treatment for severe 
haemophilia in 
Sweden.  
Steen Carlsson, K,  Höjgård, S,  
Lethagen, S,   Lindgren, A, Berntorp, E, 
Lindgren, B.  
CBA compered prophylaxis with on- demand 
used primary data time horizon 1 year. Greater 
expected net benefit with prophylaxis than 
with on- demand  
Economic 
evaluation  
CBA 
 
+ 
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2005 
Polskie archiwum 
medycyny 
wewntrznej. 113 
(6) (pp 562-569) 
The orthopaedic status 
of a selected severe 
haemophilia group.  
 Windyga J., Stefanska E., Lopaciuk S., 
Juszynski A., Wozniak D., Strzelecki O.  
 
Study aimed at describing the orthopaedic status 
of patients with severe haemophilia, regarding 
the type of replacement therapy received by 
patients prior to the study. 92 haemophiliacs with 
median age 26 were included. Six joints--knees, 
elbows and ankles were evaluated clinically using 
the Gilbert scale. Knees were the most affected 
joints. 84 patients (91.3%) reported pain. 37 % of 
patients used orthopaedic equipment 
occasionally or constantly. 25 % of patients had a 
history of orthopaedic surgery. 38% were 
unemployed and received some form of social 
subvention. On demand treatment was applied. 
None of the patients received primary 
prophylaxis. The mean consumption of clotting 
factor concentrates was 68,054 IU per patient 
during the 12 months period prior to the current 
study. The results of this study indicate that vast 
majority of severe haemophilia patients in Poland 
above 20 are affected by haemophilic 
arthropathy.  
Observational 
 
Cross sectional 
 
+ 
2003 
Haemophilia. 9 
(SUPPL. 1) (pp 27-
31) 
 
Comparing outcomes 
of different treatment 
regimens for severe 
haemophilia.  
 
Van Den Berg H.M., Fischer K., Van Der 
Bom J.G.  
 
Published retrospective reports from France, the 
Netherlands and Sweden were analysed for data 
relating to the long-term outcomes (primarily the 
development of arthropathy) of three regimens 
for the management of severe haemophilia: on-
demand treatment, intermediate-dose 
prophylaxis and high-dose prophylaxis. These 
data indicate that both prophylaxis regimens 
resulted in significantly improved long-term 
outcomes, as assessed by pain, clinical and 
radiological assessment scores. At the same time, 
the most recently reported annual factor 
consumption levels of these young adult patients 
are comparable in the on-demand and 
intermediate-dose prophylaxis cohorts, 
suggesting that the improvement in long-term 
clinical outcomes and reduced risk of arthropathy 
may lead to reduced factor consumption in adult 
patients who received early prophylactic therapy. 
 
Observational 
 
Cross sectional 
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Score 
2002 
Current Opinion 
in Pediatrics. 14 
(1) (pp 46-49) 
Current treatment of 
hemophilic 
arthropathy.  
 
 Hilgartner M.W.  
 
 
Regular infusions of recombinant factor or 
treated plasma derived factor given 
prophylactically to prevent spontaneous 
bleeding are recommended for all children to 
maintain a plasma factor level of >1%. 
Recombinant factor product or treated plasma 
derived product should be used. Prophylaxis 
should begin when bleeding occurs repeatedly 
and is superior to on-demand therapy. 
Hypertrophied synovium should be removed 
surgically or with a sclerosing agent, either 
radioactive or chemical material, to impede 
further cartilaginous and bony deterioration. 
Arthroplasty of the knee and hip have been 
successful in reducing pain and loss of motion 
when other efforts to control synovial 
hypertrophy fail 
Review article 
 
0 
2009 
Haemophilia 15.4: 
881-87 
Revisiting the cost-
effectiveness of 
primary prophylaxis 
with clotting factor 
for the treatment of 
severe haemophilia 
A.  
 Miners, A. 
 
A 2002 evaluation of primary prophylaxis 
suggested an ICER of approximately £50,000 
per additional (QALY). The primary aims of this 
study were to update a previously published 
cost-effectiveness analysis of primary 
prophylaxis vs. treating on-demand in terms of 
methods and to estimate the value of 
undertaking further primary research. The 
base case incremental cost-effectiveness ratio 
was shown to be approximately 37,000 
pounds, 10,000 pounds lower than the value 
published in 2002. The main reason for this 
difference was the use of different structural 
assumptions and methods to fit the various 
model parameters. At a WTP per additional 
QALY threshold of 30,000 pounds, the 
probability prophylaxis is cost-effective was 
13%. However, this increased to over 90% 
when alternative structural assumptions were 
employed, such as the rate at which future 
QALYs are discounted. There is considerable 
value in conducting further primary research 
related to economic aspects of primary 
prophylaxis. 
Economic 
evaluation 
 
CUA 
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2007 
Haemophilia 13 
Supplement 2: 16-
22. 
 
Identifying and 
overcoming barriers to 
prophylaxis in the 
management of 
haemophilia.  
 Petrini, P. 
 
Current treatment for patients with severe 
haemophilia involves clotting factor replacement 
given on demand or through long-term 
prophylaxis. Although prophylaxis has many 
advantages, its practice varies widely even among 
developed countries because of several barriers. 
Such barriers include CFC costs and availability; 
patient perceptions, lifestyles and bleeding 
patterns; difficulties and complications arising 
from the use of intravenous access devices 
(IVADs); the development of inhibitors; and the 
lack of randomized clinical trials. These barriers 
can be overcome by tailoring treatment regimens 
according to individual patient bleeding patterns 
and CFC pharmacokinetic profiles, using IVADs 
selectively and judiciously, helping patients 
maintain normal weight and physical exercise and 
providing the families of patients with continuous 
support from healthcare providers. 
Review article 
 
+ 
      
2007 
Haemophilia 13.3: 
227-32 
Prophylaxis in the 
haemophilia 
population-optimizing 
therapy.  
Carcao, M. D., L. M. Aledort, The Round 
Table Group. 
 
A one day meeting report held by Dr Aledort in 
2005. The meeting brought together unsolved 
issues about prophylaxis and affordability. 
Meeting attendees tackled these issues, as well as 
the socio- economic challenges of implementing 
prophylaxis 
Review article 
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Score 
2002 
Haemophilia 8.1: 
44-50. 
Quality-of-life 
differences between 
prophylactic and on-
demand factor 
replacement therapy 
in European 
haemophilia patients.  
Royal, S., Schramm, W, Bertntorp, E, 
Giagrande, A, Gringeri, Gringeri, A, 
Ludlam, C, Kronker, B, Szucs, T. 
The European Study on the Clinical Outcomes 
and Resource Utilization associated with 
Haemophilia Care was designed to compare 
various health outcomes associated with on-
demand and prophylactic factor substitution. 
A total of 1033 haemophilia patients from 16 
European haemophilia treatment centres 
were enrolled in this study. The SF-36, a 
multidimensional quality-of-life instrument, 
was administered to all participants. All 
haemophilia subjects enrolled in the study 
scored significantly lower than the population 
normative means in the three physical 
dimensions and in the general health 
dimension. Univariate indicated that patients 
treated prophylactically reported significantly 
less bodily pain, better general health, and 
scored significantly higher in the physical 
functioning, mental health, and social 
functioning dimensions. While these results 
suggest that health-related quality-of-life may 
be better for haemophilia patients treated 
prophylactically, future prospective studies 
that gather periodic quality-of-life data over 
time should be conducted. 
Observational 
 
Cross 
sectional 
 
+ 
2006 
J Thromb 
Haemost; 4: 
1228–36. 
 
Tailored Prophylaxis 
In Severe 
Haemophilia A: 
Interim Results From 
The First 5 Years Of 
The Canadian 
Haemophilia Primary 
Prophylaxis Study.  
 Feldman BM, Pai M, Rivard GE Et Al. 
 
Prophylactic treatment for severe haemophilia 
A is likely to be more effective than treatment 
when bleeding occurs, however, prophylaxis is 
costly. Study of inception cohort of 25 boys 
using a tailored prophylaxis approach to see if 
clotting factor use could be reduced with 
acceptable outcomes.  10 Canadian centres 
enrolled subjects, children were followed 
every 3 months. Initially treated with once-
weekly clotting factor; the frequency was 
escalated in a stepwise fashion if unacceptable 
bleeding occurred. Bleeding frequency, target 
joint development, physiotherapy and 
radiographic outcomes, as well as resource 
utilization, determined prospectively.  The 
median follow-up time was 4.1 years (total 
96.9 person-years). The median time to 
escalate to twice-weekly therapy was 
3.42 years (lower 95% confidence limit 
2.05 years). Nine subjects developed target 
joints at a rate of 0.09 per person-year. There 
was an average of 1.2 joint bleeds per person-
year. The cohort consumed on average 
3656 IU kg−1year−1 of factor (F) VIII. Ten 
subjects required central venous catheters 
Observational 
 
Cohort 
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2010 
Haemophilia  
Mar;16 Suppl 2:4-
9.:4-9. 
 
Devising a best practice 
approach to 
prophylaxis in boys 
with severe 
haemophilia: 
evaluation of current 
treatment strategies.  
 Carcao M, Chambost H, Ljung R.  Data from prospective studies clearly 
demonstrate the efficacy of prophylactic 
treatment of haemophilia in reducing joint- or 
life-threatening bleeding and the associated 
consequences for quality of life. Debate remains, 
however, regarding the optimal implementation 
of prophylaxis. The aim in this review was to 
identify a best practice approach to factor 
replacement prophylaxis in boys with 
haemophilia. Evaluated prophylactic treatment 
regimens currently used in Swedish, Canadian 
and French centres and highlight key issues, 
including the optimal age for starting prophylaxis, 
the optimal treatment dosage/schedule and 
patient compliance. 
Review article 
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2003 
Haemophilia. 9 
(Suppl. 1) (pp 1-4) 
 
Consensus 
perspectives on 
prophylactic therapy 
for haemophilia: 
summary statement.  
Berntorp E, Astermark J., Bjorkman S., 
Blanchette VS, Fischer K, Giangrande 
PLF, Gringeri A, Ljung R., Manco- 
Johnson MJ, Morfini M, Kilcoyne RF, 
Petrini P, Rodriguez- Merchan EC, 
Schramm W, Shapiro A, Van De Berg 
HM and Hart C.  
Participants in an international conference on 
prophylactic therapy for severe haemophilia 
developed a consensus summary of the 
findings and conclusions of the conference. In 
the consensus, participants agreed upon 
revised definitions for primary and secondary 
prophylaxis and also made recommendations 
concerning the need for an international 
system of pharmacovigilance. Considerations 
on starting prophylaxis, monitoring outcomes, 
and individualizing treatment regimens were 
discussed. Several research questions were 
identified as needing further investigation, 
including when to start and when to stop 
prophylaxis, optimal dosing and dose interval, 
and methods for assessment of long-term 
treatment effects. Such studies should include 
carefully defined cohorts, validated 
orthopaedic and quality-of-life assessment 
instruments, and cost-benefit analyses. 
Review article 
 
0 
2007 
Blood. (110) (pp 
815- 825),  
 Mortality rates, life 
expectancy, and 
causes of death in 
people with 
hemophilia A or B in 
the United Kingdom 
who were not 
infected with HIV.   
Darby SC, Kan SW, Spooner RJ, 
Giangrande PLF, Hill F, Hay C, Lee CA, 
Ludlam and Williams M. 
 
Since the 1970s, mortality in the haemophilia 
population has been dominated by HIV and 
few reports have described mortality in un-
infected individuals. This study presents 
mortality in 6018 people with haemophilia A 
or B in the United Kingdom during 1977 to 
1998 who were not infected with HIV, with 
follow-up until January 1, 2000. All-cause 
mortality did not differ significantly between 
haemophilia A and B. In severe haemophilia, 
all-cause mortality did not change significantly 
during 1977 to 1999. During this period, it 
exceeded mortality in the general population 
by a factor of 2.69 (95% [CI]: 2.37-3.05), and 
median life expectancy in severe haemophilia 
was 63 years. In moderate/mild haemophilia, 
all-cause mortality did not change significantly 
during 1985 to 1999, and median life 
expectancy was 75 years. Compared with 
mortality in the general population, mortality 
from bleeding and its consequences, and from 
liver diseases and Hodgkin disease, was 
increased, but for ischemic heart disease it 
was lower, at only 62% (95% CI: 51%-76%) of 
general population rates, and for 14 other 
specific causes it did not differ significantly 
from general population rates. There was no 
evidence of any death from variant 
Creutzfeldt-Jakob disease or from conditions 
that could be confused with it. 
Observational 
 
Cohort 
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2007 
New England 
Journal of 
Medicine. 357 
(vol 6) (pp. 535- 
544). 
Prophylaxis versus 
Episodic Treatment 
to Prevent Joint 
Disease in Boys with 
Severe Hemophilia.  
 
Manco- Johnson MJ, Abshire TC, 
Shapiro AD, Riske B, Hacker M, 
Kilkoyne R, Ingram D, Manco- 
Johnson ML , Funk S, Jacobson L, 
Valentino LA, Hoots K, Buchanan GR, 
DiMichele D, Recht M, Brown D, 
Leissinger C, Bleak S, Cohen A, 
Mathew P, Matsunga A, MAdeiros D, 
Nugent D, Thomas G, Thompson A, 
McRedmond K, Soucie M and Austin 
H 
This study randomly assigned young boys with 
severe haemophilia A to regular infusions of 
rFVIII (prophylaxis) or to an enhanced episodic 
infusion schedule of at least three doses 
totalling a minimum of 80 IU of factor VIII per 
kilogram of body weight at the time of a joint 
haemorrhage. The primary outcome was the 
incidence of bone or cartilage damage as 
detected in index joints (ankles, knees, and 
elbows) by radiography or magnetic 
resonance imaging (MRI). Sixty-five boys < 30 
mo of age were randomly assigned to 
prophylaxis (32 boys) or enhanced episodic 
therapy (33 boys). When the boys reached 6 
years of age, 93% of those in the prophylaxis 
group and 55% of those in the episodic-
therapy group were considered to have 
normal index-joint structure on MRI (P = 
0.006). The RR of MRI-detected joint damage 
with episodic therapy as compared with 
prophylaxis was 6.1 (95% confidence interval, 
1.5 to 24.4). Mean annual numbers of joint 
and total haemorrhages were higher at study 
exit in the episodic-therapy group than in the 
prophylaxis group (P<0.001 for both 
comparisons). High titres of inhibitors of factor 
VIII developed in 2 boys who received 
prophylaxis; 3 boys in the episodic-therapy 
group had a life-threatening haemorrhage. 
Hospitalizations and infections associated with 
central-catheter placement did not differ 
significantly between the two groups. 
Prophylaxis with rFVIII can prevent joint 
damage and decrease frequency of joint and 
other haemorrhages in young boys with 
severe haemophilia A. 
 
Interventional 
RCT 
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APPENDIX 2.4 NARRATIVE SYNTHESIS OF PUBLISHED ECONOMIC STUDIES  
 
Adapted from: Miners A, 2013 Haemophilia. 19(2):174-180, 2013. 
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APPENDIX 4. HAEMOPHILIA JOINT HEALTH SCOREAND HR-QoL- HEALTH STATES COLOMBIAN 
COHORT SCORES 2012 
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APPENDIX 5. DETAILED DESCRIPTION OF MEANS, STANDARD ERRORS, PROBABILITIES AND OTHER 
PARAMETERS USED TO CALCULATE PROBABILITIES DISTRIBUTIONS FOR PSA 
 
 
Λ parameter for Poisson 1 for PP and 17 for OD 
* Standard deviation calculated directly from the data of the local cohort of patients using Excel. 
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APPENDIX 6. ORIGINAL EVIDEM MATRIX WEIGHTING AND SCORING CRITERIA  
Weighting criteria of the MCDA Core Model 
Cluster Scientific criteria  
Relative weight  
Low                                   High  
Should  
not be 
considered 
Disease impact  
D1 Disease severity  1      2      3      4      5  0  
D2 Size of population affected by disease 1      2      3      4      5  0  
Context of intervention  
C1 Clinical guidelines for intervention 1      2      3      4      5  0  
C2 Comparative intervention limitations (unmet needs) 1      2      3      4      5  0  
Intervention outcomes   
I1 Improvement of efficacy/effectiveness 1      2      3      4      5  0  
I2 Improvement of safety & tolerability 1      2      3      4      5  0  
I3 Improvement of patient reported outcomes 1      2      3      4      5  0  
Type of Benefit  
T1 Public health interest (e.g., prevention, risk reduction) 1      2      3      4      5  0  
T2 Type of medical service (e.g., symptom relief, cure) 1      2      3      4      5  0  
Economics  
E1 Budget impact on health plan (cost of intervention) 1      2      3      4      5  0  
E2 Cost-effectiveness of intervention 1      2      3      4      5  0  
E3 Impact on other spending (e.g, hospitalization, disability) 1      2      3      4      5  0  
Quality of evidence  
Q1 Adherence to requirements of decision making body  1      2      3      4      5  0  
Q2 Completeness and consistency of reporting evidence (meeting 
scientific reporting standards and consistency with sources)  
1      2      3      4      5  0  
Q3 Relevance and validity of evidence (relevant to decision-makers & 
meeting scientific standards) 
1      2      3      4      5  0  
Source: https://www.evidem.org/tiki/tiki-index.php?page=FRAME-Menu 
Note: Impact on other spending (e.g, hospitalization, disability) and Adherence to requirements of decision 
making body were changed in Colombia and contextualised by including Attention to vulnerable groups of 
population and Attention to differential needs for health/health care     
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APPENDIX 7. THE PRELIMINARY WORK DEVELOPED BY CRES FOR FIELD TESTING EVIDEM  
CRES was established by Law 1122 in 2007 as an arm of the Ministry of Social Protection aimed at 
making decisions about health care coverage within POS and annually updating the premiums to be 
reimbursed from the central fund of pooling (FOSYGA) to health insurers. The preliminary work 
developed by CRES in 2012 consisted of three workshops with 11 senior academics and decision-
makers (academics, researchers, and civil servants) with broad experience of working in the context 
of the Colombian health system, and visibility among stakeholders. The main researcher was invited 
to participate in the panel as part of the discussion during all three workshops.  
Prior to the first meeting CRES experts had attempted to group 59 frequently-used criteria for 
decision-making and develop a new MCDA matrix; however, the main researcher argued against “re-
inventing the wheel”, and suggested EVIDEM, with which he was familiar,  to panel members as a 
feasible solution to be tested and implemented in Colombia. Since EVIDEM already existed and had 
been operationalised and tested elsewhere, it appeared to be a pragmatic solution to move forward. 
All participants agreed to use EVIDEM as a means to contextualise local criteria, adapting it if necessary 
and weighting pre-selected criteria throughout these panel sessions.  
Participants invited by CRES were presented with a search of international evidence of experiences 
regarding the use of explicit criteria to inform resource-allocation around the globe (Byskov et al, 
2009; Diederich et al, 2011, Gonzalez- Pier et al, 2007 and Guindo et al, 2012). As in step 1 of Miot´s 
work, participants were asked to nominate a list of additional contextual aspects they considered 
relevant for resource-allocation decision-making in Colombia. After this, from the six original clusters 
of EVIDEM, an additional contextual dimension was added to capture any local preferences not 
included in the original list. The preliminary list consisted of 18 criteria, thus as per Miot´s work, it was 
necessary to ask panel members whether specific decision criteria should be considered in decision-
making in Colombia or not. 
In order to decide on the final criteria for Colombia, CRES asked participants, through an electronic 
survey, to vote for criteria according to their perceived importance in decision-making; all participants 
voted. The voting system used the Delphi method approach [Linstone et al, 1975 and Astisagarra, 
2003]). A quantitative scale from 1 to 9 was used to decide on the final list of selected criteria, where 
9 represented the greatest importance in decision-making and 1 the lowest (Sanchez et al, 2009). This 
voting system departed from the qualitative approach presented by Miot (always/sometimes/never) 
to the South African panel. Scores were assigned in the context of the local health system without 
considering any specific health care intervention, as in the original author’s work.  
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After three voting rounds in two nominal group sessions the final list was reduced to 15 criteria, of 
which 13 belonged to the original decision criteria listed in the EVIDEM framework (one criterion less 
than Miot´s publication), and two added contextual criteria. Original EVIDEM core criteria excluded by 
consensus were: convenience and adherence to requirements of the decision-making body (similar to 
Miot, 2012) and impact on other spending. These were considered irrelevant (i.e. no decision-making 
body rules were in place at the time of voting) or limited by lack of available data in the country about 
shadow costs.  
The initially added contextual dimension was entitled “equity concerns” by participants, Thus the final 
15 criteria considered were: completeness and consistency of reporting evidence; relevance and 
validity of evidence; disease severity; size of population affected by disease; current clinical guidelines; 
current intervention limitations; improvement of efficacy/effectiveness; improvement of safety and 
tolerability; improvement of patient-reported outcomes; public health interest; type of medical 
service; budget impact on health plan; cost-effectiveness of intervention, attention to vulnerable 
groups of population; and attention to differential needs for health/health care. This first part of CRES 
work closely resembled Miot´s step 1 of contextualisation of criteria.  
Once the panel had agreed on the final criteria and their definitions, participants were asked to weight 
each criterion irrespective of any health care intervention of interest (step 2: weighting of criteria). 
Instead of the 1 to 5 scale of the original work, CRES used a Borda count approach53 (Saari, 2000) which 
is a ranking system where the number of points given to candidates for each ranking is determined by 
the number of candidates standing in the election.  CRES delivered further consensus meetings with 
different stakeholders around the country to disseminate the selected list of criteria and ask 
participants to weight each of them using the same approach.  
During November and December 2012 CRES visited seven major cities (Medellin, Cali, Bucaramanga, 
Valledupar, Pereira, Barranquilla and Bogotá), and asked a total of 201 citizens to vote on their level 
of agreement and preferences regarding each of the 15 criteria (CRES, 2012).  The list of voting 
participants included the academics on the same panel as the main researcher, patients’ associations, 
citizen´s councils and representatives from the medical societies. (See below the final list of criteria 
and weights selected for Colombia, those highlighted coincided with original criteria of the EVIDEM 
framework). 
 
                                                          
53  In Borda count the voter ranks the list of candidates in order of preference. Named after the French mathematician and political 
scientist Jean-Charles de Borda, who devised the system in 1770, It is also known as the ranked voting system, 
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APPENDIX 8. BY-CRITERION EVIDEM MATRIX (SPANISH VERSION) AND SOURCES OF HTA DATA 
 
CRITERIO DEFINICIÓN
TECNOLOGÍA: suplementación con zinc a fin de disminuir la incidencia de enfermedad diarreica aguda, en niños con bajo peso al nacer, déficit 
nutricional y del crecimiento
Gravedad de la 
enfermedad o condición 
de salud
Severidad de la condición de salud de los pacientes tratados con 
la intervención propuesta (o la gravedad de la condición de salud 
que se ha de prevenir ) respecto a la mortalidad, discapacidad, 
impacto en la calidad de vida, curso clínico (es decir agudeza, 
etapas clínicas). 
La Enfermedad diarreica aguda (EDA) puede ocurrir a cualquier edad de la vida, pero son los lactantes y niños menores de cinco años los más 
predispuestos a desarrollar la enfermedad y a presentar complicaciones como sepsis, deshidratación y muerte.  La diarrea puede durar varios días y 
puede privar al organismo del agua y las sales necesarias para la supervivencia. La mayoría de las personas que fallecen por enfermedades diarreicas en 
realidad mueren por una grave deshidratación y pérdida de líquidos. Los niños desnutridos o inmunodeprimidos son los que presentan mayor riesgo de 
enfermedades diarreicas potencialmente mortales. Las enfermedades diarreicas son la segunda causa de muerte en niños menores de cinco años, y 
ocasionan la muerte de 760,000 niños cada año (1). Durante el año 2006, fallecieron en Colombia 336 niños por enfermedad diarreica y 374 por 
problemas nutricionales; estas últimas, con mucha frecuencia relacionadas directa o indirectamente con la diarrea. Según la OMS, las muertes por 
enfermedad diarreica aguda en Colombia, constituyeron el 9% de todas las muertes en menores de 5 años en el año 2010, y según las estadísticas del 
DANE, para el año 2011 se reporta una tasa de mortalidad por EDA en menores de 5 años de 2.87 por cada 100,000 muertes en menores de 5 años (2).  
Número de personas 
afectadas por la 
población objeto de la 
intervención 
(prevalencia/incidencia)
Número de personas afectadas por la enfermedad (tratada o 
prevenida con la intervención propuesta) en una población 
específica y en un momento determinado; puede expresarse 
como en número anual de nuevos casos (incidencia anual) y /o la 
proporción de la población afectada en un momento dado en el 
tiempo (prevalencia).
En países en desarrollo, los niños menores de tres años sufren en promedio, tres episodios de diarrea al año, y cada episodio priva al niño de nutrientes 
necesarios para su crecimiento (1). En Colombia, casi la mitad de los niños tiene deficiencia de zinc, lo que los predispone a desarrollar episodios 
diarreicos. Los datos de la Encuesta Nacional de la situación nutricional en Colombia 2010 (3), muestran que el 50% de la población entre 1 y 4 años 
presentó valores inferiores a 70ug/ml, muy cercano al límite inferior, y 2 de cada 5 niños menores de 5 años presentaron deficiencias de este 
micronutriente. La prevalencia más alta se encontró en la población indígena con un 56.3%. En general, un 44%  de los menores de 5 años tiene déficit de 
zinc, con un estimado de 1,700,000 niños, de acuerdo con las proyecciones poblacionales del DANE para la población entre 1 y 4 años para el 2013. (4). 
Mejora en 
eficacia/efectividad
Capacidad de la intervención prouesta para producir un efecto 
deseado (beneficioso) cambio en los signos, los síntomas y el 
curso de la afección específica por encima y más allá de los 
cambios beneficiosos producidos por las intervenciones 
alternativas . Incluye datos sobre la eficacia y la efectividad.
En Colombia, aproximadamente el 44% de los niños tiene deficiencia de zinc, la cual se encuentra directamente relacionada con el déficit nutricional; el 
zinc juega un papel muy importante en el sistema inmunológico (de defensa),  y su deficiencia afecta la función del mismo, lo que predispone al 
desarrollo de episodios diarreicos. La evidencia sugiere que cerca de la tercera parte de la poblacion mundial vive en ciudades con alto riesgo de 
deficiencia de zinc. Según la Encuesta Nacional de la situación nutricional en Colombia 2010 (3), estudios sugieren que la suplementacion con zinc puede 
reducir la prevalencia de enfermedad diarreica y de neumonia, que son las responsables, de un número importante de muertes en el mundo cada año, 
ademas de mejorar el pronóstico y disminuir días de hospitalización. 
Guías de práctica clínica 
basadas en evidencia, 
válidas en Colombia
Concurrencia de la intervención propuesta (o alternativas 
similares) con el consenso actualizado de expertos sobre lo que 
constituye el estado del arte, las prácticas y manejo de las 
condición de interés; estas recomnendaciones suelen ser 
desarrolladas a través de un proceso explícito y tienen por objeto 
mejorar la clínica práctica. 
Dentro del marco de la Convocatoria 500 de Colciencias, para la elaboración de guías basadas en evidencia científica, se desarrolló la Guía de Práctica 
Clínica para la prevención, diagnóstico y tratamiento de la enfermedad diarreica aguda en niños menores de cinco años, las cuales han sido lanzadas 
recientemente en el país. 
Tipo de beneficio clínico
Naturaleza del beneficio clínico proporcionado por la 
intervención propuesta a nivel del paciente (por ejemplo alivio 
de síntomas, prolongación de la vida, curación). 
En Colombia casi la mitad de los niños tienen deficiencia de zinc, lo que los predispone a desarrollar episodios diarreicos, entre otras alteraciones y 
enfermedades. La evidencia clínica ha demostrado reducción en la incidencia de diarrea entre un 15% - 20%. Los hallazgos del meta-análisis realizado 
por el grupo desarrollador de la guía de práctica clínica para la prevención, diagnóstico y tratamiento de la enfermedad diarreica aguda en niños menores 
de cinco años, reporta una disminución del 12% en la incidencia de la EDA, con suplementación diaria de zinc durante 3 meses (5). 
Impacto en el 
presupuesto en el plan 
de salud
Impacto económico neto de la cobertura de la intervención sobre 
el presupuesto del plan de salud (excluyendo otros gastos). Esto 
representa la diferencia entre los gastos previstos para la 
intervención propuesta y los posibles ahorros de costos que 
pueden derivarse de la sustitución de la intervención de otro (s) 
actualmente cubierto por el plan de salud. Limitada al costo de la 
intervención (por ejemplo costo de adquisición implementación 
y mantenimiento).  
El costo base para el sulfato de zinc en jarabe (2mg/ml), es de  $ 10.117 para la presentación de 80ml, y de $ 12.623 para la presentación de 120ml. Se 
recomienda para el tratamiento profiláctico la dosis de 5mg/día para menores de 6 meses durante 3 meses, para un costo total promedio de tratamiento 
de $51.165 . En niños mayores de 6 meses, la dosis recomendada es de 10mg/día por 3 meses, para un costo total promedio de tratamiento de $102.330. 
Fuente: SISMED 2012. Listado de Precios Promedio y Unidades en la cadena de comercializacion de Medicamentos. Enero a Septiembre de 2012 (6). 
Mejora de seguridad y 
tolerancia 
Reducción en efectos sobre la salud relacionados con la 
intervención que son dañinos o no deseados, en comparación con 
intervenciones alternativas. 
El zinc administrado en niños con déficit nutricional, es una intervención segura, ya que a pesar que el único evento adverso importante a las dosis 
recomendadas es el vómito, es considerado bien tolerado en la mayoría de las ocasiones (5).
Interés en salud pública
Reducción de riegos producto de la intervención a nivel de la 
población general (ej: prevención, reducción de transmisión de la 
enfermedad, reducción de la prevalencia de factores de riesgo).  
Dentro de las estrategias del Plan Decenal de Salud Pública 2012-2021 en el componente de Atención integral y diferencial de las niñas, niños y 
adolescentes en el entorno de los servicios de salud, se encuentra disminuir la mortalidad nacional en la niñez a 15 x1000 nacidos vivos o menos. Así 
mismo, la disminución de la mortalidad en menores de 5 años hace parte de los objetivos de desarrollo del milenio.  
Mejora resultados en 
salud reportados por 
paciente
Capacidad de la intervención propuesta de producir cambios 
benéficos en desenlaces reportados por pacientes (DRP) (por 
ejemplo calidad de vida) por encima y más allá de los cambios 
benéficos producidos por las intervenciones alternativas; 
también incluye mejoras en conveniencia para laos pacientes. 
La suplementación con zinc como estrategia preventiva en niños menores de 5 años con bajo peso al nacer, o déficit nutricional y del crecimiento, ha 
demostrado disminuir la incidencia de enfermedad diarreica aguda en este grupo de pacientes, lo que interviene en desenlaces de severidad 
relacionados con el episodio diarreico agudo, tales como deshidrtación grave, pronóstico, días de hospitalización y mortalidad. Adicionalmente, se 
suplen los requerimientos nutricionales dados en las condiciones de bajo peso o desnutrición, lo que lleva a un menor riesgo de presentar episoios 
diarreicos.  
Limitación en 
desempeño de 
tecnologías alternativas 
para la enfermedad o 
condición 
Limitación de desempeño de tecnologías comparativas en su 
capacidad de prevenir, curar o mejorar la condición de interés; 
también incluye limitaciones de desempeño en materia de 
seguridad, desenlaces reportados por los pacientes y la 
conveniencia. 
 En este caso la alternativa es no realizar la suplementación con zinc. 
Equidad en grupos 
vulnerables
Grado en que la tecnología evaluada suple necesidades 
prioritarias de grupos específicos de poblaciónque están 
definidos por la sociedad como vulnerables. 
Los niños menores de cinco años son los más predispuestos a desarrollar enfermedad diarreica aguda y a presentar complicaciones como sepsis, 
deshidratación y muerte. En Colombia el 43,3% de los niños menores de 5 años tienen deficiencia de zinc, comprometiendo en mayor proporción a la 
población indígena y afrodescendiente: 56,3% y 45,6%, respectivamente (3,5).
Costo-efectividad de la 
intervención
Razón incremental de costo comparada con el beneficio 
incremental de la tecnología comparada con alternativas 
existentes. El beneficio puede expresarse como número de 
eventos evitados, años de vida ganados, QALYs/AVACs ganados, 
días adicionales libres de dolor, etc. 
El estudio de costo-efectividad realizado por el grupo desarrollador de la GPC para la prevención, diagnóstico y tratamiento de la enfermedad diarreica 
aguda en niños menores de 5 años, muestra como resultados, que el uso de zinc para prevención, genera unos elevados costos por episodio de diarrea 
evitado: $2.022.322 por caso evitado de diarrea aguda y $3.634.523 por caso evitado de diarrea persistente. El estudio concluye que la suplementación 
con zinc para niños menores de 5 años con deficiencias de zinc y alto riesgo de presentar un episodio de EDA puede ser una estrategia costo efectiva 
para el país, pero no para toda la población menor de 5 años (5).  
Completitud y calidad del 
reporte 
Grado en que la notificación de datos sobre la intervención 
propuesta está completa (ej: cumple con estándares científicos 
de notificación) y es consistente con las fuente bibliográficas 
citadas. 
El Instituto Nacional de Salud mediante el Sistema de vigilancia y control en salud pública (SIVIGILA) (8), realiza el seguimiento continuo y sistemático 
de las muertes por enfermedad diarreica aguda (EDA) en menores de 5 años, así como la consolidación de casos de EDA ( reporte colectivo) de 
periodicidad semanal, de acuerdo con procesos establecidos para su notificación, recolección y análisis de los datos. 
Relevancia y validez de la 
evidencia
Grado en que la evidencia sobre la intervención propuesta es 
relevante para la toma de decisiones (en términos de población, 
estadio de la enfermedad, descripción de comparadores, 
desenlaces, etc) y válida respecto a los estándares científicos (ej. 
diseño del estudio). Esto incluye consideraciones respecto a la 
incertidumbre (ej. resultados contradictorios entre varios 
estudios, limitado número de estudios y/o participantes).  
Existe evidencia relacionada con la suplementación de zinc tanto observacional como experimental, así como revisiones sistemáticas y meta-análisis de 
ensayos clínicos, que evalúan la efectividad y seguridad del zinc para la prevención de enfermedad diarreica. Debido a que la evidencia presenta un alto 
componente de heterogeneidad tanto en las edades estudiadas, como en las estrategias de administración de la intervención (tiempo, periodicidad y 
presentación de la tecnología) la evidencia se califica según SIGN como de calidad moderada (5).
Necesidad diferencial en 
salud (cronicidad, 
paleación)
Grado en que la tecnología evaluada suple necesidades en salud 
de grupos específicos de población que sin necesariamente ser 
catalogados como vulnerables requieren servicios diferenciales 
de salud (ej. cronicidad, paloación, manejo del dolor, etc). 
La enfermedad diarréica aguda es una entidad de inicio agudo y resolución que no debe superar los 14 días.
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TECNOLOGÍA: ticagrelor más ASA, en pacientes con SCA sin ST de riesgo intermedio o alto independiente de la estrategia de tratamiento inicial , incluyendo 
aquellos que recibieron previamente clopidogrel, el cual debe suspenderse una vez se inicie ticagrelor.
Gravedad de la 
enfermedad o 
condición de salud
Severidad de la condición de salud de los pacientes tratados con la 
intervención propuesta (o la gravedad de la condición de salud 
que se ha de prevenir ) respecto a la mortalidad, discapacidad, 
impacto en la calidad de vida, curso clínico (es decir agudeza, 
etapas clínicas). 
La enfermedad cardiovascular es la principal causa de muerte en Latinoamérica. Datos de la Organización Mundial de la Salud indican que la región cursa con 
una epidemia de enfermedad cardiovascular de grandes proporciones, lo que se puede atribuir a cambios demográficos y de hábitos de vida inherentes a la 
transición epidemiológica.  La enfermedad coronaria (EC) es la principal causa de muerte en el mundo occidental, y fue la responsable de 1 de cada 5 muertes 
en Estados Unidos en el 2004 (1). Según el NHLBI (Instituto Nacional de Sangre, Corazón y Pulmón) y el NCHS (Centro Nacional de Estadísticas en Salud), en el 
2004 la tasa global de muertes por EC fue de 150.5 por 100.000 habitantes (2). De acuerdo con las estadísticas publicadas por el Ministerio de la Protección 
Social en el informe sobre la Situación de salud en Colombia -Indicadores de salud 2007-, la enfermedad isquémica del corazón es la principal causa de 
muerte, tanto en hombres como en
mujeres mayores de 45 años. La tasa de mortalidad atribuible a esta enfermedad fue de 107,3 por 100.000 habitantes en personas de 45 a 64 años, y de 867,1 
por 100.000 habitantes para
personas de 65 años o más. (3) Según el registro de estadísticas vitales del Departamento Administrativo Nacional de Estadística (DANE), de la mortalidad por 
enfermedades del sistema circulatorio, la enfermedad isquémica del corazón fue la causa del 49,5% del total de muertes, siendo la principal etiología en 
personas mayores de 55 años, por encima del cáncer y la agresión (4). 
Número de personas 
afectadas por la 
población objeto de la 
intervención 
(prevalencia/incidenci
a)
Número de personas afectadas por la enfermedad (tratada o 
prevenida con la intervención propuesta) en una población 
específica y en un momento determinado; puede expresarse 
como en número anual de nuevos casos (incidencia anual) y /o la 
proporción de la población afectada en un momento dado en el 
tiempo (prevalencia).
En Estados Unidos, según el registro GRACE (Global Registry of Acute Coronary Events) (5) se reportan 9,000,000 de consultas al año por dolor torácico, de las 
cuales el 13% (1,072,000) corresponden a sindromes coronarios agudos; 731,000 corresponden a IAM (68%);  aproximadamente 38% se clasifican como 
Síndrome Coronario Agudo con elevación del ST (SCACEST), y 30% a Síndrome Coronario Agudo sin elevación del ST (SCASEST) (6). Según un estudio para la 
estimación de costos del SCA en Colombia (7), tomando la referencia del Instituto Nacional de Sangre, Corazón y Pulmón de los Estados Unidos (NHLBI), que 
reporta la incidencia anual de IAM de 565.000 nuevos eventos y 300.000 ataques recurrentes cada año, y aplicando esta misma proyección de incidencia con 
base en la población proyectada por el DANE (8) para Bogotá y Colombia se esperarían al año 82.293 casos para el país y 13.462 para Bogotá al año. 
Mejora en 
eficacia/efectividad
Capacidad de la intervención prouesta para producir un efecto 
deseado (beneficioso) cambio en los signos, los síntomas y el 
curso de la afección específica por encima y más allá de los 
cambios beneficiosos producidos por las intervenciones 
alternativas . Incluye datos sobre la eficacia y la efectividad.
La activación plaquetaria y su posterior agregación desempeñan un papel predominante en la formación de trombos (coágulos), y por lo tanto, son objetivos 
terapéuticos críticos en el manejo del Sindrome Coronario Agudo. El tratamiento antiplaquetario debe instaurarse lo más rápidamente posible después del 
diagnóstico de Síndrome Coronario Agudo sin elevación del ST (SCASEST), con el objetivo de reducir el riesgo de complicaciones isquémicas agudas y la 
recurrencia de episodios trombóticos (9). El ticagrelor es un medicamento antiplaquetario el cual ha demostrado ejercer un mayor y más rápido efecto en 
comparación con la alternativa más comunmente utilizada, el clopidogrel. Según los datos del estudio PLATO (Study of Platelet Inhibition and Patient 
Outcomes), El Ticagrelor redujo las muertes por causa cardiovascular (4.0% vs. 5.1% en el grupo de ticagrelor, p = 0.001), así como el Infarto Agudo de 
Miocardio (5.8% en el grupo de ticagrelor vs. 6.9% en el grupo de clopidogrel, p = 0.005) (10). 
Guías de práctica 
clínica basadas en 
evidencia, válidas en 
Colombia
Concurrencia de la intervención propuesta (o alternativas 
similares) con el consenso actualizado de expertos sobre lo que 
constituye el estado del arte, las prácticas y manejo de las 
condición de interés; estas recomnendaciones suelen ser 
desarrolladas a través de un proceso explícito y tienen por objeto 
mejorar la clínica práctica. 
Dentro del marco de la Convocatoria 500 de Colciencias para la elaboración de guías basadas en evidencia científica, se desarrolló la Guía de Práctica Clínica 
para pacientes con diagnóstico de Síndrome Coronario Agudo,  las cuales han sido lanzadas recientemente en el país. 
Tipo de beneficio 
clínico
Naturaleza del beneficio clínico proporcionado por la intervención 
propuesta a nivel del paciente (por ejemplo alivio de síntomas, 
prolongación de la vida, curación). 
En pacientes con Síndrome Coronario Agudo sin elevación del ST, el Ticagrelor ha demostrado reducir las tasas de muerte por causa cardiovascular, así como 
las tasas de Infarto Agudo de Miocardio. De acuerdo con los datos del estudio PLATO (Study of Platelet Inhibition and Patient Outcomes), el riesgo de muerte 
por causas vasculares se redujo en un 21% en comparación con clopidogrel (HR = 0,79; IC95%, 0,69-0,91; p = 0,001) y el riesgo de presentar IAM en un 16% (HR = 
0,84; IC95%, 0,75-0,95; p = 0,005) (9,10,11).
Impacto en el 
presupuesto en el 
plan de salud
Impacto económico neto de la cobertura de la intervención sobre 
el presupuesto del plan de salud (excluyendo otros gastos). Esto 
representa la diferencia entre los gastos previstos para la 
intervención propuesta y los posibles ahorros de costos que 
pueden derivarse de la sustitución de la intervención de otro (s) 
actualmente cubierto por el plan de salud. Limitada al costo de la 
intervención (por ejemplo costo de adquisición implementación y 
mantenimiento).  
El costo base del ticagrelor en tabletas de 90mg, es de aproximadamente $86.062 para la presentación de 30 tabletas. Para la dosis recomendada de 90mg 
c/12horas, se estima un costo anual de tratamiento de $2.065.488.  Fuente: SISMED 2012. Listado de Precios Promedio y Unidades en la cadena de 
comercializacion de Medicamentos. Enero a Septiembre de 2012 (12). 
Mejora de seguridad y 
tolerancia 
Reducción en efectos sobre la salud relacionados con la 
intervención que son dañinos o no deseados, en comparación con 
intervenciones alternativas. 
La evidencia muestra que no existen diferencias significativas en las tasas de sangrado mayor, o sangrado que amenaza la vida, cuando se compara el 
ticagrelor con el clopidogrel (10,11) . 
Interés en salud 
pública
Reducción de riegos producto de la intervención a nivel de la 
población general (ej: prevención, reducción de transmisión de la 
enfermedad, reducción de la prevalencia de factores de riesgo).  
En el Plan decenal de Salud Pública 2012-2021, la enfermedad isquémica del corazón hace parte de las patologías a intervenir dentro del grupo de 
enfermedades crónicas no transmisibles (13). En el Plan Nacional de Salud Pública, la enfermedad aterosclerótica cardiaca y los SCA, como principal 
manifestación, fue considerada dentro del grupo de enfermedades catastróficas, crónicas no transmisibles. 
Mejora resultados en 
salud reportados por 
paciente
Capacidad de la intervención propuesta de producir cambios 
benéficos en desenlaces reportados por pacientes (DRP) (por 
ejemplo calidad de vida) por encima y más allá de los cambios 
benéficos producidos por las intervenciones alternativas; también 
incluye mejoras en conveniencia para los pacientes. 
Un estudio que evalúa la calidad de vida relacionada con la salud en pacientes con SCA mediante el cuestionario EQ-5D no muestra diferencias significactivas 
en percepción de calidad de vida relacionada con el tratamiento con clopidogrel o ticagrelor durante un año (14). Sin embargo, estudios recientes reportan 
que basados en evidencia clínica y de economía de la salud, el tratamiento con ticagrelor durante 12 meses se encuentra asociado con un costo por QUALY 
(años de vida ajustados por calidad) por debajo de los umbrales aceptados como costo-efectivos (15).  
Limitación en 
desempeño de 
tecnologías 
alternativas para la 
enfermedad o 
condición 
Limitación de desempeño de tecnologías comparativas en su 
capacidad de prevenir, curar o mejorar la condición de interés; 
también incluye limitaciones de desempeño en materia de 
seguridad, desenlaces reportados por los pacientes y la 
conveniencia. 
El uso de clopidogrel, considerado como el agente más comunmente usado dentro del tratamiento antiplaquetario en pacientes con SCA sin elevación del ST, 
muestra una menor efectividad en términos de disminución del riesgo de muerte por causa cardiovascular, así como disminución del riesgo de Infarto Agudo 
de Miocardio. No se reportan diferencias significativas en eventos adversos cuando se compara con el ticagrelor. 
Equidad en grupos 
vulnerables
Grado en que la tecnología evaluada suple necesidades 
prioritarias de grupos específicos de poblaciónque están definidos 
por la sociedad como vulnerables. 
La enfermedad coronaria afecta principalmente a los mayores de 45 años. Es la primera causa de muerte en adultos mayores (mayores de 65 años) (9). 
Costo-efectividad de 
la intervención
Razón incremental de costo comparada con el beneficio 
incremental de la tecnología comparada con alternativas 
existentes. El beneficio puede expresarse como número de 
eventos evitados, años de vida ganados, QALYs/AVACs ganados, 
días adicionales libres de dolor, etc. 
El análisis de costo-utilidad realizado dentro del marco del desarrollo de la Guía de Práctica Clínica del Síndrome Coronario Agudo en Colombia, concluye que 
el uso de ticagrelor para el tratamiento de pacientes con SCA es una estrategia costo-efectiva para el SGSSS. En el caso base, el costo por año de vida ajustado 
por calidad (AVAC) ganado con ticagrelor es de $28.411.503. Para un umbral de disposición a pagar equivalente a 3 veces el PIB per cápita en Colombia, la 
probabilidad de que el ticagrelor sea una estrategia costo-efectiva es cercana al 75% (9).
Completitud y calidad 
del reporte 
Grado en que la notificación de datos sobre la intervención 
propuesta está completa (ej: cumple con estándares científicos de 
notificación) y es consistente con las fuente bibliográficas citadas. 
Los datos reportados  hacen parte de proyectos internacionales tales como el GRACE (Global Registry of Acute Coronary Events) que reune datos de 10.693 
pacientes con SCA entre 1999 y 2001 en Europa, América, Australia y Nueva Zelanda, o la Encuesta del corazón Minnesota (tendencias de la enfermedad 
coronaria aguda mortalidad, morbilidad y cuidado médico de 1985 - 1997). A nivel nacional no existen protocolos de vigilacia para la notificación o registro de 
eventos coronarios agudos. 
Relevancia y validez 
de la evidencia
Grado en que la evidencia sobre la intervención propuesta es 
relevante para la toma de decisiones (en términos de población, 
estadio de la enfermedad, descripción de comparadores, 
desenlaces, etc) y válida respecto a los estándares científicos (ej. 
diseño del estudio). Esto incluye consideraciones respecto a la 
incertidumbre (ej. resultados contradictorios entre varios 
estudios, limitado número de estudios y/o participantes).  
La evidencia científica relacionada con el tratamiento con ticagrelor como antiplaquetario en pacientes con SCA sin elevación del ST , se califica como de 
moderada calidad, con disponibilidad de ensayos clínicos multicéntricos, aleatorizados. En su mayoría, los datos reportados en la literatura, y en los cuales se 
basan las recomendaciones actuales de la Guía de Práctica Clínica para pacientes con diagnóstico de Síndrome Coronario Agudo , se basan en estudios de 
buena calidad metodológica (9).
Necesidad diferencial 
en salud (cronicidad, 
paliación)
Grado en que la tecnología evaluada suple necesidades en salud 
de grupos específicos de población que sin necesariamente ser 
catalogados como vulnerables requieren servicios diferenciales 
de salud (ej. cronicidad, paliación, manejo del dolor, etc). 
El Ticagrelor hace parte de la estrategia terapéutica antiplaquetaria indicada posterior a un evento coronario agudo; a pesar de no ser un tratamiento crónico, 
previene las complicaciones derivadas de la enfermdad coronaria y el sindrome coronario agudo. 
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TECNOLOGÍA: Inhibidores de aromatasa  (Anastrozol ) como tratamiento de pirmera línea en pacientes posmenopáusicas con cáncer de mama metastásico 
receptor hormonal positivo.
Gravedad de la 
enfermedad o 
condición de salud
Severidad de la condición de salud de los pacientes tratados 
con la intervención propuesta (o la gravedad de la condición 
de salud que se ha de prevenir ) respecto a la mortalidad, 
discapacidad, impacto en la calidad de vida, curso clínico (es 
decir agudeza, etapas clínicas). 
El cáncer de mama es el cáncer más frecuente en mujeres, con un estimado de 1.38 millones de nuevos casos diagnosticados en el 2008 (23% de todos los 
cánceres). Actualmente, es el cáncer de mayor incidencia del sexo femenino, con una mortalidad similar a la del cáncer de cérvix. Aunque las tasas globales 
de mortalidad son menores, debido a la mayor sobrevida en regiones desarrolladas, el cáncer de mama continúa siendo la causa más frecuente de muerte 
por cáncer en mujeres, tanto en los países desarrolados (189,000 muertes/año) como en los países en vías de desarrollo (269,000 muertes/año) (1).  El 
cáncer de mama es una enfermedad con una evolución natural compleja por lo que, a pesar de los avances de la oncología moderna, es la primera causa de 
muerte por neoplasia en la mujer a nivel mundial,  con más de un millón de casos nuevos cada año, de los cuales, aproximadamente la mitad ocurren en 
países desarrollados; sin embargo, es en los países en vías de desarrollo donde ocurren la mayoría de las muertes por esta causa (2).
Número de 
personas afectadas 
por la población 
objeto de la 
intervención 
(prevalencia/incide
ncia)
Número de personas afectadas por la enfermedad (tratada 
o prevenida con la intervención propuesta) en una 
población específica y en un momento determinado; puede 
expresarse como en número anual de nuevos casos 
(incidencia anual) y /o la proporción de la población 
afectada en un momento dado en el tiempo (prevalencia).
Las tasas de incidencia a nivel mundial varían entre regiones, siendo mayores en los países desarrollados (mayor a 80 por 100,000 mujeres), y más bajas en 
la mayoría de países en vías de desarrollo (menor a 40 por 100,000 mujeres). Para el caso de Colombia, durante el periodo de 2002-2006, estudios locales 
reportan una tasa cruda de incidencia anual de 32.6 por 100.000 mujeres y una tasa cruda corregida de mortalidad anual de 9.5 por 100.000 muertes en 
mujeres (3). Según datos reportados por la Agencia Internacional para la Investigación en Cáncer (IARC), la incidencia anual estandarizada por edad para 
Colombia es de 31.2 por cada 100.000 mujeres, y la mortalidad de 10 por cada 100.000 muertes de mujeres (4). Para el caso de cáncer metastásico, datos 
colombianos reportan que los estadíos avanzados corresponden al 8.1% del total de casos en el año 2005 , y al 8.6% en el año 2008 (5). 
Mejora en 
eficacia/efectivida
d
Capacidad de la intervención prouesta para producir un 
efecto deseado (beneficioso) cambio en los signos, los 
síntomas y el curso de la afección específica por encima y 
más allá de los cambios beneficiosos producidos por las 
intervenciones alternativas . Incluye datos sobre la eficacia 
y la efectividad.
La mayoría de los casos de cáncer de mama metastásico son sensibles a las hormonas estrogénicas femeninas; estas células malignas sensibles, necesitan 
de los estrógenos para mantenerse vivas; por lo tanto, la eliminación de cualquier estrógeno circulante constituye una terapia muy efectiva en el 
tratamiento de este tipo de neoplasias sensibles a hormonas. La terapia hormonal elimina la influencia del estrógeno en las células malignas del seno. 
Dentro de las alternativas terapéuticas para el cáncer de seno avanzado se encuentran el tamoxifeno y los inhibidores de aromatasa (6). 
El anastrozol es un inhibidor competitivo de la aromatasa, que ha demostrado reducir la concentración plasmática de estradiol en más del 80%, sin 
modificar la producción de otras hormonas. El anastrozol ha demostrado eficacia superior al tamoxifeno con efectos positivos estadísticamente 
significativos en la respuesta tumoral, principalmente en términos de progresión libre de enfermedad; una revisión sistemática publicada en el año 2009, 
reporta un HR 0.78 (IC 95% 0.71 - 0.86); es decir, que el riesgo relativo de progresión de la enfermedad disminuye en un 22% con el anastrazol, comparado 
con el tamoxifeno (7). 
Guías de práctica 
clínica basadas en 
evidencia, válidas 
en Colombia
Concurrencia de la intervención propuesta (o alternativas 
similares) con el consenso actualizado de expertos sobre lo 
que constituye el estado del arte, las prácticas y manejo de 
las condición de interés; estas recomnendaciones suelen 
ser desarrolladas a través de un proceso explícito y tienen 
por objeto mejorar la clínica práctica. 
Dentro del marco de la Convocatoria 500 de Colciencias para la elaboración de guías basadas en evidencia científica, se desarrolló la Guía de Práctica Clínica 
para la detección temprana, tratamiento integral, segumiento y rehabilitación del Cáncer de Mama,  las cuales han sido lanzadas recientemente en el país. 
Tipo de beneficio 
clínico
Naturaleza del beneficio clínico proporcionado por la 
intervención propuesta a nivel del paciente (por ejemplo 
alivio de síntomas, prolongación de la vida, curación). 
En pacientes posmenopáusicas con cáncer de mama metastásico, el anastrozol ha mostrado diferencias significativas en progresión libre de enfermedad, y 
respuesta clínica (disminución del tamaño del tumor parcial o total, y enfermedad estable por más de 24 semanas), (6,7). 
Impacto en el 
presupuesto en el 
plan de salud
Impacto económico neto de la cobertura de la intervención 
sobre el presupuesto del plan de salud (excluyendo otros 
gastos). Esto representa la diferencia entre los gastos 
previstos para la intervención propuesta y los posibles 
ahorros de costos que pueden derivarse de la sustitución de 
la intervención de otro (s) actualmente cubierto por el plan 
de salud. Limitada al costo de la intervención (por ejemplo 
costo de adquisición implementación y mantenimiento).  
El costo base para el inhibidor de aromatasa, Anastrazol (tab 1mg), es de aproximadamente  $513.056 para la presentación de 28 tabletas. Teniendo en 
cuenta que la dosis indicada es de 1mg/día, el costo del tratamiento anual será de aproximadamente  $6.596.434. Fuente: SISMED 2012. Listado de Precios 
Promedio y Unidades en la cadena de comercializacion de Medicamentos. Enero a Septiembre de 2012 (8). 
Mejora de 
seguridad y 
tolerancia 
Reducción en efectos sobre la salud relacionados con la 
intervención que son dañinos o no deseados, en 
comparación con intervenciones alternativas. 
El anastrozol provee un adecuado perfil de seguridad, y presenta de acuerdo con datos de un meta- análisis del 2011 (9), una disminución en la 
probabilidad de producir eventos tromboembólicos en un 53%, y de sangrado vaginal en un 70%, cuando son comparados con tamoxifeno. 
Interés en salud 
pública
Reducción de riegos producto de la intervención a nivel de 
la población general (ej: prevención, reducción de 
transmisión de la enfermedad, reducción de la prevalencia 
de factores de riesgo).  
Se encuentra dentro de las líneas estratégicas, tanto de detección temprana, como de atención, recuperación y superación de los daños causados por el 
cáncer dentro del Plan Decenal para el Control del Cáncer de Colombia 2012-2021, en donde una de las metas específicas incluye Implementar la Política 
Farmacéutica Nacional (Documento Conpes 155 de 2012), en relación con  la gestión y control de medicamentos oncológicos, cuyo objetivo es garantizar el 
acceso oportuno y de calidad al diagnóstico y tratamiento de cinco cánceres con mortalidad prematura evitable, en el 100% de los casos, dentro de los que 
se encuentra el cáncer de mama (10).  
Mejora resultados 
en salud 
reportados por 
paciente
Capacidad de la intervención propuesta de producir 
cambios benéficos en desenlaces reportados por pacientes 
(DRP) (por ejemplo calidad de vida) por encima y más allá 
de los cambios benéficos producidos por las intervenciones 
alternativas; también incluye mejoras en conveniencia para 
los pacientes. 
La evidencia disponible en relación con calidad de vida es limitada; sin embargo, se han encontrado algunas diferencias en algunas escalas de medición de 
este desenlace a favor de los inhibidores de aromatasa como el anastrozol. Adicionalmente, aunque la evidencia científica no demuestra diferencias 
significativas en relación con eventos adversos como náuseas, vómito, diarrea, ni dolor articular, si existe un menor riesgo de presentar eventos 
tromboembólicos y sangrado vaginal con el uso de anastrozol, en comparación con tamoxifeno (7). 
Limitación en 
desempeño de 
tecnologías 
alternativas para la 
enfermedad o 
condición 
Limitación de desempeño de tecnologías comparativas en 
su capacidad de prevenir, curar o mejorar la condición de 
interés; también incluye limitaciones de desempeño en 
materia de seguridad, desenlaces reportados por los 
pacientes y la conveniencia. 
El uso de tamoxifeno, considerado como el agente más comunmente usado dentro del tratamiento hormonal de primera línea en pacientes 
posmenopáusicas con cáncer de mama metastásico receptor hormonal positivo, muestra una menor efectividad en términos de supervivencia libre de 
progresión, y mayor probabilidad de producir eventos adversos, cuando se compara con anastrozol. Sin embargo, no se han demostrado diferencias entre 
estos dos medicamentos en la supervivencia global (7). 
Equidad en grupos 
vulnerables
Grado en que la tecnología evaluada suple necesidades 
prioritarias de grupos específicos de poblaciónque están 
definidos por la sociedad como vulnerables. 
El anastrozol se encuentra indicado en todas las pacientes posmenopáusicas con cáncer de mama metastásico receptor hormonal positivo. 
Costo-efectividad 
de la intervención
Razón incremental de costo comparada con el beneficio 
incremental de la tecnología comparada con alternativas 
existentes. El beneficio puede expresarse como número de 
eventos evitados, años de vida ganados, QALYs/AVACs 
ganados, días adicionales libres de dolor, etc. 
El estudio de Costo efectividad de inhibidores de aromatasa en cáncer de mama avanzado realizado en el marco de la Guía de Práctica Clínica de Cáncer de 
mama, concluye que  en mujeres con cáncer de mama avanzado receptor hormonal positivo, los inhibidores de la aromatasa
comparados con tamoxifeno en primera línea de tratamiento hormonal, serían costo-efectivos para Colombia. Los resultados muestran que en términos de 
supervivencia global no hay diferencia entre los tratamientos; sin embargo los hay para supervivencia libre de progresión y eventos adversos los cuales son 
sangrado vaginal y eventos tromboembólicos. Para esta evaluación las medidas de resultado en salud fueron los años de vida libres de enfermedad (AVLE) 
y los años de vida perdidos ajustados por discapacidad (AVAD o DALYs en inglés). Los inhibidores de aromatasa fueron más costosos y efectivos que el 
tamoxifeno, el costo por AVGLE fue de $2.812.147,08 con descuento y de $5.564.228,57 sin descuento. El costo por AVAD evitado fue $6.173.144,15 y de 
$3.170.898,35 sin y con descuento. De acuerdo al umbral de PIB, los inhibidores serían costo-efectivos para el país en esta indicación (11). 
Completitud y 
calidad del reporte 
Grado en que la notificación de datos sobre la intervención 
propuesta está completa (ej: cumple con estándares 
científicos de notificación) y es consistente con las fuente 
bibliográficas citadas. 
Existen a nivel nacional los servicios de vigilancia epidemiólogica de cáncer, distribuidos por ciudades (registro poblacional de cáncer),  y grupos de 
vigilancia epidemiologica del cáncer, como el del Instituto Nacional de Cancerología. A nivel mundial, el proyecto GLOBOCAN provee información acerca de 
incidencia, mortalidad, prevalencia y años de vida perdidos ajustados por discapacidad (AVAD o DALYs en inglés) de los tipos de cáncer más frecuentes en 
184 paises, dentro de los cuales se encuentra Colombia. 
Relevancia y 
validez de la 
evidencia
Grado en que la evidencia sobre la intervención propuesta 
es relevante para la toma de decisiones (en términos de 
población, estadio de la enfermedad, descripción de 
comparadores, desenlaces, etc) y válida respecto a los 
estándares científicos (ej. diseño del estudio). Esto incluye 
consideraciones respecto a la incertidumbre (ej. resultados 
contradictorios entre varios estudios, limitado número de 
estudios y/o participantes).  
La evidencia científica relacionada con el tratamiento hormonal con inhibidores de aromatasa en pacientes con cáncer de mama metastásico en este grupo 
de pacientes, y en particular del anastrozol, es de buena calidad, con disponibilidad de revisiones sistemáticas y meta-análisis de ensayos clínicos. En su 
mayoría, los datos reportados en la literatura, y en los cuales se basan las recomendaciones actuales de la Guía de Práctica Clínica para la detección 
temprana, tratamiento integral, segumiento y rehabilitación del Cáncer de Mama, se basan en estudios de buena calidad metodológica. 
Necesidad 
diferencial en 
salud (cronicidad, 
paliación)
Grado en que la tecnología evaluada suple necesidades en 
salud de grupos específicos de población que sin 
necesariamente ser catalogados como vulnerables 
requieren servicios diferenciales de salud (ej. cronicidad, 
paliación, manejo del dolor, etc). 
El cáncer de mama metastásico en mujeres posmenopáusicas, confiere un estadío tratable, pero no curable de la enfermedad; las intervenciones en estas 
pacientes se dirigen a estrategias paliativas, inhibición de progresión de la enfermedad, mayor tiempo de sobrevida, y a una mejor calidad de vida (9).  
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CRITERIO DEFINICIÓN Profilaxis con Factor VIII en pacientes con Hemofilia A severa 
Gravedad de la enfermedad o 
condición de salud
Severidad de la condición de salud de los 
pacientes tratados con la intervención 
propuesta (o la gravedad de la condición de 
salud que se ha de prevenir ) respecto a la 
mortalidad, discapacidad, impacto en la calidad 
de vida, curso clínico (es decir agudeza, etapas 
clínicas). 
La hemofilia A es una enfermedad genética ligada al cromosoma X, que se expresa por una disminución del Factor VIII de la coagulación, 
produciendo una  tendencia permanente al sangrado (1). La edad de presentación, la localización y la severidad del sangrado dependen del grado 
de severidad de la enfermedad, la cual se determina por el nivel de actividad del factor VIII; los pacientes con hemofilia A severa presentan 
menos del 1% de actividad del factor, presentando una tendencia a desarrollar sangrados espontáneos, principlamente del tipo hemartrosis o 
hemorragias intra-articulares que constituyen entre el 70-80% de todas las hemorragias en hemofílicos (2). Esto origina una patología característica 
denominada artropatía
hemofílica, que desarrolla lesiones articulares progresivas, las cuales conducen a una severa limitación de la función articular, dolor y serias 
secuelas invalidantes. Por su frecuencia y evolución crónica, la artropatía hemofílica es la complicación de la enfermedad con mayor morbilidad, 
siendo como objetivo primario del tratamiento, la prevención de su desarrollo (3, 4)
Número de personas afectadas 
por la población objeto de la 
intervención 
(prevalencia/incidencia)
Número de personas afectadas por la 
enfermedad (tratada o prevenida con la 
intervención propuesta) en una población 
específica y en un momento determinado; 
puede expresarse como en número anual de 
nuevos casos (incidencia anual) y /o la 
proporción de la población afectada en un 
momento dado en el tiempo (prevalencia).
La hemofilia A afecta a uno de cada 5.000-10.000 varones, y representa aproximadamente un 85% de los casos de hemofilia. (2). Según datos de la 
Federación Mundial de Hemofilia, Encuesta Global de 2010 (WFH Global Survey 2010), 162.781 personas viven con hemofilia en el mundo, de las 
cuales 125.049 son pacientes  con hemofilia tipo A. Para Colombia se reportan 1,915 pacientes con hemofilia, con 1,446 correspondientes a 
Hemofilia A (5), de los cuales se estiman aproximadamente 800- 1040 casos clasificados como severos, correspondientes al 55% del total de 
pacientes con Hemofilia A. (2) . 
Mejora en eficacia/efectividad
Capacidad de la intervención prouesta para 
producir un efecto deseado (beneficioso) 
cambio en los signos, los síntomas y el curso de 
la afección específica por encima y más allá de 
los cambios beneficiosos producidos por las 
intervenciones alternativas . Incluye datos sobre 
la eficacia y la efectividad.
Los concentrados del Factor VIII derivados del plasma humano, tienen una alta seguridad y similar eficacia que los concentrados recombinantes 
(1). Una revisión sistemática de 6 ensayos clínicos randomizados, con 142 participantes en total, que comparan el tratamiento profiláctico vs el 
tratamiento según demanda (factor VIII), demuestra una disminución del riesgo de presentar cualquier tipo de sangrado del 70% (RR de 0.3; 95% 
IC; 0.12 a 0.76), y del 78%  (RR 0.22; 95% IC; 0.08 a 0.63)  para sangrado de articulaciones a favor del tratamiento profiláctico, aportando que además 
una profilaxis iniciada tempranamente previene el desarrollo de inhibidores y ayuda a prevenir las hemorragias con riesgo vital (6).  
Guías de práctica clínica 
basadas en evidencia, válidas 
en Colombia
Concurrencia de la intervención propuesta (o 
alternativas similares) con el consenso 
actualizado de expertos sobre lo que constituye 
el estado del arte, las prácticas y manejo de las 
condición de interés; estas recomnendaciones 
suelen ser desarrolladas a través de un proceso 
explícito y tienen por objeto mejorar la clínica 
práctica. 
No se han desarrollados Guías de práctica clinica basadas en evidencia en Colombia; sin embargo, existen la Guía Clínica de Hemofilia, 
desarrollada en Chile, por el Ministerio de Salud en el año 2013, así como Guía de tratamiento de la hemofilia - Consenso de Médicos especialistas 
en Hemofilia de la República Argentina , 2011. 
Tipo de beneficio clínico
Naturaleza del beneficio clínico proporcionado 
por la intervención propuesta a nivel del 
paciente (por ejemplo alivio de síntomas, 
prolongación de la vida, curación). 
Los pacientes hemofílicos con niveles de Factor VIII por encima del 2% raramente presentan enfermedad articular grave. A partir de esta 
observación se instaura la terapia profiláctica, la cual previene los episodios de sangrado, y busca mantener niveles de Factor VIII > 1% con una 
administración intermitente del Factor deficitario (1). Este tipo de tratamiento, considerado como el de elección en los pacientes con hemofilia 
severa, ha demostrado ser más efectivo en reducir las secuelas articulares y la invalidez secundaria en los pacientes hemofílicos severos, 
traduciéndose en una mejoría de la calidad de vida (2). 
Impacto en el presupuesto en 
el plan de salud
Impacto económico neto de la cobertura de la 
intervención sobre el presupuesto del plan de 
salud (excluyendo otros gastos). Esto representa 
la diferencia entre los gastos previstos para la 
intervención propuesta y los posibles ahorros 
de costos que pueden derivarse de la 
sustitución de la intervención de otro (s) 
actualmente cubierto por el plan de salud. 
Limitada al costo de la intervención (por 
ejemplo costo de adquisición implementación y 
mantenimiento).  
El costo base para el Factor humano anihemofílico (derivado del plasma) es de aproximadamente  $ 265.853 para el frasco por 220UI, de $431.727 
para el de 500UI, y de $956,433, para la presentación por 1000UI. Se establece un costo promedio por UI de $900. Para la estrategia profiláctica se 
estima un requerimiento de 25UI/kg 3 veces a la semana por 46 semanas al año, para un costo promedio anual de tratamiento de $108.675.000 (7) 
Fuente: SISMED 2012. Listado de Precios Promedio y Unidades en la cadena de comercializacion de Medicamentos. Enero a Septiembre de 2012
Mejora de seguridad y 
tolerancia 
Reducción en efectos sobre la salud 
relacionados con la intervención que son 
dañinos o no deseados, en comparación con 
intervenciones alternativas. 
La estrategia profiláctica, considerada como la de elección en los pacientes con hemofilia severa, ha demostrado ser más efectiva en reducir las 
secuelas articulares y la invalidez secundaria en los pacientes hemofílicos severos, traduciéndose en una mejoría de la calidad de vida en 
comparación con la estrategia a demanda (2). 
Interés en salud pública
Reducción de riegos producto de la intervención 
a nivel de la población general (ej: prevención, 
reducción de transmisión de la enfermedad, 
reducción de la prevalencia de factores de 
riesgo).  
La hemofilia se considera una enfermedad huérfana. Su prevalencia es de menos de 1 por cada 5000 habitantes y, por consiguiente, está 
reconocida en la Ley 1392 de 2010 y la Ley 1438 de 2011 (8).
Mejora resultados en salud 
reportados por paciente
Capacidad de la intervención propuesta de 
producir cambios benéficos en desenlaces 
reportados por pacientes (DRP) (por ejemplo 
calidad de vida) por encima y más allá de los 
cambios benéficos producidos por las 
intervenciones alternativas; también incluye 
mejoras en conveniencia para laos pacientes. 
Se define como profilaxis, al tratamiento inyectable endovenoso de concentrado de factor VIII en forma regular y con anticipación, con el fin de 
prevenir las hemorragias. El fundamento de la profilaxis primaria es impedir el daño articular y de la prevención secundaria, detener o minimizar 
este daño (1).
Limitación en desempeño de 
tecnologías alternativas para la 
enfermedad o condición 
Limitación de desempeño de tecnologías 
comparativas en su capacidad de prevenir, curar 
o mejorar la condición de interés; también 
incluye limitaciones de desempeño en materia 
de seguridad, desenlaces reportados por los 
pacientes y la conveniencia. 
La alternativa y abordaje clásico en el tratamieto de la Hemofilia A consiste en la administración a demanda del factor VIII exógeno; es decir, 
solamente en los casos en que se presente un episodio de sangrado articular o extra-articular. Este tipo de abordaje, aunque sigue siendo el más 
prevalente, a demostrado ofrecer resultados clínicos sub-óptimos, ya que el sangrado sigue ocurriendo, asi como el daño articular, traduciéndose 
en una pero calidad de vida relacionada con la salud. (HR-Qol) (2). 
Equidad en grupos vulnerables
Grado en que la tecnología evaluada suple 
necesidades prioritarias de grupos específicos 
de poblaciónque están definidos por la sociedad 
como vulnerables. 
El Ministerio de Salud y Protección Social, mediante la Resolución 430 de 2013, define al déficit congénito del Factor VIII (Hemofilia A) en el 
listado de enfermedades huérfanas; lo anterior en cumplimiento de la Ley 1392 de 2010, por la cual se reconocen las enfermedades huérfanas 
como de especial interés, para las que se adoptan normas tendientes a garantizar la protección social por parte del Estado colombiano a la 
población que padece de enfermedades huérfanas y sus cuidadores (8). 
Costo-efectividad de la 
intervención
Razón incremental de costo comparada con el 
beneficio incremental de la tecnología 
comparada con alternativas existentes. El 
beneficio puede expresarse como número de 
eventos evitados, años de vida ganados, 
QALYs/AVACs ganados, días adicionales libres 
de dolor, etc. 
Análisis de costo-utilidad que compara la profilaxis primaria con factor VIII de por vida, con el tratamiento a demanda en hemofilia A severa en 
Colombia,  muestra una razón incremental de costo efectividad de COL$110,947,357.8 (USD$ 58,224.8)por QALY ganado, considerándose una 
estrategia no costo-efectiva, de acuerdo con el umbral teórico de 3 veces el PIB per capita, establecida como la regla de disposición a pagar de 
$48.458.861 (2). 
Completitud y calidad del 
reporte 
Grado en que la notificación de datos sobre la 
intervención propuesta está completa (ej: 
cumple con estándares científicos de 
notificación) y es consistente con las fuente 
bibliográficas citadas. 
En 1998, se inicia la recolección de información acerca de hemofilia por parte de la Federación Mundial de Hemofilia al rededor del mundo. La 
encuesta mundial recolecta información demográfica básica, datos relacionados con recursos en el cuidado de pacientes, e información de 
prevalencia de complicaciones infecciosas tales como VIH y Hepatitis C. El documento más reciente es publicado en el año 2010 (5). 
Relevancia y validez de la 
evidencia
Grado en que la evidencia sobre la intervención 
propuesta es relevante para la toma de 
decisiones (en términos de población, estadio 
de la enfermedad, descripción de 
comparadores, desenlaces, etc) y válida 
respecto a los estándares científicos (ej. diseño 
del estudio). Esto incluye consideraciones 
respecto a la incertidumbre (ej. resultados 
contradictorios entre varios estudios, limitado 
número de estudios y/o participantes).  
Existe en la literatura mundial evidencia de buena calidad; se encuentran publicadas revisiones sitemáticas que comparan la estrategia 
profiláctica versus la terapia a demanda, que demuestran que la estrategia profiláctica proporciona un efecto protector en el desarrollo, tanto de 
sangrados de cualquier tipo,  como de sangrado articular. Múltiples estudios de cohorte son consistentes con estos hallazgos, y respaldan la 
efectividad de la profilaxis primaria para disminuir la incidencia de eventos hemorrágicos y pronóstico de la artropatía (1).
Necesidad diferencial en salud 
(cronicidad, paleación)
Grado en que la tecnología evaluada suple 
necesidades en salud de grupos específicos de 
población que sin necesariamente ser 
catalogados como vulnerables requieren 
servicios diferenciales de salud (ej. cronicidad, 
palición, manejo del dolor, etc). 
Tras la adopción de nuevas tecnologías en salud, la Hemofilia A se a convertido en una condición crónica manejable en los últimos años. 
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APPENDIX 9. INFORMATION SHEET AND CONSENT FORM (SPANISH VERSION) 
HOJA DE INFORMACIÓN  
Título del proyecto: “EVALUANDO LA FACTIBILIDAD DE CONDUCIR Y USAR LA EVALUACIÓN DE TECNOLOGÍAS 
SANITARIAS EN COLOMBIA- El caso de la hemofilia severa tipo A” 
Buen día, 
Mi nombre es Héctor Eduardo Castro Jaramillo, soy un médico Colombiano con formación en economía de salud, 
salud pública y políticas de salud, actualmente estoy finalizando un Doctorado en salud pública y economía de 
salud con la Universidad de Londres (London School of Hygiene & Tropical Medicine) y para poder graduarme y 
obtener el título correspondiente debo presentar un trabajo original de investigación. 
La Evaluación de Tecnologías Sanitarias, es una técnica que tomado fuerza desde finales de los años 70s y que 
compara los beneficios y costos de diferentes tecnologías en salud. La Evaluación de Tecnologías Sanitarias es 
utilizada en la actualidad para informar la toma de decisiones en salud en diferentes contextos.   
La hemofilia A por su lado, es una enfermedad que afecta a 1 de cada 5.000 a 10.000 hombres en el mundo y en 
nuestro país se estima que cerca de 2500 personas viven con esta patología (aproximadamente 800 de ellas 
presentan casos severos de la enfermedad). El tratamiento consiste en reponer el factor de coagulación (FVII) 
faltante de manera congénita, reestablecer los mecanismos naturales de coagulación y reducir el riesgo de 
hemorragias que presentan dichos pacientes.  
En Colombia el acceso a tratamiento con factores de coagulación ha mejorado en años recientes, no obstante 
persisten diferencias de acceso entre zonas rurales y urbanas, entre aquellos que tienen EPS y los que no; así 
mismo la  calidad de tratamiento varia de un lugar a otro y hay diferentes formas de tratar la enfermedad que 
no han sido comparadas plenamente en nuestro medio. Gran parte de la información relacionada con el impacto 
que tiene el tratamiento en la calidad de vida de los pacientes con Hemofilia proviene de otros países, muchos 
de ellos con más recursos que el nuestro. 
El objetivo del presente estudio es analizar mediante el caso de la Hemofilia severa tipo A como la Evaluación 
de Tecnologías Sanitarias puede ser usada en nuestro contexto con el fin de identificar la mejor opción de 
tratamiento, de tal forma que más pacientes de esta y otras patologías puedan beneficiarse del mejor 
tratamiento disponible y de una manera sostenible. Este estudio requiere recolectar datos relacionados con 
experiencias y percepciones de aquellos involucrados en la conducción y uso de la Evaluación de Tecnologías 
Sanitarias en Colombia. Así mismo pudiera requerir información pasada o  futura relacionada con la historia 
clínica, el tipo de tratamiento recibido y la percepción general sobre el estado de salud de los participantes.  
En caso de estar interesado en participar lo invito a diligenciar el formato de consentimiento informado en señal 
de aprobación. Sí a lo largo del estudio tiene preguntas adicionales sobre el proyecto no dude en comunicarlas 
al investigador principal o a alguna de las personas involucradas, igualmente puede comunicarse al número 310- 
8226382. 
Muchas gracias por su tiempo y disposición al permitir que la investigación científica siga creciendo en nuestro 
país. 
 
 
HECTOR EDUARDO CASTRO JARAMILLO  MD, MSc, DrPH (cand)  
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LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE 
CONSENTIMIENTO INFORMADO  
 
Título del proyecto: “EVALUANDO LA FACTIBILIDAD DE CONDUCIR Y USAR LA EVALUACIÓN DE 
TECNOLOGÍAS SANITARIAS EN COLOMBIA- El caso de la Hemofilia severa tipo A” 
Nombre del investigador principal: Héctor Eduardo Castro Jaramillo 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
Nombre del participante   Firma     Fecha 
________________________  ____________________    ________________ 
Nombre de quien toma consentimiento             Firma      Fecha  
(Sí difiere de investigador) 
__________________________  ____________________    ________________ 
Investigador principal     Firma       Fecha 
__________________________  _____________________    ________________ 
 
 
 
1 copia para el participante; 1 copia para el investigador principal; 1 (original) copia para archivar en el centro de 
estudio 
 
Casilla para su inicial 
  
1. Confirmo que he leído y entendido la información de participante proporcionada en el la 
hoja de información en la fecha _______________________para el estudio anotado anteriormente. 
He tenido la oportunidad de considerar la información, hacer preguntas y estas me han sido 
contestadas completamente.  
 

2. Entiendo que mi participación es voluntaria y estoy en libertad de retirarme del estudio 
en cualquier momento, sin necesidad de dar explicaciones, sin que mis derechos legales o mí 
cuidado en salud (en caso de ser paciente) sean afectados.  
 
3. Así mismo autorizo al investigador principal a grabar, transcribir y analizar  las entrevistas 
a que hubiere lugar con fines puramente académicos. 
 
4. Estoy de acuerdo en hacer parte del estudio mencionado anteriormente 
 
Sí usted es un paciente en tratamiento para Hemofilia A, por favor diligencie la 
siguiente parte: 
 

5. Entiendo que la información proveniente de mi historia clínica o información recolectada 
durante el estudio será custodiada por individuos responsables de 
________________________________, por autoridades regulatorias o mi EPS, donde sea relevante mi 
participación en esta investigación. Autorizo a estos individuos a acceder a mi información. 
   

6. Estoy de acuerdo en que le informen a mi médico tratante de que participo en este estudio.  
 
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APENDDIX 10. ETHICAL CONSIDERATIONS  
All individuals received an information sheet and consent form in Spanish which explained the 
objectives of the study, and stressed that their participation was completely voluntary (Appendix 9). 
Participants were asked to consent to being audio-recorded during the interviews and focus group. 
When local sources of data were needed to estimate parameters to fill data gaps for insertion into the 
haemophilia model, participants received a different information sheet and consent form in Spanish, 
appropriate to their role played in this research.  
All forms complied with the London School of Hygiene and Tropical Medicine (LSHTM) ethics approval 
requirements for non-interventional studies. All documentary, transcript and observation data was 
anonymised. Interviews and focus group took place in a suitable location for the purpose of this study. 
Each participant was given a contact number they could call to ask questions about the study after the 
interviews or focus group were completed. Following transcription, all original audio-recordings were 
to be stored for a year and then destroyed in December 2014. 
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